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Chapter 1
Introduction on Barrett’s esophagus
Barrett’s esophagus (BE) consists of a metaplasia in which the normal squamous 
cells lining the esophagus are replaced by a mixture of gastric and intestinal lining 
cells. The intestinal-type lining cells are often referred to as specialized columnar 
cells and include e.g. goblet cells. For a number of years, some scientists thought 
that there were two types of BE; one in which the normal lining was replaced with 
gastric type cells only, and the second in which intestinal cells were present. Pres-
ently, intestinal metaplasia is required for the diagnosis of BE because intestinal 
metaplasia is the only type of esophageal columnar epithelium that clearly predis-
poses to malignancy 1, 2. 
BE is a complication of chronic gastroesophageal reflux disease (GERD), prima-
rily in white men. GERD is a disease in which there is reflux of acidic fluid from the 
stomach and bile contents from the duodenum into the esophagus. It most com-
monly causes heartburn, but many patients do not have any symptoms.
A reason for limited understanding of the development of BE is, that all patients 
undergoing medical examinations when GERD symptoms are present, are either 
suffering from reflux esophagitis or are already suffering from BE. Only a subpopu-
lation of patients with reflux esophagitis develop BE, thus regular examination on 
patients with reflux esophagitis has not delivered a large population with BE. Un-
fortunately, most patients are diagnosed with BE at first clinical presentation. Con-
sequently only limited (if any) patients are available for testing putative hypotheses 
on the early onset and progression of this disease. Basic research into BE has fo-
cused on determining the molecular events required for the initial squamous-co-
lumnar transition, the genes required for progression, and possible methods of in-
hibiting or reversing the pre-cancerous and cancerous changes.
Although BE is a premalignant condition, it is the main risk factor for the devel-
opment of esophageal adenocarcinoma (EAC). EAC is the fastest rising malignancy 
in Western countries over the last three decades, the EAC treatment options are 
poor and it has a high mortality rate 3. GERD is associated with an increased risk of 
both BE and EAC development 4. Persistent gastroesophageal reflux activates sev-
eral pathways leading to BE and eventually EAC. However, the underlying mecha-
nisms leading to the GERD-BE-EAC cascade remain unknown. 
The adaptive immune response in reflux esophagitis differs from that in BE, 
while the composition of the reflux during the GERD-BE-EAC cascade remains con-
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stant. Reflux esophagitis in GERD is characterized by a cell-mediated immune re-
sponse, while a humoral immune response predominates in BE 5. Moreover, use of 
anti-inflammatory drugs such as non-steroid anti-inflammatory drugs (NSAIDs) 
and aspirin have been shown to diminish mucosal inflammation and establish a 
lower incidence of BE and EAC in both humans and animals 6. In addition, depressed 
cellular immunity is both associated with BE development 7, and with decreased 
immune surveillance leading to cancer 8.
As it is almost impossible to establish the transition from reflux esophagitis into 
BE in humans, we used an established animal model with surgically induced reflux 
esophagitis 9, 10 to study the role of the immune response in the development of 
reflux esophagitis, and the conversion of squamous epithelium into BE. The devel-
opment of BE was established in all rats 6 months after surgically induced chronic 
reflux. The conversion from squamous into columnar epithelium mimicked the hu-
man BE histology. Parallel with the development of intestinal metaplasia, a transi-
tion of the immune response pattern was noted. In reflux esophagitis, the submu-
cosal layer showed a cell-mediated Th1-like inflammation profile, while in BE, the 
submucosal layer contained a predominant humoral Th2-like inflammation profile 
(Chapter 2). The role of the immune response was studied in various rat strains that 
had a predisposition for the Th1 and/or Th2 immune response. Th1-prone Lewis 
rats showed Th1 effector cells at an early onset of the hyperplasia-esophagitis-BE 
cascade, as well as the longest esophageal segment with reflux esophagitis com-
pared to the Th2-prone BN and intermediate Wistar rat strain. Moreover, Lewis rats 
activated Th2 effector cells earlier after surgically induced reflux and developed the 
longest BE segment compared to Th2-prone BN and intermediate Wistar rats. We 
concluded that a Th1-predominant immune status may predispose to the develop-
ment of BE following reflux esophagitis (Chapter 3).
Tumor necrosis factor (TNF) is a pro-inflammatory cytokine involved in the Th1 
immune response 11. Esophageal TNF expression is responsive to local concentra-
tions of reflux components 12 and inflammatory cytokines 13, but is also controlled 
on a genetic level. We assessed the association of the TNF-b (NcoI) polymorphism, 
and the local effect on TNF production in the esophagitis-BE-EAC cascade. The 
TNF-b NcoI A/A genotype showed a significantly higher frequency and TNF was lo-
cally expressed in BE and EAC. These data indicate that TNF plays a role in the de-
velopment of BE and EAC (Chapter 4).
The adaptive immune response against toxic substances is related with the nu-
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clear pregnane X receptor (PXR) 14, 15. PXR plays a key role in the regulation of hepa-
tobiliary transport systems and of enzymes that confers a protective role against 
toxic bile acids 16. PXR was expressed in BE and EAC tissue, and nuclear localization 
was seen in EAC tissue. Upon stimulation with lithocholic acid, PXR translocated to 
the nuclei of EAC cells. The PXR polymorphism was associated with BE. Therefore, 
PXR may play a role in the prediction of BE disease and possibly in the treatment of 
esophageal disease to prevent EAC (Chapter 5). 
The stratified squamous epithelium of the healthy esophagus possesses a vari-
ety of intrinsic defenses that enable it to resist gastric and bile reflux 17, 18. Growth 
factors such as epidermal growth factor (EGF) and transforming growth factor-a 
(TGF-a) are associated with epithelial defense mechanisms 19. EGF plays an impor-
tant role in the protection and repair of mucosal damage, and non-physiologic lev-
els are associated with gastrointestinal tumors. We found that genetic variation of 
EGF was associated with reduced EGF expression and increased risk for reflux es-
ophagitis, BE, and EAC development. Over-expression of the EGF-receptor in es-
ophageal adenocarcinoma is associated with advanced pathologic tumor classifi-
cation and lymph node metastasis, however, not with an increased risk for tumor 
development or survival. We hypothesized from our results that the decreased EGF 
activity in the esophagus could trigger the promotion of a tumor environment, 
thereby either directly or indirectly affecting the risk for EAC development. This in-
dicates that reduced mucosal protection resulting from genetically decreased EGF 
expression enhances esophageal tumor development (Chapter 6).
Myo9B is a protein involved in epithelial cell cytoskeletal organization and pre-
dominantly expressed in the immune system 20. A defect in the intestinal barrier 
function by genetic variation of the Myo9B gene could be a factor for the genesis 
of intestinal inflammation in celiac disease and inflammatory bowel disease 21, 22. 
Increased mucosal permeability is recognized as one of the earliest histological 
changes in GERD 23. Genetic variation of Myo9B was associated with an increased 
risk for BE and EAC development. Cytoplasmic Myo9B expression was determined 
in reflux esophagitis, BE, and EAC, but most prominent in epithelial cells of BE and 
EAC. Myo9B might play a role in the etiology of BE and EAC by disturbing the cy-
toskeletal and immunological organization, therefore increasing the permeability 
of the epithelial barrier (Chapter 7).
As with the intestinal epithelium, the Barrett’s epithelium contains proliferative 
crypt-like compartments. In the intestine, self-renewal of the epithelium is driven 
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by Notch signaling. Notch inhibition results in rapid conversion of all proliferative 
cells into differentiated goblet cells 24. The activation of Notch signaling is critically 
dependent on an intramembrane protease complex termed γ-secretase. This pro-
tease complex is also implicated in the pathogenic processing of the amyloid pre-
cursor protein in Alzheimer’s disease 25. For this reason, multiple γ-secretase inhibi-
tors have been developed as potential Alzheimer’s drugs. Somewhat fortuitously, 
these inhibitors are efficient Notch inhibitors. Not surprisingly, administration of 
these inhibitors to rodents induces changes in the intestine that resemble the ef-
fects that occur upon genetic loss of Notch signaling 24, 26, while (pre-) clinical stud-
ies have revealed a single major side effect of γ-secretase inhibitors: the induction 
of goblet cells in the intestine 27. In BE, Notch inhibition converted the proliferative 
Barrett’s cells into arrested terminally differentiated goblet cells, whereas the nor-
mal squamous epithelium was unaffected. In some cases, the Barrett’s epithelium 
was entirely exfoliated, leaving bare submucosal tissue. These data imply that local 
application of Notch inhibitors may present a simple therapeutic strategy for BE 
conversion (Chapter 8).
The research presented herein identified histological and immunohistochemi-
cal characteristics in the development of GERD and BE, we evaluated biomarkers 
and genetic factors involved in the GERD-BE-EAC cascade, and eventually intro-
duced a possible option for therapeutic intervention with Notch inhibitors. With 
increasing availability of compelling information on various biomarkers, e.g. TNF, 
PXR, EGF and Myo9B, there has been an interest in evaluation of panels combining 
clinical features, endoscopic criteria, and molecular biomarkers as tools of risk strat-
ification in BE. In future, we hope to identify the patients at risk. While GERD may be 
considered an immune-mediated disease, this concept opens ways to develop 
new treatment leading to the prevention of carcinogenesis in BE. Our research 
might be a small step forward in the identification of biomarkers and immunologi-
cal targets in the GERD-BE-EAC cascade, however, many of the fields are still open 
and future efforts are necessary.
14
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Abstract
Background: Barrett’s esophagus (BE) is a pre-malignant condition caused by gas-
tro-esophageal reflux disease (GERD) and predisposes to esophageal adenocarci-
noma. The conversion of GERD into BE occurs in a subsection of patients and is 
hardly ever observed, while BE is diagnosed at clinical presentation. Therefore, the 
underlying pathogenic mechanisms of BE development remain unclear and need 
to be studied in a GERD-BE disease model. In a well-validated rodent model for BE, 
the immunohistochemical processes involved in the initiation and chronic persist-
ence of BE were determined.
Materials and methods: BE was surgically induced in Wistar rats by gastrectomy 
with esophagojejunostomy. At 0, 3, and 6 months the presence of histological in-
flammation and metaplasia was analyzed. Proliferative cells (Ki67), intestinal meta-
plasia (CDX2), goblet cells (WE9), and local inflammatory markers for monocytes 
(ED1), macrophages (ED2), T cells (CD3), cytotoxic T cells (CD8), B cells (CD45RA), 
and plasma cells (IgG) were determined.
Results: Esophageal lesions at 0-3 months after surgery were characterized by es-
ophagitis and increased numbers of the Th1 effector cells macrophages and cyto-
toxic T cells without significant metaplasia, and at 3-6 months after surgery charac-
terized by BE as specialized intestinal metaplasia with CDX2 and WE9 expression, 
and a marked influx of the Th2 effector cells eosinophils, B cells, and plasma cells. In 
addition, lymphoid aggregations were formed over time, which correlated in size 
with an increasing inflammatory response (r=0.68).
Conclusions: GERD results in an early cell-mediated response in esophagitis while 
the later humoral response occurs in human BE-like. This suggests that the devel-
opment of intestinal metaplasia is accompanied by a gradual shift in immune re-
sponse. Therefore the immune response might be involved in the induction of BE.
19
Immune response in the development of esophagitis and Barrett’s esophagus
CH  1
CH  2 
CH  3
CH  4
CH  5
CH  6
CH  7
CH  8
CH  9
CH  10
Introduction
Barrett’s esophagus (BE) is a pre-malignant condition, observed exclusively in a 
proportion of patients with gastro-esophageal reflux disease (GERD). BE is the most 
prominent risk factor for the development of esophageal adenocarcinoma (EAC), 
to which it has an annual progression rate of 0.5 -1% 1, 2. EAC has a high mortality 
rate and is currently the fastest rising malignancy in the Western world 3, 4. There is 
currently no curative therapy for BE; endoscopy combined with histology-based 
surveillance for early detection of EAC and symptom relief are the only tools to of-
fer patients. A better understanding of the pathologic mechanisms underlying this 
disease cascade is a prerequisite for the development of therapeutic options. 5, 6.
The individual alterations required for malignant progression in the GERD-BE-
EAC cascade are poorly understood. A prospective patient-based evaluation would 
require a large cohort and considerable time span as GERD only converts to BE in 
a small percentage of cases. The diagnosis of BE occurs at first clinical presentation 
and BE patients already display a predominantly humoral immune response. As it 
is almost impossible to establish the spatial and temporal relationship of BE devel-
opment in humans, the aid of an established animal model with surgically induced 
reflux esophagitis 27, 28 to study the changes in the immune response parallel with 
the histological development of intestinal metaplasia is inevitable.
Persistent gastro-esophageal reflux is associated with an increased risk of BE 
and EAC development 7, 8. The focus on the composition and the role of reflux, in-
cluding gastric and bile acids 9-11, suggested that in particular bile acids are impor-
tant in BE development 12. Bile acids can increase transcription of CDX2 in esopha-
geal squamous cells, thereby initiating metaplastic transformation 13, 14.
It has been thought that chronic reflux into the distal esophagus damages the 
tight junctions between the epithelial cells causing the intercellular spaces to dilate 
and H+ ions to enter into the epithelium 15-17. Acute reflux-induced chemical injury 
and death of the surface esophageal epithelial cells has been assumed to recruit 
neutrophils to the epithelium. Damage to the deeper layers of the epithelium may 
elicit a proliferative response, leading to basal cell and papillary hyperplasia 18-20. 
However, a recent study suggested an alternative concept in which reflux does not 
cause direct chemical injury, but stimulates esophageal epithelial cells to secrete 
chemokines which mediate damage of esophageal tissue through an immune re-
sponse 21. 
20
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The inflammatory immune response has been associated with the transition 
from GERD to BE 22. Recent studies showed that the inflammatory process in GERD 
differs from that in BE, while the composition of the reflux during the GERD-BE-
EAC cascade remains constant. GERD is characterized by a cell-mediated immune 
response, while a humoral immune response predominates in BE 23. In addition, 
depressed cellular immunity is both associated with BE development 24, and with 
decreased immune surveillance leading to cancer 25, 26.
In current study, an animal model was used in order to obtain more information 
on the initial steps of BE development. The obtained data support our hypothesis 
that the development of BE occurs in surgically induced GERD. Parallel with the 
BE development, a shift in the immune response from a cell-mediated immune 
response in GERD to a predominately Th2 immune response in BE is determined. 
These data suggest that the immune response might play a role in BE develop-
ment.
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Materials and methods
Animals
Six-week-old male Wistar rats were obtained from Harlan, England and housed 
under standard pathogen-free conditions with a maximum of 3 animals per cage. 
Experienced technicians carried out all animal handling. The animals were fed a 
commercially available natural diet for rats (SDS, England) and had free access to 
tap water. After an acclimatization period of 1 week, the animals were randomly 
divided into three groups in a time course design of t = 0, 3, and 6 months. General 
health status and weight was monitored at least twice per week; weight loss of 
more than 20% of the preoperative body weight, severe regurgitation, aspiration 
not recovering within 24h, or apathetic behavior prompted us to exclude the ani-
mal from the study. The local experimental animal committee approved the experi-
mental study protocol.
Surgical procedure
Several rat models were tested in our preliminary study (data not shown); first a 
model based on esophagoduodenal anastomosis, second a model based on es-
ophagojejunostomy with gastrectomy, and third a model based on esophagoje-
junostomy with ligation and preservation of the stomach 27, 28. The  esophagoduo-
denal model had a 7mm large anastomosis that closed spontaneously in 3 out of 
5 rats, and the other 2 rats did not show reflux esophagitis after 2 months. The 
esophagojejunostomy model with gastrectomy (GEJ) was performed in 30 rats to 
determine the development of SIM over time. Each month 2 rats post-GEJ and 1 
SHAM rat were sacrificed on a timeline from 0 to 6 months. Ten rats died prior to 
reaching their study endpoint. The result of this preliminary study revealed that 
no macroscopic or microscopic differences were observed between the native rats 
and the SHAM operated rats in any of the arms of the experiment. However, when 
the esophageal samples of the GEJ rats were studied, two typical stages of GEJ-
induced changes could be distinguished; an initial phase with esophagitis and a 
late phase with formation of intestinal metaplasia. These defects were most promi-
nent at respectively 3 months (initial phase) and 6 months (late phase) post-GEJ. 
The rats with a esophagojejunostomy and the ligated stomach in place, showed 
the same histology as the rats with esophagojejunostomy with gastrectomy, but 
more animals (50%) died due to necrosis of the stomach. We measured the pH of 
22
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the reflux on paper test strips (AlkaLife, Eindhoven, The Netherlands) at the surgi-
cal anastomosis and more proximal in the esophagus; at all times the pH showed a 
value around 6.0. We did not find an acidic variety in the reflux of the three differ-
ent rat models. Based on the survival and the histological findings, in the present 
study, SIM was induced by gastrectomy with esophagojejunostomy (GEJ). The 
technique was performed as previously reported 27, 29, 30 (Figure 1). SHAM rats only 
had abdominal laparotomy, with palpitation of the esophagus and the jejunum. 
No incisions were made in six control rats. The rats were randomly sacrificed at 0, 
3, and 6 months post-GEJ. The esophagus was then removed, and Swiss rolls were 
prepared with the luminal side at the inside and the distal end of the esophagus in 
the centre. Each Swiss roll was fixed in 10% neutral buffered formalin for 24 hours, 
and embedded in paraffin. The embedded samples were stored at RT until used for 
histology and immunohistochemistry.
Pathological analysis
Paraffin samples were cut at 4mm, deparaffinized in xylene, hydrated using a grad-
ed series of alcohol, and stained with hematoxylin-eosin (H&E). Six levels of the 
Swiss rolls were stained for histopathological analysis. A specialized gastrointes-
tinal pathologist (HvD) assessed all slides following international standard criteria 
Figure 1. 
Schematic representation of the gastrectomy with esophagojejunostomy (GEJ); the normal rat anatomy (A), 
status after gastrectomy (B), and an end-to-side esophagojejunal anastomosis at 2cm distal from the inser-
tion of the bile duct with a blind-ending duodenum (C).
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for the presence of hyperplasia, hyperkeratinization, papillomatosis, ulceration, fo-
cal metaplasia, SIM, and carcinoma with subtype. Ulceration was defined as large 
amounts of inflammatory cells that replace the epithelial layer. Focal metaplasia 
was defined as the presence of ducts with mixed, squamous and columnar epithe-
lium at distance from the intestinal segment around the anastomosis. SIM was de-
fined as intestinal columnar epithelium with goblet cells above the anastomositic 
site marked by the black monocryl suture. Parts of squamous epithelium within SIM 
and a continuous basal membrane of SIM with the esophagus also differentiated 
the jejunum from SIM at the site of the anastomosis. The rats with a small segment 
of dysplasia (1/21) and esophageal cancer (3/21) were primarily excluded, but that 
did not have influence on the mean mucosal thickness, the SIM segment length 
nor on the histological and immunohistochemical data. Therefore, these rats were 
not excluded from our data.
Immunohistochemical analysis
For immunohistochemistry, sections of 4mm were blocked for endogenous peroxi-
dase activity with 1% H2O2 in 100% methanol for 30 minutes. Antigen retrieval was 
performed with 10mM monocitric acid (pH 6.0) at 100°C for 15 minutes, except 
for OX8 staining, that does not require antigen retrieval. The slides were blocked 
with non-immune serum for 20 minutes at room temperature. The sections were 
stained using primary antibodies against intestinal epithelium (anti-CDX2 clone 
AMT 28; 1:100 dilution; Novocastra Laboratories Ltd, Newcastle, UK), goblet cells 
(anti-WE9; 1:200; gift from Dr. D.K. Podolsky, Gastrointestinal Unit, Massachusetts 
General Hospital, Boston, USA), proliferative cells (anti-Ki67; 1:500; BD Pharmingen, 
San Diego, USA), monocytes and macrophages (anti-ED1; 1:100; Serotec, Oxford, 
UK), tissue macrophages (anti-ED2; 1:100; Serotec, Oxford, UK), T cells (anti-CD3; 
1:100; BD Pharmingen, San Diego, USA), CD8+ T cells (anti-OX8; 1:500; Serotec, 
Oxford, UK), B cells (anti-OX33 {CD45RA}; 1:300; Serotec, Oxford, UK), and anti-IgG 
(Goat-anti-rat IgG; 1:100; Jackson). Binding of the primary antibody was visualized 
by the addition of Envision. Normal rat esophagus, rat colon, rat spleen and rat 
mesenterial lymph nodes were used as a control.
Two independent observers (VM, JGK) evaluated the sections for the immuno-
histochemical stainings and the mean error between observers was always <5%. 
To determine the grade of inflammation, the number of immune cells (i.e. ED1, 
OX8, OX33, IgG) were scored in 5 randomly selected microscopic fields at 3 months 
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post-GEJ, and at 6 months post-GEJ in the proximal non-SIM esophagus (called 6 
months prox) as well as in the distal esophagus with SIM. The slides were assessed 
using a Zeiss microscope (Axioskop 20, Carl Zeiss, Sliedrecht, The Netherlands) with 
a standard magnification (200x).
The mean length of the SIM segment, the mucosal thickness at set distances 
from the anastomosis, and the area of the lymphoid aggregations in the tissues 
were determined on images, recorded with a Nikon camera (DS-5M-U1) and ana-
lyzed with Nikon Eclipse Net 2000 software (Nikon, Badhoevedorp, The Nether-
lands) that were calibrated with our Zeiss Axioskop 20 microscope.
Statistical analysis
The study was powered for the known 30% mortality rate of this model to yield a 
total of 20 animals in each arm after a 6-months follow-up. One-sample variables 
were analyzed by the Student’s t-test and expressed as the mean of at least 3 ani-
mals with a standard error of the mean (SEM). Statistical relevance of correlations 
was determined with Pearson’s correlation test. Nominal variables were analyzed 
with the c2-test. A two-sided p-value ≤ 0.05 was considered to be statistically sig-
nificant. All statistical analyses were conducted with the SPSS software package 
v11.1 (SPSS, Chicago, IL).
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Results
In total, 60 rats were included in this study, among which 6 untreated rats, 3 SHAM 
rats at 3 months, 3 GEJ rats at 3 months, 27 SHAM rats at 6 months, and 21 GEJ rats 
at 6 months after surgery (Table 1).
Table 1. 
T=0 (n=6) / 
SHAM (n=30)
T=3months 
(n=3)
T=6months 
(n=21)
MACROSCOPIC VIEW
Proximal esophagus Normal Normal Pathological 
thickening
Distal esophagus Normal Pathological 
thickening
Pathological 
thickening
H&E
Proximal esophagus Squamous Hyperplasia Hyperplasia, 
Ulcers, 
Lymphoid 
aggregations
Patchy BE 
submucosal
Distal esophagus Squamous Hyperplasia, 
Ulcers, 
Lymphoid 
aggregations, 
Patchy BE 
submucosal
Lymphoid 
aggregations,
BE
MARKERS
Proximal esophagus
Monocytes/macrophages (ED1) + + ++
CD3 T cells + + ++
CD8 T cells - + ++
B cells (OX33) - - +
Plasma cells (IgG) - - +
Proliferation (Ki67) Basal membrane - Submucosa
BE (CDX2)/Goblet cells (WE9) - - Submucosa
Distal esophagus
Monocytes/macrophages (ED1) + ++ ++
CD3 T cells + ++ ++
CD8 T cells + ++ ++
B cells (OX33) - + ++
Plasma cells (IgG) - + ++
Proliferation (Ki67) Basal membrane Submucosa BE mucosa
BE (CDX2)/Goblet cells (WE9) - Submucosa BE mucosa
26
Chapter 2
Macroscopic analysis
At 3 months post-GEJ
Macroscopic analysis of the SHAM esophagus revealed no obvious pathology; clos-
er inspection showed an esophagus of standard thickness with a continuous white 
mucosal layer. At 3 months post-GEJ, all rats presented a pathological, thickened 
tissue at the distal esophagus. The lumen contained red superficial ulcers located 
in the white mucosal layer of both the proximal and distal esophagus.
At 6 months post-GEJ
Macroscopic analysis of the SHAM operated rats after 6 months still revealed no 
obvious abnormalities; the esophagus was of standard thickness with a continu-
ous white mucosal layer. The GEJ rats at 6 months all presented a pathological, 
thickened, solid distal esophagus while the lumen and the anastomosis were still 
accessible. Whitish nodular patches were prominent in the lumen of the distal es-
ophagus. Red superficial ulcers were randomly spread in the white mucosal layer 
of the proximal esophagus.
Histological analysis
At 3 months post-GEJ
Microscopic analysis of the SHAM esophagus in H&E stainings showed a regular 
pattern of the multi-layered squamous epithelium without inflammation at the 
surface or in the deeper layers (Figure 2a and 2d). In contrast, the esophagus of 
all GEJ rats showed an irregular mucosal pattern with hyperplasia, hyperkerato-
sis, papillomatosis, and ulceration of the distal esophagus. Lymphoid aggregations 
had developed at the level of the basal membrane (Figure 2b, 2e, and Figure 3). 
Therefore, the mucosal thickness was determined at four steady distances from the 
surgical anastomosis, and the SHAM and the GEJ groups were separately analyzed. 
The course of the mucosal thickness from the proximal to the distal esophagus was 
plotted in a graph, and the slope of the mucosal thickness was significantly steeper 
at 3 months post-GEJ compared to SHAM rats (p<0.001) (Figure 4).
Closer analysis of the H&E stained specimen demonstrated the development of 
small focal areas of SIM with goblet cells in 30% of the GEJ rats at 3 months. Patchy 
sites with columnar epithelium and goblet cells were observed in the deeper mu-
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cosal layers at the basal membrane of the distal esophagus. CDX2 and WE9 stain-
ing confirmed the presence of columnar epithelium and goblet cells in this initial 
phase (Figure 5a and 5c). SHAM rats did not show CDX2 or WE9 expression (data 
not shown).
At 6 months post-GEJ
Comparing the esophagus of SHAM rats with that of rats at 6 months post-GEJ 
revealed marked macroscopic differences. All GEJ rats presented a pathological, ir-
regular mucosal pattern and the proximal esophagus was always characterized by 
hyperplasia, hyperkeratosis, papillomatosis, and ulceration (Figure 3). Microscopic 
analysis of the H&E stained specimens revealed that all rats at 6 months post-GEJ 
had developed SIM in the distal esophagus above the anastomotic site (Figure 2f ), 
while the esophagus of the SHAM group animals did not show such abnormali-
Figure 2. 
Hematoxylin and eosin staining (H&E) of rat esophagus at 0 (SHAM), 3, and 6 months post-GEJ. Figures 2A-C 
(Magnification 1.5x) are Swiss rolls of the complete esophagus with the distal esophagus in the centre and 
the proximal esophagus as end tail. Figures 2D-F are magnified at the indicated sites (Magnification 12.5x). 
SHAM rat esophagus with a standard mucosa (A and D). At 3 months post-GEJ, the presence of a distally in-
creased mucosal thickness, an absent keratin layer, small lymphoid aggregations (dark purple grouped cells) 
and focal SIM at the basal layer (B and E). At 6 months post-GEJ, the presence of an overall increased mucosal 
thickness, proximal esophagitis with ulcerations and focal SIM at the basal layer, medially ulcerative tissue 
with small lymphoid aggregations (dark purple grouped cells) and SIM at the basal layer, distally complete 
SIM (21/21 rats with BE) with large lymphoid aggregations (la) (C and F).
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ties (Figure 2c). Among the 21 GEJ rats, three developed esophageal cancer at 6 
months post-GEJ: 1 EAC, 1 mixed adenosquamous cell carcinoma, and 1 squamous 
Figure 3. 
Presence of hyperplasia, hyperkeratosis, papillomatosis, ulceration, and metaplasia in the esophageal mu-
cosa of the distal esophagus at 3 months (solid bars, n=3) and both the proximal and distal esophagus 6 
months (hatched bars, n=21) post-GEJ.
Figure 4. 
Mean mucosal thickness, measured at 4 steady distances from the anastomosis. The value of the first bar 
(black) represents the measurement at 40mm proximally from the anastomosis, the last bar (white) repre-
sents the measurement at the anastomosis, and the two bars in between are at 10mm and 20mm proximally 
from the anastomosis, respectively. The mucosal thickness differs significantly between 0 and 3 months 
(p<0.001), between 0 and 6 months (p<0.001), and between 3 and 6 months post-GEJ (p<0.001).
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cell carcinoma. The course of the mucosal thickness from the proximal to the distal 
esophagus was plotted in a graph, and the slope of the mucosal thickness was sig-
nificantly steeper at 6 months post-GEJ compared to the SHAM rats (p<0.001) and 
the GEJ rats at 3 months (p<0.001) (Figure 4).
CDX2 and WE9 staining confirmed the presence of columnar epithelium and 
goblet cells (Figure 5b and 5d). In addition, specific expression in focal areas at the 
level of the basal layer in the medial esophagus was observed, defining small is-
lands of SIM in the medial rat esophagus. Closer analysis of the stained specimen 
demonstrated the development of several small foci of SIM with goblet cells in the 
proximal and medial esophagus of all GEJ rats at 6 months. PAS staining revealed 
the presence of separated focal metaplasia at several height levels in the esophagus 
(Figure 6). Because of the patchy, inhomogenous SIM design, it was not possible to 
isolate BE mucosal thickness and differentiate the mucosal thickness between the 
various histological outcomes, like esophagitis, SIM, dysplasia and carcinoma.
Figure 5. 
SIM in the rat esophagus. CDX2 staining indicates the focal presence of columnar epithelial cells in the esopha-
gus at 3 months post-GEJ (A) while clearly present at 6 months (B). WE9 staining for mucin 2 indicates the focal 
presence of goblet cells in the esophagus at 3 months post-GEJ (A) while clearly present at 6 months (B).
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Immunohistochemical analysis
At 3 months post-GEJ
The cellular composition of the mucosal inflammation was defined with markers 
for monocytes and macrophages (ED1), T cells (CD3), cytotoxic T cells (CD8), B cells 
(OX33), and plasma cells (IgG) (Figure 7). Macrophages and cytotoxic T cells are 
Th1-derived effector cells as these cells play an important role in the cell-mediated 
immunity. Immune cells related to the humoral immune response such as B cells 
and plasma cells are Th2-derived effector cells.
The proximal esophagus at 3 months post-GEJ contained a hyperplastic muco-
sa with a low number of inflammatory cells, mainly consisting of monocytes, mac-
rophages, and T cells located between the squamous epithelial cells. Almost no B 
cells and plasma cells were observed (data not shown). In the distal esophagus, the 
total number of inflammatory cells per microscopic field was 5-fold higher com-
Figure 6. 
H&E staining of a Swiss roll with the complete esophagus at 6 months post-GEJ shows an irregular mucosa 
from the proximal to the distal end. SIM known as columnar metaplasia with goblet cells in a patchy design 
in the rat esophagus. Focal columnar epithelium with goblet cells is magnified 40x at 10 and 20mm from the 
distal, anastomotic side. PAS staining of the enlarged sites indicates focal goblet cells at both levels of the 
medial esophagus.
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GEJ rats (data not shown). The distal esophagus demonstrated a high number of 
Figure 7. 
Typical examples of the immunohistochemical staining of rat esophagus at 3 and 6 months post-GEJ. ED1 
staining for monocytes and macrophages (red staining) at 3 and 6 months. CD8+ T cells (red) at 3 months 
and 6 months. OX33 staining for B cells (red), a large proportion of these cells expressed IgG (red) at 3 months 
and 6 months.
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Figure 8. 
Increased numbers of inflammatory cells in SIM. (A) Mean numbers (mean±SE) of inflammatory cells per mi-
croscopic field (200x) were obtained by counting the immune cells in 5 randomly selected microscopic fields 
in the distal esophagus at 3 months, in the proximal non-SIM esophagus at 6 months, and at the distal SIM 
esophagus at 6 months. Inflammatory cells were more prevalent in the distal SIM than in the proximal non-
SIM at 6 months (*p<0.0001), B cells and plasma cells were 4-fold more prevalent in SIM at 6 months than at 
3 months, plasma cells were also more prevalent in non-SIM at 6months than at 3 months (**p<0.05). (B) A 
shift from predominantly Th1 effector cells at 3 months post-GEJ into predominantly Th2 effector cells at 6 
months post-GEJ is observed.
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monocytes, macrophages, cytotoxic T cells, and a lower number of B cells and IgG 
producing plasma cells. The number of inflammatory cells was compared to GEJ 
rats at 6 months and is described in the next section (Figure 8).
Ki67 expression of the esophageal epithelial cells was shown at the basal layer 
of the SHAM esophagus. More cells expressed Ki67 in papillary hyperplasia, and 
the highest proliferation was found in focal SIM, where all epithelial cells expressed 
Ki67 (data not shown).
Figure 9. 
The lymphoid aggregates at 3 months post-GEJ show randomly spread T cells (CD3), B cells (OX33), and pro-
liferative (Ki67) cells. The large lymphoid follicle at 6 months post-GEJ contains strong central proliferation 
surrounded by a B cell zone (OX33) and a marginal T cell zone (CD3). 
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There was formation of lymphoid aggregates, which was not found in the es-
ophagus of SHAM rats, but present at 3 months post-GEJ (Figure 2b). The lymphoid 
aggregates correlated in size with the significantly increasing mucosal thickness (r 
=0.67). They showed a distribution with a high number of T cells and a slightly lower 
number of B cells in the centre and surrounding zone. Ki67 expression was hardly ac-
tive in the centre and slightly more present in the surrounding zone (Figure 9).
At 6 months post-GEJ
At 6 months, all GEJ rats (21/21) had complete SIM in the distal esophagus with a 
mean length of 3.96mm (±0.37) and this was confirmed by histology (H&E, PAS, 
CDX2, WE9). There was an increasing proliferation from the proximal to the distal 
esophagus, which was even clearer than the progress from proximal to distal at 3 
months post-GEJ; Ki67 showed the highest and strongest expression in all epithe-
lial cells of SIM (data not shown).
Papillary hyperplasia of the proximal esophagus was accompanied by macro-
phages and CD8+ T cells, as was found in the distal segment of the GEJ rats at 3 
months. The ulcerative areas in the medial and distal esophagus showed a higher 
number of these cells and were compared to the distal esophagus of the GEJ rats at 
3 months. At 6 months post-GEJ, high numbers of B cells and IgG producing plasma 
cells were observed (Figure 7 and 8a). The inflammatory response had shifted from 
a predominance of monocytes, macrophages, and cytotoxic T cells at 3 months, to 
a predominance of B cells and plasma cells at 6 months post-GEJ (Figure 8b), indi-
cating the activation of a Th2 immune reaction. 
Large lymphoid follicles were formed in the esophageal mucosa, which corre-
lated in size with the significantly increasing mucosal thickness at 3 and 6 months 
(r =0.68) (Figure 3). Of notice, in 4/21 rats, significantly larger lymphoid aggregates 
were detected underneath the SIM segment compared to the inflamed squamous 
epithelium (mean area 2.05±0.26 vs 0.04±0.02mm2), none of them were rats with 
dysplasia or esophageal cancer. In the lymphoid aggregates in SIM segregated B 
and T cell areas were found on H&E (data not shown). These expressed macrophag-
es and CD8+ T cells, and strongly expressed CD3 T cells, B cells and IgG (Figure 9). 
Moreover, in contrast to smaller lymphoid aggregates at 3 months post-GEJ, Ki67 
was highly active in the germinal centre, and  T and B cells were organized in the 
surrounding marginal zone of the lymphoid aggregations (Figure 9).
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Discussion
Present study in an established rat model showed that the development of SIM 
runs parallel with the immune shift from an early cell-mediated immune response 
during GERD into a late humoral reaction during BE. In the samples obtained at 3 
months post-GEJ as well as in the proximal (SIM free) regions at 6 months post-GEJ 
large numbers of CD8+ T cells and macrophages were found. This is indicative for a 
Th1-derived immune response indeed suggesting that a cell-mediated immune re-
sponse (Th1) is strongly associated with GERD. A BE-like histology was particularly 
observed in the distal esophagus at 6 months post-GEJ. The inflammatory cells that 
characterized the SIM areas consisted predominantly of eosinophils, B cells, and 
IgG producing plasma cells, known as Th2-derived immune cells, and, occasionally, 
even large lymphoid aggregates were observed. This indicates that SIM is closely 
associated with both a temporal and spatial presentation of a chronic humoral im-
mune response (Th2). Strikingly, SIM seems to develop in a patchy pattern in the 
submucosa progressing to the epithelial surface, rather than a continuous process 
of BE epithelium growing from the distal into the proximal esophagus (Table 1). 
This study compliments the animal studies that found a greater destruction of 
the rat esophageal mucosa after exposure to duodenal juice than gastric juice 28, 
31-33. Our surgical model is characterized by chronic reflux causing the development 
of chronic mucosal inflammation in GERD, followed by SIM, and eventually EAC 
in some rats (1/21 rats in this study). The histological and immunohistochemical 
stages of our model were very similar to its equivalent in humans although a rat 
model can only mimic human disease. The gene expression profile 34, 35 as well as 
the Notch pathway expression 30 of esophageal SIM following surgically induced 
reflux in present rat model indicates that this indeed represents intestinal metapla-
sia of BE, and not proximal migration of jejunum. 
In human studies, acid suppression therapy with PPIs  is known to be effective 
in reducing inflammatory changes in the esophagus and therefore BE and EAC 36. 
However, PPIs do not completely seem to protect from BE and EAC 37-40. Acid sup-
pression therapy mainly affects the acid component of the reflux and allows other 
components to persist. Esophageal exposure to bile acids is seen as a key factor 
in the etiology of GERD, BE and the development of EAC 41-44. PPI therapy can ap-
parently not fully protect the esophagus from the development of metaplasia or 
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adenocarcinoma by oxidative damage, irreversible dilated intercellular spaces of 
the esophageal epithelium or bile injury. 
Physiological glands of the human esophagus are thought to play a role in the 
immune response during esophagitis and BE 23. Rat esophagus and the proximal 
part of the stomach are non-glandular, thus the anatomy differs from that in hu-
man. However, the lymphoid aggregates, which develop during the inflammatory 
processes, resemble secondary lymphoid tissue. This supports the hypothesis that 
human isolated lymph follicles in BE are newly formed structures that react against 
severe inflammation. The mechanism of isolated lymph follicles or lymphoid tissue 
remains unknown.
A depressed cellular immunity is associated with decreased immune surveil-
lance leading to cancer 25, 26, 45, 46. As a depressed cellular immune response was ob-
served in peripheral mononuclear cells in patients with BE 24, it may encourage 
the malignant transformation of BE. It has been argued  that chronic inflammatory 
stimuli initially generate a Th1 pro-inflammatory cytokine response 47. However, 
Th2 cytokine production is upregulated via COX2 generation and there is negative 
feedback leading to inhibition of the Th1 response. Both the Th1 and Th2 immune 
response are active in an environment with inflammatory stimuli. This balanced 
state between the cellular and humoral immune response exists in esophagitis, BE, 
and EAC. Pro-inflammatory cytokine induce neutrophil and T cell accumulation in 
the pathogenesis of acute reflux esophagitis 21, 48. Where the cellular response is the 
major pathway for esophagitis development, both cellular and humoral immune 
responses are implicated in BE, with a predominant humoral immune profile char-
acterizing BE 23, 49, 50. This has lead to present hypothesis that the balance between 
the cellular and humoral immune response first leads to an activated cellular im-
mune response in reflux esophagitis followed by the depressed cellular immune 
response and consequently a predominant humoral immune profile in BE.
In conclusion, present study shows that the shift from a cell-mediated immune 
response into a humoral immune response runs parallel to the development of 
intestinal metaplasia. This process can be distinguished in an initial and in a late 
phase, which coincides with the clinical and pathologic disorders GERD and BE, 
respectively. The up-regulation from a Th1- into a Th2-mediated immune response 
seems to trigger BE development. However, BE is a multi-factorial disease and the 
functional role of the immune response as well as the genetic immune status need 
further elucidation.
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Abstract
Background: Chronic gastro-duodenal reflux causes Barrett’s esophagus (BE) that 
may progress to esophageal adenocarcinoma, which is currently the fastest grow-
ing malignancy in the Western population. The transition from reflux esophagitis 
into BE has been associated with a shift from the cellular (Th1) towards the humoral 
(Th2) immune response. Here, the function of the immune response for the initia-
tion and persistence of BE was analyzed. 
Materials and methods: Esophageal metaplasia and inflammation were deter-
mined by conventional histology and immunohistochemistry in a validated surgi-
cal rodent model in Th1 prone Lewis, Th2 prone Brown Norway and intermediate 
Th1/Th2 Wistar rats.
Results: While all three rat strains developed esophageal hyperplasia and severe 
esophagitis with predominantly Th1 immune cells, the time line and severity of 
the response showed marked differences. The mean Barrett’s lesion was longer in 
Lewis than in Wistar and BN rats. Hyperplasia was seen in Lewis rats at 2 and 5 
weeks after surgery with the highest number of monocytes and macrophages. At 
long term, all strains had developed BE, but most cytotoxic T cells and mast cells 
were seen early in Lewis rats at 9 and 12 weeks after surgery, and later in BN rats at 
24 weeks after surgery.
Conclusion: These results imply that the development of BE metaplasia occurs un-
der a Th1 predominant immune response, which then shifts towards Th2 predomi-
nance. This suggests that patients with a Th1 immune status may be more suscep-
tible to the development of BE than Th2 prone patients.
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Introduction 
Ongoing gastro-esophageal reflux of acid and bile induces chronic inflammation 
of the esophagus 1-3. It is as such an important risk factor for the development of 
both Barrett’s esophagus (BE) and esophageal adenocarcinoma 4-6. The incidence 
of esophageal adenocarcinoma has been rapidly increasing in the western popula-
tion over the last three decades 7, 8. Although reflux is a crucial factor in the patho-
genesis of esophagitis and BE, pH, volume and composition of the refluxate by 
themselves do not explain the marked inter-individual differences in progress from 
esophagitis to BE and eventually esophageal adenocarcinoma 9-12. 
Previously, we found that the transition from esophagitis to BE is associated 
with a shift from a cellular (Th1) towards a humoral (Th2) immune response 13, 14. 
These findings suggest that a Th1 response is involved in BE development, whereas 
a Th2 response is more important to maintain the chronic status of BE.
Our hypothesis is that the host immune system plays a crucial role in the develop-
ment of esophagitis and BE. If so, the immunological background of the host could 
influence the onset and outcome of esophagitis. If esophagitis is indeed primarily a 
Th1-based disease, we expect that a genetic background for a preferential Th1 re-
sponse predisposes to more severe inflammation, hyperplasia and ulceration. On the 
other hand, Th2 prone individuals might be more sensitive to develop BE. It is well 
known that various rat strains have a genetic predisposition for either Th1 or Th2 
immune response 15-19. This is illustrated by the level of expression of specific mark-
ers, such as IL2 and IFNγ for cellular immunity, and IgE, IL4, IL5, IL9, IL10 and IL13 for 
humoral immunity. Figure 1 shows the ranking of the rat strains for a preferential Th1 
and/ or Th2 immune response 15. Based on this, we selected Lewis rats as Th1 repre-
sentatives, Brown Norway rats as Th2 representatives, and Wistar rats as the interme-
diate T1/T2 strain and induced BE in these animals using a well established protocol 
20-22. To investigate our hypothesis, we then studied histology, immunohistochemis-
try, and their dynamics during the development of BE in these rats.
Figure 1. 
Ranking of rat strains for a preferential Th1 and/ or Th2 immune response. Based on data from 15-19
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Materials and methods
Animals
Six-week-old male Wistar, BN, and Lewis rats were obtained from Harlan, England 
and housed under standard pathogen-free conditions with a maximum of 3 ani-
mals per cage.
Experienced technicians performed all animal handling. The animals were fed a 
commercially available natural diet for rats (SDS, England) and had free access to tap 
water. After an acclimatization period of 1 week, the animals were randomly divided 
into three groups in a time course design of t = 0, 2, 5, 9, 12, and 24 weeks. These time 
intervals were based on previous studies, in which reflux esophagitis without BE was 
found at 12 weeks after surgical interference, and BE-like histology defined as spe-
cialized intestinal metaplasia (SIM) had developed at 24 weeks after surgery. 
General health status and weight was monitored at least twice per week; weight 
loss of more than 20% of the preoperative body weight, severe regurgitation, as-
piration not recovering within 24h, or apathetic behavior lead to exclusion of the 
animal from the study. The local experimental animal committee (Erasmus MC – 
University Medical Centre Rotterdam, The Netherlands) approved the experimen-
tal study protocol.
Surgical procedure
Based on a preliminary study (not shown), we designed a setup that was powered 
for a 30% mortality rate of this model to yield a total of 5 animals in each arm after a 
6-months follow-up. Essentially the surgical procedure of Levrat 21 was followed with 
the modification of a gastrectomy instead of only ligation of the stomach. Briefly, 
the procedure consisted of gastrectomy with esophagojejunostomy. As controls, 
SHAM-operated rats were used to exclude a putative effect of the surgery itself. 
SHAM rats only had abdominal laparotomy, with palpitation of the esophagus and 
jejunum. No incisions were made in seven control rats. The rats were randomly sac-
rificed at 0, 2, 5, 9, 12, and 24 weeks post-GEJ. After sacrificing the rats, we took out 
the esophagus from below the larynx until the jejunum or stomach in non-operat-
ed rats, and a small piece of the jejunal anastomosis or gastro-esophageal junction 
was included to the esophageal sample. Swiss rolls were prepared with the luminal 
side at the inside and the distal end of the esophagus in the centre. Each Swiss roll 
was longitudinally divided in two, and either fixed in 10% neutral buffered formalin 
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for 24 hours, and embedded in paraffin, or frozen in Tissue tek (Sakura Finetek Eu-
rope, UK) and stored in the -80°C. The paraffin embedded samples were stored at 
room temperature until used for histology and immunohistochemistry.
Pathological analysis
Paraffin samples were cut at 4mm, deparaffinized in xylene, hydrated using a grad-
ed series of alcohol, and stained with routine hematoxylin and eosin (H&E) and 
periodic acid Schiff (PAS). Six levels of the Swiss rolls were stained for histopatho-
logical analysis. A specialized gastrointestinal pathologist assessed all slides for the 
presence of hyperplasia, ulceration, and columnar metaplasia. Ulceration as a con-
sequence of reflux esophagitis was defined as large amounts of inflammatory cells 
that replace the epithelial layer. Specialized intestinal metaplasia (SIM) was defined 
as intestinal columnar epithelium with goblet cells above the anastomositic site 
marked by the black monofilament suture. Parts of squamous epithelium within 
SIM and a continuous basal membrane of SIM with the esophagus also differenti-
ated the jejunum from SIM at the site of the anastomosis.
Immunohistochemical analysis
For immunohistochemistry, sections of 4mm were blocked for endogenous per-
oxidase activity with 1% H2O2 in 100% methanol for 30 minutes. Antigen retrieval 
was performed with 10mM monocitric acid (pH 6.0) at 100°C for 15 minutes. The 
slides were blocked with non-immune serum for 20 minutes at room temperature. 
The sections were stained using primary antibodies against intestinal epithelium 
(anti-CDX2 clone AMT 28; 1:100 dilution; Novocastra Laboratories Ltd, Newcastle, 
UK) and proliferative cells (anti-Ki67; 1:500; BD Pharmingen, San Diego, USA). Bind-
ing of the primary antibody was visualized by the addition of Envision. Normal rat 
esophagus, rat colon, rat spleen and rat mesenteric lymph nodes were used as a 
control.
Frozen tissue sections were dried overnight at room temperature with silicagel. 
Sections were fixed with acetone and 0.05% H2O2 to quench endogenous peroxi-
dase activity. Subsequently the sections were blocked with 10% normal rat serum 
for 20 minutes, followed by a 1 hour at room temperature incubation with primary 
antibodies against CD8, CD93, and CD68 (Serotec Ltd, Oxford, UK). Antibodies were 
used in a 1:100 dilution for CD8 and CD93 and a 1:2000 dilution for CD68. Subse-
quently the sections were washed with PBS, followed by incubation with a strepta-
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vidin-labelled horseradish peroxidase (1:200; Dako, Glostrup, Denmark) for 45 min. 
After washing with PBS sections were visualized with DAB (3,3’-Diaminobenzidine) 
and counterstained with hematoxylin, sections were evaluated under a light mi-
croscope (Zeiss, Axioskop, Sliedrecht, The Netherlands). We used rat spleen tissue 
as a positive control, as negative controls an isotype control was used and the pri-
mary antibody was omitted.
Two independent observers (VM, JGK) evaluated the sections for the immu-
nohistochemical staining, the mean error between observers was always <5%. To 
determine the grade of inflammation, the mean number of immune cells were 
determined from at least 3 fields for CD8 and CD93, or, in case of CD68, marked 
as negative, moderate (10-100 positive cells/field), and high (>100 positive cells/
field). The slides were assessed using a Zeiss microscope (Axioskop 20, Carl Zeiss, 
Sliedrecht, The Netherlands) with a standard magnification (200x).
The incidence of esophageal lesions and the mean length of the SIM segment 
were determined on images, recorded with a Nikon camera (DS-5M-U1) and ana-
lyzed with Nikon Eclipse Net 2000 software (Nikon, Badhoevedorp, The Nether-
lands) that were calibrated with our Zeiss Axioskop 20 microscope.
Statistical analysis
The study was powered for the previously observed 30% mortality rate of this 
model to yield a total of 20 animals in each arm after 6-months follow-up. Mean 
differences between the Barrett’s length of the rat groups and the cell expression 
were determined by Student’s T-test. A two-sided p-value ≤ 0.05 was considered 
to be statistically significant. All statistical analyses were conducted with the SPSS 
software package v11.1 (SPSS, Chicago, IL).
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Results
Incidence of Esophagitis and BE in the GEJ Rat Model
In total, 110 rats were involved in this study, of which 7 were untreated control rats, 
15 SHAM operated rats, 49 GEJ operated rats, 39 rats died after GEJ (16 Wistar, 11 
Lewis and 11 Wistar), and 1 Lewis rat died pre-operative.
The esophageal histology findings in Lewis, Wistar and BN rats at 2, 5, 9, 12, and 
24 weeks post-surgery are shown in Table 1. No macroscopic and microscopic lesions 
were observed in control and SHAM rats, whereas esophageal lesions were observed 
in all rats that underwent GEJ. Histologically, a normal rat esophagus has a thin epi-
thelial layer with squamous cells, and few inflammatory cells in the submucosal layer 
(Figure 2.a). Marked squamous epithelial cell hyperplasia was observed in all GEJ rats. 
At 2 weeks after GEJ, hyperplasia was observed in the proximal and middle part of 
the esophagus of all rat strains. At 5, 9, 12, and 24 weeks after GEJ, hyperplasia was 
Table 1a.
Incidence of esophageal lesions and histological changes after GEJ in Lewis rats
Period after operation (Lewis rats) 2 weeks 
(N=3)
5 weeks 
(N=6)
9 weeks 
(N=3)
12 weeks 
(N=3)
24 weeks 
(N=3)
Incidence of esophageal lesions (%)
Squamous cell hyperplasia 3 (100) 3 (100) 3 (100) 3 (100) 3 (100)
Esophagitis 3 (100) 3 (100) 3 (100) 3 (100) 3 (100)
Barrett’s esophagus 0 (0) 4 (66) 2 (66) 3 (100) 3 (100)
Table 1b.
Incidence of esophageal lesions and histological changes after GEJ in Wistar rats
Period after operation (Wistar rats) 2 weeks 
(N=4)
5 weeks 
(N=4)
9 weeks 
(N=3)
12 weeks 
(N=3)
24 weeks 
(N=4)
Incidence of esophageal lesions (%)
Squamous cell hyperplasia 4 (100) 4 (100) 3 (100) 3 (100) 4 (100)
Esophagitis 4 (100) 0 (0) 1 (33) 3 (100) 4 (100)
Barrett’s esophagus 0 (0) 0 (0) 1 (33) 1 (33) 4 (100)
Table 1c.
Incidence of esophageal lesions and histological changes after GEJ in BN rats
Period after operation (BN rats) 2 weeks 
(N=3)
5 weeks 
(N=4)
9 weeks 
(N=2)
12 weeks 
(N=2)
24 weeks 
(N=2)
Incidence of esophageal lesions (%)
Squamous cell hyperplasia 3 (100) 4 (100) 2 (100) 2 (100) 2 (100)
Esophagitis 3 (100) 4 (100) 2 (100) 2 (100) 2 (100)
Barrett’s esophagus 0 (0) 3 (75) 1 (50) 1 (50) 2 (100)
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always observed in the proximal esophagus, except for Wistar rats at 5 weeks after 
GEJ. Esophagitis was found in all rats after GEJ and characterized by elongation of the 
lamina propria papillae, basal cell hyperplasia, and inflammatory cell infiltration with 
ulceration (Figure 2.b). At 2 weeks after GEJ, esophagitis was observed in the distal 
part of the esophagus of all rat strains. At 5, 9, 12, and 24 weeks after GEJ, esophagitis 
was always observed in the middle and distal esophagus, except for Wistar rats at 5 
weeks after GEJ. Columnar epithelium with goblet cells was found in some areas of 
the esophageal lesions. PAS positive material was only detected in the goblet cells 
but not in the squamous (hyperplastic) epithelium (Figure 2.c). Ki67 specific stain-
Figure 2. 
Hematoxylin and eosin staining (H&E) of rat esophagus at 0 (SHAM), 9, and 24 weeks after GEJ. Figure 2a 
(Magnification 20x) shows twice the normal rat esophagus with squamous epithelium and few inflamma-
tory cells in the submucosal layer. Figure 2b (Magnification 20x) shows the effect of reflux esophagitis at 9 
weeks after GEJ with elongation of the lamina propria papillae, basal cell hyperplasia, and inflammatory cell 
infiltration with ulceration. Columnar epithelium with goblet cells was found in some areas of the esopha-
geal lesions. Figures 2c-d are magnified at the distal esophagus (Magnification 10x). PAS was detected in the 
goblet cells but not in the squamous (hyperplastic) epithelium (Figure 2.c). Ki67 showed the proliferation of 
the esophageal lesions, whereas Ki67 was expressed in the nuclei of columnar epithelium in BE, whereas the 
expression in the crypts is the strongest (Figure 2.d).
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ing showed proliferation of the esophageal lesions, whereas Ki67 was expressed at 
the basal membrane of squamous epithelium (data not shown), and in the nuclei of 
columnar epithelium in BE (Figure 2.d). BE was observed onwards from 5 weeks after 
GEJ in Lewis and BN rats and its incidence and length increased over time (Table 2). 
The mean length of the Barrett’s lesion was significantly different for Lewis versus BN 
rats at 9 weeks (p= 0.003), but not significantly different at 5 weeks (p= 0.875), at 12 
weeks (p= 0.080), and at 24 weeks (p= 0.061). 
There was a significant difference in the mean length of the Barrett’s lesion for 
Lewis versus Wistar rats at 5 weeks (p= 0.025), at 9 weeks (p= 0.002), at 12 weeks 
(p= 0.002), and at 24 weeks (p= 0.007). 
Expression and localization of inflammatory cells
To examine the associations between the immune response and development of 
BE, the dynamics of esophageal lesions and inflammatory cell expression were mea-
sured at 2, 5, 9, 12, and 24 weeks after GEJ in hyperplasia, ulceration and BE (Figure 
3a-f ). Cytotoxic T cells and mast cells were counted in all rats in all histological lesions 
and at all time-intervals. For macrophages a repetitive inter- and intra-observer vari-
ety occurred that made it not possible to perform cell-counting. Macrophages were 
marked as negative, moderate (10-100 positive cells/field), and high (>100 positive 
cells/field). High numbers of macrophages were seen in hyperplasia and BE of Wistar 
rats at 5 weeks, and in ulcerations at 9, 12, and 24 weeks after GEJ (figure 4.a). High 
numbers of macrophages were observed in hyperplasia of Lewis rats at 2, 5, 12, and 
24 weeks, in ulcerations at 9, 12, and 24 weeks, while in BE only low to moderate 
numbers of macrophages were found (Figure 4.a). High numbers of macrophages 
were observed in hyperplasia of BN rats at 9 and 12 weeks, in ulcerations at 2, 5, 9, 12, 
and 24 weeks, while in BE only few macrophages were seen (Figure 4.a). 
High numbers of cytotoxic T cells were observed in hyperplasia of BN rats at 9 
weeks, in contrast to Lewis rats at 2, 5, 9, and 24 (p=0.06) weeks, however due to 
the low number of animals per group, statistical differences could not be shown 
(Figure 4.b). High numbers of cytotoxic T cells were observed in ulcerations of BN 
rats at 9 weeks, but moderate numbers at 2, 12, and 24 weeks. There was no sta-
tistical difference among BN rats at 24 weeks between hyperplasia and ulceration 
(p=0.06). Only at 12 weeks higher numbers of cytytoxic T cells were observed in 
Lewis rats (Figure 4.b). High numbers of cytotoxic T cells were also observed in BE 
of BN rats at 24 weeks, while lower numbers were observed at 9 and 12 weeks com-
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pared to Lewis rats (Figure 4.b). There was no statistical difference among Lewis rats 
at 12 weeks between ulcerations and BE (p=0.07).
The number of mast cells were equally presented in both hyperplasia and ul-
Figure 3. 
Inflammatory cell expression was measured at 2, 5, 9, 12, and 24 weeks after GEJ in hyperplasia, ulceration 
and BE. Figure 3.a shows a brown-red staining of cytotoxic T cells in the submucosa of hyperplastic esopha-
geal tissue. Figure 3.b shows a brown-red staining of cytotoxic T cells in the whole ulcerative tissue. Figure 3.c 
shows a brown-red staining of cytotoxic T cells in the submucosa of BE. Figure 3.d shows a brown-red stain-
ing of mast cells in the submucosa of hyperplastic esophageal tissue. Figure 3.e shows a brown-red staining 
of cytotoxic T cells in the whole ulcerative tissue. Figure 3.f shows a brown-red staining of cytotoxic T cells in 
the submucosa of BE. 
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Figure 4 
Macrophages were seen more often in hyperplasia 
and ulceration compared to BE (figure 4.a). Lewis 
rats showed the strongest expression in hyperplasia 
at 2, 5, 12, and 24 weeks, in ulceration at 9, 12, and 
24 weeks, and few macrophages were seen in BE at 
12 and 24 weeks. Wistar rats showed the strongest 
expression in hyperplasia at 5 weeks, in ulceration at 
9, 12, and 24 weeks, and in BE at 5 weeks. BN rats 
showed the strongest expression in hyperplasia at 9 
and 12 weeks, in ulceration at 9, 12, and 24 weeks, 
and few macrophages were seen in BE at 12 and 24 
weeks. (Figure 4.a). 
Cytotoxic T cells were observed strongly in hyperpla-
sia and ulceration of BN rats at 9 weeks, and in BE 
of BN rats at 24 weeks. Lewis rats express more cyto-
toxic T cells in BE at 9 and 12 weeks (Figure 4.b).
Mast cells were almost equally observed in hyperpla-
sia and ulceration of BN and Lewis rats at the time-
line. Lewis rats express more mast cells at 9 weeks 
than at 12 weeks in ulceration (*p<0.001), and in 
BE at 9 and 12 weeks, whereas BN rats express more 
mast cells in BE at 24 weeks (Figure 4.c).
A
C
B
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ceration of BN and Lewis rats at the timeline, with higher numbers being seen at 9, 
12, and 24 weeks (Figure 4.c). There was a statistically significant difference among 
Lewis rats between 9 and 12 weeks in ulcerations (*p<0.001). There was no statisti-
cal difference among BN rats between 5 and 24 weeks in hyperplasia (p=0.06). The 
highest number of mast cells was observed in BE of BN rats at 24 weeks, but lower 
numbers were observed at 9 and 12 weeks compared to Lewis rats  (Figure 4.c).
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Discussion
We found that surgically induced chronic reflux in genetically different rats induced 
esophagitis leading to BE in all species. This process was associated with an active 
immune response. We found that all Th1 prone Lewis rats developed BE at 12 weeks 
after GEJ compared to 50% of Th2 prone BN rats and 33% of intermediate Wistar 
rats. Lewis rats also tended to develop a larger Barrett segment, implying that a Th1 
predisposition is likely to be associated with the development of BE. 
Depending on the predisposition of the Th1/Th2 immune response, an antigenic 
stimulus is likely to be presented  to different effector cells, i.e., monocytes/ mac-
rophages (CD68) and cytotoxic T cells (CD8) in animals with a preferential Th1 re-
sponse and mast cells (CD93) in animals with a Th2 response. The Th1 effector cells 
were seen at the onset of the hyperplasia-esophagitis-BE cascade and Th1 prone 
Lewis rats expressed macrophages in an early stage compared to BN and Wistar rats. 
The high number of cytotoxic T cells in BE of BN rats indicate that Th2-prone ani-
mals are indeed able to generate a strong Th1 response. The number of mast cells 
increased in the hyperplasia-esophagitis-BE cascade and over time this was found in 
both Lewis and BN rats. Lewis rats had significantly more mast cells in esophageal ul-
cerations at 9 weeks compared to 12 weeks (p<0.001) and activated the mast cells in 
BE earlier than BN rats. Therefore, Lewis rats expressed an early Th1 immune response 
in hyperplasia and a strong and early Th2 immune response in BE.
This study was performed using an established surgical rat model for reflux 
esophagitis 20, 21. In a pilot study, we used Wistar rats in order to test the effect of 
the surgical technique. This confirmed earlier findings that rats with esophago-
jejunostomy and ligated stomach without gastrectomy showed the same his-
tology at 0, 3, and 6 months after surgery as rats undergoing esophagojejunos-
tomy with gastrectomy 21. The pH of the reflux was measured with pH paper 
strips (AlkaLife, Eindhoven, The Netherlands) at the surgical anastomosis and 
more proximal in the esophagus and confirmed that the pH showed a value of 
approximately 6.0 at all times. We did not find a variety in acidity in the reflux-
ate comparing the two different surgery techniques (data not shown). How-
ever, more animals died after ligation of the stomach because of either necrosis 
or perforation of the stomach. 
In present study, we ended up with a relatively low cohort of animals as a result 
of the low survival rate. The number of animals in all groups was however sufficient 
56
Chapter 3
to perform our statistical analysis and showed significant differences between the 
rats strains and in some cases between the various immune cells.
It is commonly accepted that the ability of a rodent to make Th1 or Th2 re-
sponses is influenced by animal housing conditions 23. Indeed, various studies have 
demonstrated that prophylactic or therapeutic feeding of self-peptides to rodents 
could prevent experimental autoimmune diseases of various kinds 24, 25. The regula-
tory T cells, induced by antigen feeding, that prevented these autoimmune diseas-
es were generated in Peyer’s Patches and had the characteristics of Th2 cells or Th3 
cells 24, 25. Functionally, these cells down-regulated the activity of tissue-damaging 
Th1 cells by secreting cytokines such as TGF-β 25. While others have suggested that 
environmental factors such as hydrophobic bile acids and zinc deficiency play a 
crucial role in BE development 26, all animals in our study were kept under the same 
housing conditions and feeding, which allowed us to study only the differences 
resulting from the Th1 and Th2 prone immune response in the rat strains.
We are aware that a rat model can only mimic human disease. Rat esophagus 
and the proximal part of the stomach are non-glandular, thus the anatomy differs 
from that in humans. However, the lymphoid aggregates, which develop during 
the inflammatory processes, closely resemble those of human secondary lymphoid 
tissue 14. This supports the hypothesis that human isolated lymph follicles play a 
role in the development of BE and might be a possible diagnostic criterion 27.
In a previous rat model study, a larger BE segment in BN rats compared to 
Sprague-Dawley rats was found. In contrast to pro-inflammatory cytokines, the 
Th2 cytokines such as IL-10 are increased in BE as compared to the levels in normal 
esophagus and esophagitis 28. With regard to ranking of Th1/Th2 predisposition in 
rat strains (Figure 1 15-19), it is suggested that Sprague-Dawley rats are intermedi-
ate in the preference for a Th1 or Th2 immune response, thus comparable with 
Wistar rats. The present study also indicates that regarding BE the incidence was 
indeed more common and extent larger in Th2 prone BN rats than in intermedi-
ate Wistar rats. This is accompanied by infiltration of the BE mucosa with relatively 
high numbers of Th2 effector cells such as plasma cells and mast cells, although the 
absolute numbers of Th1 effector cells such as macrophages and cytotoxic T cells 
may also be high in BE. This is in line with previous human studies 13 14. Therefore, 
we expected the Th2 immune response to play a key role in the development of 
BE. However, in present study the Th2 -prone BN rats expressed more Th1 effector 
cells in BE, while the Th1-prone Lewis rats expressed more Th2 effector cells early 
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in BE. This suggests that the Th2 immune response plays a major role in BE, but still 
Th1-prone rats were found to be more susceptible to develop BE. 
Polymorphism studies have suggested that hereditary or acquired individual 
differences, i.e. in immunological parameters, are associated with the development 
of BE 29. Interestingly, when comparing BE between the three rat strains, the inci-
dence was more common and extent of BE was larger in Lewis rats than in Wistar 
and BN rats. Since Lewis rats are known to be genetically Th1 predisposed, it ap-
pears that genetic differences in the immune response is involved in the develop-
ment of BE 30. The pathogenesis of the effect of the Th1 immune response on the 
development of BE remains unknown and needs further study.
In conclusion, this study shows that the genetic Th1 immune status of Lewis 
rats resulted in an earlier and more extended development of BE. This suggests 
that while BE patients have a Th2-type chronic inflammation in the esophagus, pa-
tients with a Th1 immune status might be more susceptible to the development 
of BE than Th2 prone patients. Identification and eventually inhibition of the im-
munological and genetic mechanisms might generate novel targets for BE and 
esophageal cancer prevention.
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Abstract
Objective: Esophageal cancer development is a sequence that starts with re-
flux esophagitis (RE), followed by Barrett’s esophagitis (BE), dysplasia, and finally 
esophageal adenocarcinoma (EAC). Tumor necrosis factor (TNF) is a potent anti-
neoplastic agent, hence DNA-polymorphisms that reduce TNF levels potentially 
enhance development of BE and EAC. The aim of this study was to determine the 
impact of TNF gene variation on the RE-BE-EAC cascade.
Methods: DNA from 887 Caucasian participants (197 controls, 305 RE, 257 BE, 128 
EAC) was tested for the gene polymorphism TNF-b NcoI, and TNF production was 
determined by TNF-a specific immunohistochemistry on esophageal biopsies from 
these BE (n=31) and EAC (n=4) patients.
Results: As compared to healthy controls the TNF-b NcoI A/A genotype was sig-
nificantly more prevalent in BE (p=0.04) and EAC patients (p=0.02), but not in RE 
patients (p=0.1). While TNF-a protein levels were invariably high in esophageal bi-
opsies from EAC patients, most esophageal BE samples showed low to moderate 
TNF levels. 
Conclusions: Chronic inflammation, like in BE, markedly increase the risk of malig-
nant transformation. In this study, the significantly higher frequency of the TNF-b 
NcoI A/A genotype and the local TNF expression indicate that the pro-inflammato-
ry cytokine TNF plays a role in the development of BE and EAC.
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Introduction
Esophageal adenocarcinoma (EAC) is the fastest rising malignancy of the Western 
world 1. EAC frequently arises from Barrett’s esophagus (BE), a chronic inflamma-
tory condition characterized by a change in the normal esophageal epithelium into 
reflux esophagitis (RE) and intestinal metaplasia as a result of gastroesophageal 
and bile reflux  2, 3, and genomic instability 4. 
Both epidemiologic and functional studies have implicated chronic inflamma-
tion in the development of liver, esophagus, stomach, and colon cancer 5. During 
this process, deregulated cytokine function between the immune and neoplastic 
cells can alter cell growth, differentiation, and apoptosis 6.
Tumor necrosis factor (TNF) is a key cytokine in both systemic inflammatory 
responses and anti-tumor activity 6, 7. Esophageal TNF expression is responsive to 
local concentrations of reflux components 8 and inflammatory cytokines 9, but is 
also controlled on a genetic level. A polymorphism in the promoter region of the 
TNF-b gene (Figure 1) 10 affects both the production of TNF-a and TNF-b 11, 12, and 
deregulation has been associated with an increased risk of intestinal cancer devel-
opment 13, 14.
Present study assessed the association of the TNF-b (NcoI) polymorphism, and 
the local effect on TNF production in the RE-BE-EAC cascade.
Figure 1 
Genomic organization of the TNF genes in the MHC class III region at chromosome 6 (6p21). The location 
of MHC class I and II genes is indicated. Closed boxes refer to untranslated parts; open boxes to exons. The 
position of the bi-allelic NcoI restriction fragment length polymorphism in the first intron of the TNF-b gene 
is shown by the notation above the figure.
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Material and methods
Study design
Between November 2002 and March 2006, all sequential patients with RE, BE, 
and EAC who visited the endoscopy unit of the Erasmus MC – University Medical 
Center Rotterdam or the IJsselland Hospital, Capelle aan den IJssel were invited to 
participate in this study. Participants underwent upper endoscopy for evaluation 
of reflux-related symptoms, surveillance of BE, or odynophagia or dysphagia. The 
presence of RE was confirmed at endoscopy and the length of any columnar-lined 
segment was determined by measuring the distance between the squamo-colum-
nar junction and the proximal margin of the longitudinal gastric folds. Participants 
were only included if they had i) RE without the presence of BE, ii) BE defined as 
a columnar lined segment in the esophagus of ≥ 2 cm in length with specialized 
intestinal metaplasia at histology found in at least one of the biopsies taken, or iii) 
EAC defined at histology as an adenocarcinoma in BE or adenocarcinoma of the 
gastro-esophageal junction with more than 50% of the tumor mass in the esopha-
gus. Biopsies were taken from patients with macroscopic signs of columnar meta-
plasia. Only samples from patients with histological BE were included in the BE 
group, but due to our criteria patients who only had histological evidence for BE at 
the z-line or at <2cm from the z-line were excluded from our study. In the patient 
population that we studied there were two patients with BE at 1cm and two with 
BE at 0cm. These four patients were excluded from our study.
Between October 2004 and April 2005, healthy volunteers (referred to as normal 
control subjects) were recruited from the general population via general practitioner 
practices. They were assessed by means of a questionnaire and were eligible as con-
trol if they had a negative history for reflux symptoms and of esophageal diseases. 
Patients who ever had reflux complaints, retrosternal pain, or regurgitation were ex-
cluded from the control group, as well those who used antacids, H2-receptor antago-
nists, or proton pump inhibitors. 
This study was approved by the local institutional review boards of the participat-
ing centers. All participants were genetically unrelated Dutch Caucasians, and aged 
over 18. Prior to inclusion, all participants signed a written informed consent.
Genotyping of the TNF (NcoI) polymorphism
Genomic DNA was extracted from 5 ml of whole blood by standard procedures 
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(Wizard Genomic DNA Purification-kit; Promega, Madison, WI). Single nucleotide 
polymorphism (SNP) analysis of TNF-b (+252A/G) genotypes was performed on 20 
ng DNA (Kbiosciences, Herts, UK) with a competitive allele-specific PCR system 15 
by a technician unaware of the clinical findings for these patients.
Immunohistochemical analysis of TNF
From the 257 BE patients we selected those from which sufficient biopsy mate-
rial from the BE segment was available (n=31) to further study TNF expression by 
immunohistochemistry. Exclusion criteria were BE patients using any type of acid 
suppression as medication. Paraffin samples were cut at 4mm, deparaffinized in xy-
lene, hydrated using a graded series of alcohol, and stained with hematoxylin and 
eosin (H&E). An expert gastrointestinal pathologist blinded for the results of the 
genotyping, scored all H&E slides for squamous epithelium, RE, BE, and EAC. The se-
quential paraffin slide was used for TNF staining after inactivation of endogenous 
peroxidase activity with 1% H2O2 in 100% methanol for 30 minutes. Subsequently 
antigen retrieval was performed by boiling the slides in 10mM monocitric acid (pH 
6.0) for 15 minutes, and allowing them to slowly cool down to room temperature. 
The slides were then blocked with non-immune serum for 20 minutes at room 
temperature. The sections were stained with a primary antibody against TNF-a 
(mouse-anti-human TNF; 1:100 dilution; ImmunoTools, Friesoythe, Germany). Bind-
ing of the primary antibody was visualized by the addition of a secundary biotiny-
lated antibody (goat-anti-mouse IgG1; 1:200 dilution; DAKO, Glostrup, Denmark), 
and streptavidin-avidin-biotin-complex labeled with horseradish peroxidase (strep 
ABComplex; 1:200 dilution; DAKO). EAC biopsies (n=4 patients) were used as a posi-
tive control.
Two independent observers (VM, KvZ) evaluated the sections of the immuno-
histochemical stainings. The slides were assessed using a Zeiss microscope (Ax-
ioskop 20, Carl Zeiss, Sliedrecht, The Netherlands) with a standard magnification 
(200x), and the images were recorded with a Nikon camera (DS-5M-U1) and Nikon 
Eclipse Net 2000 software (Nikon, Badhoevedorp, The Netherlands).
Statistical analysis
The study was powered (80%) to allow detection of a 10% difference in allele distri-
bution between the patient groups (significance level 5%). 
Differences between allele distributions of the TNF NcoI polymorphism, as well 
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as differences between the patient groups in number, age, and gender were de-
termined by Chi-square analysis. Age and sex corrected odds ratios (OR) and 95% 
confidence intervals (95% CI) were calculated for the association between healthy 
controls and RE, BE, or EAC respectively by logistic regression analysis. Disease cau-
sality was calculated for RE, BE, and EAC, being a cascade, with ordinal regression. A 
two-sided p-value ≤ 0.05 was considered to be statistically significant. All statistical 
analyses were conducted with the SPSS software package v11.1 (SPSS, Chicago, IL).
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Results
Patient characteristics
In total, samples of 887 persons eligible for inclusion were collected. These con-
sisted of 197 healthy controls, 305 patients with RE, 257 with BE, and 128 with EAC. 
Of the 257 BE patients, 19 were on PPI’s. The characteristics of the participants are 
summarized in Table 1. In line with previous studies 16, male gender was more com-
mon in BE (p=0.04) and EAC (p=0.001) compared to the healthy subjects and the 
RE group. On average, patients with BE (p=0.002) and EAC (p=0.002) were slightly 
older than healthy controls and RE patients (Table 1). When comparing the EAC 
group with the BE group, the expected higher age (p=0.154) and prevalence of the 
male gender (p=0.005) of EAC patients were confirmed (Table 1). 
Table 1.
Characteristics of the study population.
Patient data Control RE BE EAC
Number 197 305 257 128
Age 57±14 55±13 61±12** 63±10**
Male (%) 59 55 68* 82**
Length of BE segment (cm) N.D. 0 4.1±2.4 N.D.
*p=0.04;**p<0.001, both in comparison with controls
The TNF NcoI A/A-genotype is more frequent in RE, BE, and EAC
Using the healthy controls as the reference, the association of a TNF-b polymor-
phism was tested for patients with RE, BE, or EAC. The allele frequencies for the NcoI 
(+252A/G) polymorphism (rs909253) among the 197 unrelated Dutch Caucasian 
controls was 39.1% (G) and 60.9% (A) respectively (Table 2). The allele frequency of 
the major allele (A) was 66.2% in RE, 69.5% in BE, and 71.1% in EAC (Table 2). The 
distribution of genotype frequencies for the polymorphism investigated was con-
sistent with Hardy-Weinberg equilibrium in both the patient and control groups 
(p>0.05).
Comparing the raw data of the patient groups with the controls suggested that 
TNF-b (NcoI) A/G heterozygosity was observed more frequently in BE (OR=1.60; 
95% CI:1.07-2.38) and EAC (OR=1.66; 95% CI:1.04-2.67), but not in RE (OR=1.23; 95% 
CI:0.83-1.80) (Table 3.a). However, after correction for age and gender between the 
four study groups the TNF-b (NcoI) A/A genotype was significantly more common 
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in BE (OR=1.98; 95% CI:1.03-3.81) and EAC (OR=2.87; 95% CI:1.17-7.05), but not in 
RE (OR=1.69; 95%CI:0.91-3.15) as compared to the control group (Table 3.b). The 
associated odds ratios significantly differed from controls for both BE (p=0.04) and 
EAC (p=0.02). The A allele shift towards BE and EAC indicates that the A/A genotype 
is predominantly associated with the presence of BE and EAC (Figure 2). Figure 2 
shows the ordinal regression of disease and points out a decrease of RE and an 
increase of BE and EAC towards the A/A genotype. Thus, the balance in the RE-BE-
EAC cascade is more on the RE side for the G/G genotype and shifts towards BE and 
EAC for the A/G group and even more for the A/A group.
Figure 2
Distribution of the polymorphism in the TNF-b gene over the four study groups. The Odds Ratios show an 
increased risk for the development of BE and EAC, 2.0 and 2.9 respectively, in the homozygous A/A group 
compared to the healthy controls. An increase of the A allele can be observed.
Table 2. 
Percentage distributions for the alleles of the TNF-b polymorphism tested
Alleles Controln=197
RE
n=305
BE#
n=257
EAC
n=128
A/A 69 (35%) 126 (41%) 122 (48%) 63 (49%)
A/G 102 (52%) 152 (50%) 113 (44%) 56 (44%)
G/G 26 (13%) 27 (9%) 22 (9%) 9 (7%)
Allele frequency
A 0.609 0.662 0.695 0.711
G 0.391 0.338 0.305 0.289
# 31 random patients were tested for histological TNF expression
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The TNF polymorphism is associated with gender
The RE-BE-EAC disease cascade is thought to progress more rapidly in males than 
in females 17. This suggests a stronger correlation between causative agents and 
disease in males than in females. We tested for gender specific differences in dis-
ease stage distribution between the TNF-b (NcoI) genotypes.
Figure 3 divides the 3 genotypes for RE, BE and EAC in female (Figure 3.a) and 
male (Figure 3.b) patients. The Y-axis represents the chance of disease development 
in percentages and on the X-axis the age is shown. The genotypes are grouped per 
disease as A/A with black symbols, A/G with openwork, and G/G with gray sym-
bols. Females with RE cross all BE genotypes around the age of 80, with the A/A 
genotype (black symbols) for RE and BE crossing at youngest age (Figure 3.a). This 
indicates that females with RE and the A/A genotype have a stronger causative 
relation with BE than the A/G and G/G genotype. BE and the EAC genotypes never 
cross before the age of 80, which means that there seems no causality between 
BE and EAC in females, but the causality between these diseases could appear at a 
higher age.
On average, the males in our study population seemed to develop BE at the age 
of 55 (Figure 3.b). However males with the A/A genotype do so at a younger age than 
males with an A/G or G/G genotype. Likewise the average age of EAC development is 
around 75 years of age, with the A/A genotype crossing some years earlier than the 
Table 3.a 
Comparison of the Odds Ratios calculated for the genotypes in the TNF-b polymorphism
Genotype RE vs controlOR (95%CI)
BE vs control
OR (95%CI)
EAC vs control
OR (95%CI)
A/A 0.70 (0.39-1.26) 0.76 (0.41-1.43) 0.63 (0.28-1.44)
A/G 1.23 (0.83-1.80) 1.60 (1.07-2.38)* 1.66 (1.04-2.67)**
G/G^ 1 (control) 1 (control) 1 (control)
^ Minor allele; *p=0.04; **p=0.02
Table 3.b 
Odds Ratios after correction for age and gender
Genotype RE vs controlOR (95%CI)
BE vs control
OR (95%CI)
EAC vs control
OR (95%CI)
A/A 1.69 (0.91-3.15) 1.98 (1.03-3.81)* 2.87 (1.17-7.05)**
A/G 1.41 (0.77-2.56) 1.24 (0.66-2.35) 1.71 (0.70-4.16)
G/G^ 1 (control) 1 (control) 1 (control)
^ Minor allele; *p=0.04; **p=0.02
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A/G and G/G genotypes. These results indicate that male RE patients with a TNF-b 
(NcoI) A/A genotype have an increased risk for the development of BE into EAC.
RE, BE and EAC patients were then grouped together and compared for their 
TNF-b (NcoI) genotype with the healthy controls as a reference. TNF-b (NcoI) A/A ho-
mozygosity was significantly more frequent in the diseased group (OR=2.26; 95% 
CI:1.30-3.93), whereas the TNF-b (NcoI) A/G heterozygotic group was not (OR=1.15; 
95% CI:0.89-2.59) (Table 4).
Figure 3
Causality for esophageal disease in females (A) and males (B). The RE-BE-EAC cascade represents a causal re-
lation when the lines cross. The age is shown on the X-axis and the chance of developing esophageal disease 
is shown as percentage on the Y-axis. 
A: The genotypes for RE and BE in females cross around the age of 80 years, and the A/A genotype (black) 
crosses at younger age when compared to the A/G and G/G genotype. The genotype-lines for BE and EAC in 
females never cross. 
B: The genotypes for RE and BE in males cross between 50 and 55 years, and the A/A genotype (black) crosses 
at youngest age when compared to the A/G and G/G genotype. The genotype-lines for BE and EAC in males 
cross at approximately the age of 70, and again at youngest age for the A/A genotype.
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Differences in TNF levels between BE and EAC
We then sought to determine both the intensity and the histological site of TNF 
expression in BE mucosa by TNF-a specific immunohistochemical staining (Figure 
4). EAC biopsies (n=4 patients) were used as a positive control and showed a strong 
TNF-a expression throughout the mucosa and submucosa (Figure 4.d). Typical ex-
amples of subsequently a negative, mild, and strong TNF-a expression (brown) in 
several BE sections are shown in Figure 4.a-c.
The staining for TNF-a was negative in 5/31 patients, including 2 patients from 
the A/A, and 3 patients from the A/G group. Mild TNF-a expression (19/31) was only 
seen in the homozygous groups, namely 9 with the A/A genotype and 10 with the 
Table 4. 
Odds ratios for the presence of the different TNF-b genotypes among patients with esophageal disease 
versus healthy controls
Genotype Disease group vs controlsOR (95%CI)
Significance 
p-value
A/A 2.26 (1.30-3.93) 0.004
A/G 1.15 (0.89-2.59) 0.130
G/G^ 1 (control) 0.008
^ Minor allele
Figure 4
Typical examples of the TNF-a expression (brown) in BE sections. A negative staining (5.a), a mild staining in 
crypts and inflammatory cells (5.b), and a strong staining (dark brown) (5.c) are shown. TNF-a over-expres-
sion (dark-brown) in all crypt- and inflammatory cells is seen in EAC (5.d).
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G/G genotype. Strong TNF-a expression was found in 7/31 patients of whom only 1 
belonged to the homozygous A/A group, 3 to the A/G, and 3 to the G/G genotype. 
Overall, there was a trend with the homozygous A/A group showing the lowest 
TNF-a expression while the highest expression was observed in the homozygous 
G/G group. 
When analysing the tissue histology of the patients tested for TNF-a expression it 
was noted that the negative TNF score showed three patients without any pre-malig-
nant tissue changes, one with hyperplasia and one with hyperplasia and ulceration; 
the mild TNF score showed twelve patients without tissue changes and seven with 
hyperplasia; the strong TNF score showed three patients without tissue changes, one 
with hyperplasia and five with hyperplasia and papillomatosis. The tissue inflam-
mation shows a trend towards normal tissue without TNF expression, and stronger 
inflammation (hyperplasia, papillomatosis and ulceration) in strong TNF expression. 
This means that the inflammation correlates with the TNF expression.
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Discussion
BE is a pre-malignant esophageal condition and the main risk factor for develop-
ing EAC. The progression from reflux esophagitis (RE) towards EAC follows a se-
quence of stages, including RE, BE, dysplasia, and eventually EAC 2, 18, 19. The exact 
mechanism through which RE predisposes to EAC is currently unknown, but it has 
recently been shown that the chronic esophageal inflammatory characters of RE 
and BE play a crucial role in this process 3, 20. 
Several studies showed that BE was associated with a pro-inflammatory geno-
type and a predominantly humoral immune response 21-23.
TNF, a pro-inflammatory cytokine 24, initiates signals for controlled cell prolifera-
tion and apoptosis to prevent cells for the pathogenesis of inflammatory, autoim-
mune, and malignant diseases 10. TNF-a is expressed in the esophagus in response 
to inflammation, and it has been shown that TNF levels increase along the RE-BE-
EAC cascade 24-26. TNF gene polymorphisms that reduce the expression of TNF have 
been shown to contribute to the severity of infectious diseases and cancer 25. We 
postulated that the BE and EAC development is largely dependent on the indi-
vidual immune responses in the presence of RE. In this study we tested for an as-
sociation between the functional TNF-b NcoI polymorphism, that decreases TNF 
production and its susceptibility for BE and EAC development in RE.
The allele frequencies among our 197 Dutch Caucasian healthy subjects for the 
TNF-b (NcoI) polymorphism (rs909253) was 39.1% (G) and 60.9% (A), respectively, 
which is similar to the European HapMap distribution of 35.8% (G) and 64.2% (A) 27. 
The distribution of the three genotypes in the healthy cohort was G/G (13.2%), A/G 
(51.8%), and A/A (35%), which was also similar to the observed distribution in the 
European HapMap with 8.3% for G/G, 55% for A/G, and 36.7% for A/A. The slightly 
lower prevalence of both the G allele and G/G genotype in the European HapMap 
cohort compared to our healthy controls could be explained by the composition 
of the cohort, because the Hap Map project did not exclude reflux disease patients 
(Table 2). We therefore conclude that in spite of its relative small size our control 
population is a valid representation of the Dutch population. 
The sequential RE, BE, and EAC patients who visited our endoscopy unit were 
included. This means that some patients were already in surveillance programs, 
but this did not lead to bias in age, gender or genotype. The age of our study 
groups is similar to the age in previous studies that describe the incidence and 
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prevalence of BE and EAC 17, 28, 29. The mean age at BE presentation is 55y. As above-
mentioned, the genotype distribution has been compared with the European Hap-
Map population and did not show (statistical) difference 27.
As compared to healthy controls the TNF-b NcoI A/A genotype was significantly 
more prevalent in BE (48%; p=0.04) and EAC patients (49%; p=0.02), but not in RE 
patients (41%; p=0.1). Thus, the homozygous A/A genotype was associated with 
an increased risk of 2.0 for BE, and 2.9 for EAC development, but there was no as-
sociation with RE (Table 3.b). Above results indicate that the TNF-b A/A genotype 
predisposes to reflux related complications such as BE and EAC in the presence of 
gastroesophageal reflux, rather than that it predisposes to RE itself. 
Males with an A/A genotype seem to develop BE and EAC at an earlier age then 
those with the A/G or G/G genotype (Figure 3.b). In women, this correlation be-
tween genotype and onset was only observed for BE, but not for EAC. This may be 
due to the fact that women tend to develop BE and EAC at later age 17, resulting in 
significantly less women with BE and EAC in our study cohort. 
We did not attempt to make a statistical analysis of the histological TNF-a ex-
pression, because the number of available biopsy samples was too small. Unfortu-
nately, we did not succeed to develop a reproducible esophageal TNF-b staining. 
While indeed an omission we believe that not testing for immunohistological TNF-b 
expression is only a minor problem because the functional TNF polymorphism af-
fects both the TNF-a and the TNF-b level and therefore determining only TNF-a will 
provide us with a global idea of the total TNF production.
In our cohort, local TNF-a protein expression was invariably high in esophageal 
biopsies from EAC patients whereas it displayed marked variation in BE patients. In 
line with our study, a previous study showed that local TNF-a expression was up-
regulated in the progression of BE to EAC compared with normal squamous mu-
cosa, but expression of TNF-a was not increased in RE patients 24. EAC is seen as an 
immunological tumor 30, however the exact mechanism remains unknown. Cancer 
in BE arises through a sequence of genetics that endow the cells with six essential 
physiologic hallmarks of cancer; the ability to proliferate without exogenous stimula-
tion, to resist growth-inhibitory signals, to avoid triggering apoptosis, to resist cell 
senescence, to develop new vascular supplies (angiogenesis), and to invade and me-
tastasize 31. Under normal conditions, the esophageal mucosa is in a state of ‘control-
led’ inflammation regulated by a delicate balance of pro-inflammatory and anti-in-
flammatory cytokines. An environment with low levels of TNF-a is in imbalance and 
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cannot activate an optimal proliferation and apoptosis via the MAPK-pathway, NF-κB 
pathway, or TNFR superfamily. Hence, any aberration in the degradation of TNF-a can 
ultimately cause an increase in oncogene activation. In this study, we presented the 
lowest local TNF-a expression in BE tissue of the homozygous A/A group, indicating 
that people with a genetically determined down-modulation of TNF-a expression 
are more prone to develop BE and subsequently EAC.
In future studies, it might be relevant to investigate the TNF levels in inflamed 
esophageal squamous mucosa in BE patients to that of RE patients for evaluating a 
relation between disease causality and TNF genotypes. Unfortunately, we did not 
have a high number of RE biopsies nor squamous mucosa from BE patients of our 
polymorphism cohort, so that the relation between the TNF levels of these cohorts 
could not be investigated.
In conclusion, we demonstrate that the homozygous A/A TNF-b genotype is 
associated with a significantly increased risk for the development of BE and EAC as 
compared to the healthy population indicating that individual differences in TNF 
expression levels are important determinants in the development of EAC.
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Abstract
Background: The continuous exposure of esophageal epithelium to refluxate may 
induce ectopic expression of bile-responsive genes and contribute to the devel-
opment of Barrett’s esophagus (BE) and esophageal adenocarcinoma. In normal 
physiology of the gut and liver, the nuclear receptor Pregnane X Receptor (PXR) is 
an important factor in the detoxification of xenobiotics and bile acid homeostasis. 
This study aimed to investigate the expression and genetic variation of PXR in re-
flux esophagitis (RE), Barrett’s esophagus (BE) and esophageal adenocarcinoma.
Methods: PXR mRNA levels and protein expression were determined in biopsies 
from patients with adenocarcinoma, BE, or RE, and healthy controls. Esophageal 
cell lines were stimulated with lithocholic acid and rifampicin. PXR polymorphisms 
25385C/T, 7635A/G, and 8055C/T were genotyped in 249 BE patients, 233 RE pa-
tients, and 201 controls matched for age and gender.
Results: PXR mRNA levels were significantly higher in adenocarcinoma tissue and 
columnar Barrett’s epithelium, compared to squamous epithelium of these BE pa-
tients (p<0.001), and RE patients (p=0.003). Immunohistochemical staining of PXR 
showed predominantly cytoplasmic expression in BE tissue, whereas nuclear ex-
pression was found in adenocarcinoma tissue. In cell lines, stimulation with litho-
cholic acid did not increase PXR mRNA levels, but did induce nuclear translocation 
of PXR protein. Genotyping of the PXR 7635A/G polymorphism revealed that the G 
allele was significantly more prevalent in BE than in RE or controls (p=0.037).
Conclusions: PXR expresses in BE and adenocarcinoma tissue, and showed nuclear 
localization in adenocarcinoma tissue. Upon stimulation with lithocholic acid, PXR 
translocates to the nuclei of OE19 adenocarcinoma cells. Together with the ob-
served association of a PXR polymorphism and BE, this data implies that PXR may 
have a function in prediction and treatment of esophageal disease.
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Background
Persistent regurgitation of gastroduodenal contents into the lower esophagus causes 
mucosal injury manifested as reflux esophagitis (RE).[1,2] As a complication of chronic 
RE, a Barrett’s esophagus (BE) can develop.[3,4] BE is defined as an acquired condition 
in which the stratified squamous epithelium of the lower esophagus is replaced by 
specialized intestinal epithelium.[5] It is the sole commonly recognized risk factor for 
the development of esophageal adenocarcinoma (EAC).[6, 7] While the importance 
of acid and bile exposure in the development of BE is well established,[1,5,9,10] only 
a small percentage of BE patients will ultimately develop EAC. It remains largely un-
clear which factors control the rate of neoplastic progression in BE.[11] A growing 
body of evidence suggests that the intrinsic adaptive response to the toxic bile acids 
from the gastroduodenal contents is unable to prevent injury to the esophageal lin-
ing, thus suggesting a role for bile-induced signaling in the progression of BE.[12] 
An important step in understanding the adaptive defence mechanism against 
toxic substances has been the identification and characterization of the nuclear 
pregnane X receptor (PXR).[13-16] PXR belongs to the nuclear receptor subfamily 
of ligand-activated transcription factors that play a key role in the regulation of bil-
iary transport systems and enzymes that confer a protective role against toxic bile 
acids.[12] This group of nuclear receptors includes the constitutive androstrane 
receptor and the vitamin D receptor.[17,18] In humans, PXR is most abundantly 
found in the liver, the small intestine and the colon.[13,15,16,19] It is activated by 
a structurally diverse array of xenobiotics and endogenous compounds, including 
bile acids and steroid hormones.[13,17,18] Variability at the PXR genetic locus is 
therefore thought to be associated with pathophysiological changes in steroid, 
cholesterol or bile acid levels.[14] Polymorphisms in the PXR gene are associated 
with diseases such as inflammatory bowel disease and primary sclerosing cholan-
gitis.[20,21] As these chronic inflammatory diseases are associated with aberrant 
bile acid metabolism, there may also be a link between PXR and BE. 
The specific aim of this study was to explore the expression and distribution of 
PXR in BE and adenocarcinoma patients and analyse possible associations in the 
PXR gene with esophageal disease. We show that PXR expresses in tissue of BE 
and adenocarcinoma patients, and nuclear translocation in esophageal adenocar-
cinoma cells through bile acid stimulation. In addition, a link between PXR poly-
morphisms and esophageal disease was found.
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Methods
Human specimens
For immunohistochemistry, biopsies were taken of adenocarcinoma tissue (n=19), 
columnar epithelium from BE patients (n=28) and squamous epithelium from RE 
patients (n=8). As healthy controls we included subjects that had no gastroesopha-
geal reflux disease (GERD) symptoms or endoscopically detected aberrations of 
the esophagus (n=3). Table 1 gives patient characteristics of the population used 
for analysis of PXR mRNA levels. mRNA levels were determined in a total of 119 
esophageal samples, counting biopsies from 11 adenocarcinoma patients, dupli-
cate biopsies of both the squamous and the columnar epithelium from BE patients 
(n=21), squamous epithelium of RE patients (n=7), and squamous epithelium of 
healthy controls (n=5) without GERD symptoms or endoscopically detected aber-
rations of the esophagus. All BE patients had histologically confirmed intestinal 
metaplasia without high-grade dysplasia.
Characteristics of the group included in this study for genotyping are shown in 
Table 2. The total of 683 genetically unrelated Caucasians included 249 BE patients, 
233 RE patients and 201 controls without any history of GERD symptoms, who all vis-
ited the endoscopy unit of the Erasmus MC-University Medical Center Rotterdam or 
the IJsselland Hospital in Capelle aan den IJssel between November 2002 and Febru-
ary 2005.[22] This study was approved by the institutional ethics review committees, 
and all patients gave informed consent before participating in the study. 
Table 1 
Patient characteristics for PXR mRNA analysis 
RE
(n=7)
BE
(n=21)
EAC
(n=11)
Age, y (range)* 43 (21-60) 61 (34-78) 62 (42-73)
Male, (%)* 71 71 82
Type of epithelium Sq Sq, CE tumor
Abbreviations: RE=reflux esophagitis; BE=Barrett’s esophagus; EAC=esophageal adenocarcinoma; 
Sq=squamous epithelium; CE=columnar epithelium
*Groups did not differ significantly in gender. As expected, BE and EAC patients were somewhat older 
than RE patients
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Cell lines
The human adenocarcinoma cell line OE19 and human squamous epithelial cell line 
HET1A were obtained from the ATCC. OE19 cells were grown in RPMI 1640 supple-
mented with 10% fetal calf serum (FCS), 2 mmol/l glutamine, 100 units/ml penicilline 
and streptomycin. HET1A cells were cultured in serum-free BRFF-EPM2 medium sup-
plemented with 100 units/ml penicilline and streptomycin. Cells were maintained 
routinely at 37°C in 5% CO2 humidified atmosphere. After a period of at least 24 hrs 
to allow cells to adhere they were stimulated with 10 μM of rifampicine, 50 μM litho-
cholic acid (LCA), or 50 or 100 μM taurolithochoic acid (TLCA) for 24 hrs.
Real-Time PCR mRNA quantification from human esophagus samples
Total RNA was extracted from tissue biopsies using TriReagent (Sigma, St Louis, MO) 
and purified using an RNeasy micro column kit (Qiagen, Hilden, CA). One-fortieth 
of a 1 μg cDNA synthesis reaction (iScript cDNA Synthesis Kit; Bio-Rad) was used in 
a 25 μl Real Time-PCR using SYBR GreenER (Invitrogen, Carlsbad, CA). The following 
primers were used for PXR gene amplification: 5’- ATGGCAGTGTCTGGAACTAC-3’ 
and 5’- CAGTTGACACAGCTCGAAAG-3’. Duplicate samples were run three times in 
independent PCR-runs and the average level of PXR was normalized to GAPDH us-
ing the dCt method.[23]
Immunohistochemistry
Formalin fixed, paraffin embedded, five μm sections were mouned on glass slides. 
Microwave pretreatment in glycin-HCl/EDTA buffer (50 mM Glycin, 10 mM EDTA, 
pH 3.5) was performed for 10 min. After blocking for nonspecific antibody binding, 
sections were incubated overnight at 4°C with PXR antibody (diluted 1:200, Biole-
gend; San Diego, USA), followed by a biotin-labeled mouse anti-rabbit IgG (diluted 
Table 2 
Patient characteristics per group for genotyping
HC
(n=201)
RE 
(n=233)
BE 
(n=249)
Age, y (range) 57 (18-90) 54 (19-88) 61 (33-95)
Male, (%) 57 54 69
Length of BE segment, cm (SD) na 0 4.23 (2.39)
Abbreviations: HC=healthy controls; RE=reflux esophagitis; BE=Barrett’s esophagus; na=not applicable
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1:200; Dako, Glostrup, Danmark) and streptavidin-horseradish peroxidase (diluted 
1:300, Dako) and visualized with diaminobenzidine. Aspecific background controls 
were done by omitting the primary antibody. Samples of the terminal ileum served 
as positive controls. 
Confocal microscopy
Cells were cultured on coverslips washed with phosphate buffered saline (PBS) and 
fixed with 2% paraformaldehyde for 10 min. After washing, cells were permeabi-
lized with 0.2% Triton X100 for 20 min and then blocked with 5% goat serum and 
5% normal human plasma in PBS with 5% BSA. Cells were incubated with mouse 
IgG or anti-hPXR antibody (1:200; Biolegend, San Diego, USA) at 4°C overnight and 
then probed with 1:200 dilution of goat anti-rabbit Alexafluor 594 (Invitrogen; Or-
egon, USA). Hoechst 33342 was used to stain nuclei. Coverslips were mounted onto 
glass slides with gelvatol and visualized under a Zeiss LSM 410 laser-scanning con-
focal microscope (Zeiss, Oberkochen, Germany).
Genotyping 
Genomic DNA was extracted from 5 ml of whole blood by a wizard genomic DNA 
purification kit (Promega, Madison, USA). We analyzed polymorphisms -25385C/T, 
7635A/G and 8055C/T as these should be informative for eight PXR polymorphisms 
and were observed by Zhang et al.[14] to have an effect on PXR function in hu-
mans. Assay validation setup was performed by K-Biosciences (Herts, UK) before 
performing a double blind analysis of PXR SNPs with a competitive allele-specific 
PCR system using primers designed in flanking region of the SNP located at -25385; 
TGGTCATTTTTTGGCAATCCCAGGTT[C/T]TCTTTTCTACCTGTTTGCTCAATCG at 7635; 
AGGAGCCATCCTCCCTCTTCCTCTC[A/G]CCCCCAACTTCTGGATTATGGGATG and at 
8055; GCTTGCTGAGAAGCTGCCCCTCCAT[C/T]CTGTTACCATCCACAGGTGGCTTCC 
of the PXR gene NR1I2.
Statistical analyses
The study was powered (80%) to allow detection of a 10% difference in genotype 
distribution of the PXR polymorphisms between the groups by performing Chi-
square analysis. Odds ratio (OR) and 95% confidence interval (95% CI) were calcu-
lated by risk estimate analysis. All statistical analyses were conducted using SPSS 
v11.0 (SPSS, Chicago, IL) and 2-tailed significance was taken as p<0.05. 
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Results
PXR gene expression is elevated in BE and adenocarcinoma
PXR mRNA was determined in a group of 44 subjects with different esophageal 
pathologies by Real-Time PCR (Table 1). As shown in Figure 1A, levels of PXR mRNA 
were found consistently higher in columnar tissue compared to matching squa-
mous tissue (p<0.001), in which levels of PXR transcripts were barely detectable. 
The relative levels of PXR mRNA in the BE columnar epithelium were higher than 
in squamous epithelium of RE (p=0.003, Figure 1B) and healthy controls (p=0.002, 
data not shown). Also PXR gene expression in tissue of adenocarcinoma patients 
was significantly higher than in squamous samples from BE patients and healthy 
controls. Comparing RE with controls, only one patient showed a strong increase in 
Figure 1
Relative mRNA levels of PXR in esophageal epithelium as determined by quantitative Real-Time PCR. (A) PXR 
levels in columnar epithelium (CE) are normalized to adjacent squamous epithelium (Sq) using 2(-ddCt) 
method[23] and are plotted for each of 21 Barrett’s esophagus (BE) patients. Error bars express a range which 
is a result of incorporating the standard deviation into the calculation. The mean of this population renders a 
strong significant increase of PXR mRNA levels in CE compared to Sq of BE patients (p<0.001). (B) Relative PXR 
mRNA levels are calculated using 2(-dCt). Levels in Sq from patients with reflux esophagitis, and patients with 
BE are compared to CE from the esophagus of BE patients (p=0.003 and p<0.001 respectively). mRNA levels in 
tissue from adenocarcinoma patients did not differ statistically from CE of BE patients, but was significantly 
higher than all Sq tissues.
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PXR mRNA and thus overall difference in mRNA levels between these two groups 
did not reach statistic significance (Figure 1B).
PXR protein distribution in BE and adenocarcinoma tissue
To test if the presence of PXR mRNA corresponded with the expression of PXR 
protein, esophageal biopsies of 39 patients were stained for PXR by immunohisto-
chemistry. Figure 2 depicts representative stainings of PXR on esophageal biopsy 
Figure 2 
Result of PXR immunohistochemical staining on esophageal biopsy specimens. A) Esophagus of healthy con-
trols is lined by a stratified squamous epithelium and is negative for PXR (200x). B) The esophageal mucosa of 
patients with reflux esophagitis is damaged and inflamed and demonstrates a weak signal for PXR (brown) in 
the cytoplasm of epithelium (200x). C) Barrett’s epithelium is characterized by a single layer of columnar epithe-
lium with the presence of typical goblet cells. Cytoplasmic as well as some nuclear PXR expression is observed 
(400x). D) Cells of adenoma tissue show high levels of nuclear PXR expression (400x). E) Quantification showed 
that the percentage of cases with PXR-positive nuclei was significantly higher in EAC than in BE (p<0.01).
87
Expression, localization and polymorphisms of the nuclear receptor PXR in Barrett’s esophagus and esophageal adenocarcinoma
CH  1
CH  2 
CH  3
CH  4
CH  5
CH  6
CH  7
CH  8
CH  9
specimens of healthy controls, and RE, BE, and adenocarcinoma patients. None of 
the normal squamous esophageal samples (n=3) stained positive for PXR (Figure 
2A). Also, no specific PXR signal was detected in RE samples (Figure 2B). In patients 
with histologically confirmed BE (n=28), six cases of nuclear positivity were found 
(Figure 2C). In 17/19 adenocarcinoma patients, PXR expression was observed in the 
nuclei of cancer cells (Figure 2D). This was significantly higher compared to nuclear 
PXR expression in BE tissue (p<0.01, Figure 2E).
Exposure to bile acids does not affect PXR mRNA levels, but does induce 
nuclear translocation
PXR mRNA levels were analyzed in HET1A and OE19 cells upon stimulation with 50 
Figure 3 
PXR mRNA levels and nuclear translocation of PXR protein in esophageal cell lines stimulated with bile acids. 
(A) PXR mRNA levels are significantly higher in OE19 than in HET1A (p=0.02). Bile stimulation with 50 μM or 100 
μM of TLCA did not affect PXR mRNA levels compared to unstimulated conditions. (B) After immunofluorescent 
staining of PXR (red) and nuclei (green), localization in OE19 cells was visualized by a confocal laser microscope. 
In unstimulated cells, PXR was predominantly found in the cytoplasm. Upon 24 hours of stimulation with ri-
fampicine (10 μM), LCA, or TLCA (50 μM), PXR translocated from the cytoplasm to the nuclei.
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or 100 μM TLCA. PXR levels in the OE19 adenocarcinoma cell line were higher than 
in the squamous epithelial HET1A cells (p=0.02), but mRNA levels did not differ be-
tween unstimulated cells and cells stimulated with TLCA (Figure 3A). Figure 3B shows 
immunofluorescence of PXR in the nuclei of OE19 cells. More nuclear PXR staining was 
observed in cells stimulated with 10 μM rifampicine, 50 μM LCA, and 50 μM TLCA when 
compared to unstimulated cells. PXR staining was most intense for TLCA stimulated 
OE19 cells. In summary, exposure of adenocarcinoma cells to bile acids and xenobiotics 
induces nuclear translocation of PXR independent of PXR gene levels.
PXR polymorphism 7635AG is associated with BE 
Polymorphisms at location 7635 and 8055C of the PXR gene have previously been 
found to be located in different linkage disequillibrium blocks and are thought to 
have an effect on PXR activity.[14] In our cohort the PXR gene polymorphisms were 
in Hardy-Weinberg Equilibrium. No significant association of SNP -25385C/T with 
BE or RE was found (p>0.5; data not shown). Allele frequencies of SNP 7635A/G and 
8055C/T for patient and healthy control populations are listed in Table 3. Minor al-
lele frequencies of these SNPs were in consensus with previous observations in Eu-
ropean control cohorts.[14,24,25] Subjects carrying the SNP 7635G allele had an in-
creased risk of BE (OR 1.36, 95% CI 1.03-1.79). In comparing genotype distributions, 
an increase was demonstrated in the minor allele frequency among BE patients as 
compared with RE patients and healthy controls for both 7635A/G and 8055C/T. 
For SNP 7635A/G this trend was statistically significant (p=0.037, Figure 4).
Table 3 
Allele frequencies of PXR SNPs at locus 7635 and 8055
SNP 
locus Allele
Allele, n (frequency) HC vs RE, 
OR (95% CI)
HC vs BE, 
OR (95% CI)HC RE BE
7635 AG
267 (0.674)
129 (0.326)
294 (0.636)
168 (0.364)
298 (0.603)
196 (0.397) 1.18 (0.89-1.57)
1.36  
(1.03-1.79)
8055 CT
321 (0.863) 
51 (0.137)
381 (0.832)
77 (0.168)
397 (0.814)
91 (0.186) 1.27 (0.87-1.87) 1.44 (0.99-2.10)
Abbreviations: HC=healthy controls; RE=reflux esophagitis; BE=Barrett’s esophagus
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Figure 4 
Genotype distributions of PXR polymorphisms across populations of healthy controls (HC), patients with re-
flux esophagitis (RE) and Barrett’s esophagus (BE). The distribution of AA (open), AG (crosshatched) and GG 
(diaganol stripes) at locus 7635 of the PXR gene are depicted per patient group. As the pathologic condition 
of the esophagus progresses from healthy to RE to BE, prevalence of ancestral homozygous genotype de-
creases (p= 0.037).
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Discussion
The precise pathophysiological mechanisms causing BE is still unclear, but the com-
bination of gastric acid and bile acids from the gastroduodenal reflux is commonly 
acknowledged as the key factor in the development of BE.[26] At low pH, bile acids 
are thought to cause esophageal mucosal injury, which has been substantiated 
both in vitro and in animal model systems.[27,28,29] 
The NR1I family of orphan nuclear receptors are known to prevent toxic accu-
mulations of xenobiotics within cells by regulating a broad range of cellular trans-
porters.[17, 30, 31] The nuclear receptor PXR is a member of this family and func-
tions in the enterohepatic organs as detoxifier and regulator of bile acid homeos-
tasis.[12-16] It can bind a variety of bile acids[32,33] and subsequently regulate the 
expression of a multitude proteins that transport bile acids across cell membranes.
[34,35,36] These include the multidrug resistance (MDR)1 gene,[37,38] which en-
codes the efflux protein P-glycoprotein that removes xenobiotics from cells.[39] 
Other bile acid transporters that are induced by PXR include the multidrug resist-
ance associated protein (MRP)2 and 3[40-42] and the organic anion transporting 
polypeptide (OATP)1 and 2.[42-44] From studies in mice it was concluded that the 
function of PXR is of particular importance when bile acid concentrations reach 
pathophysiologic levels.[33,45]
PXR expression is known in the liver and intestinal tract, but in cancer it has yet 
to be explored. In this study we aimed to explore the expression and significance of 
PXR in esophageal pathology. We did not detect PXR in normal squamous epithe-
lium or in the squamous epithelium of RE patients. PXR did express at both mRNA 
and protein level in columnar epithelium, and was significantly lower in adjacent 
squamous esophageal epithelium of the same patient. In samples from adenocarci-
noma patients nuclear expression of PXR was found. Translocation from cytoplasm 
to the nuclei of adenocarcinoma cells was observed in vitro after stimulation with 
rifampicine or litholic acid.       
Previous studies have suggested that PXR expression in cancer cells can in-
terfere with the metabolism and responsiveness to chemotherapeutics, such as 
irinotecon and tamoxifen.[46,47] They suggest this drug resistance involves the 
metabolizing enzyme CYP3A4, one of the key target genes of PXR.[15] These ef-
fects on the metabolism of anticancer agents are especially important considering 
that PXR ligands include endogenous steroids and bile acids, as well as numer-
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ous environmental chemicals and dietary constituents. It has yet to be investigat-
ed whether higher levels of PXR in the esophagus also affects responsiveness to 
chemotherapy. 
Given the relatively low rare allele frequency for SNP 8055C/T our population 
size may have been insufficient to detect a statistically significant association. Vali-
dation of our findings will require a well-characterized population from a multi-
center study. Recent studies associate PXR polymorphisms with other pathogenic 
conditions of the gastrointestinal tract, such as inflammatory bowel disease[20] 
and primary sclerosing cholangitis.[21] Since associations with the two PXR SNPs 
in this study are in line with previous findings in IBD,[20] this draws attention on a 
possible link of the functional effect of these SNPs with chronic inflammation. It is 
well known that inflammation, through the activation of NF-κB pathway leads to a 
decrease of CAR, PXR and RXR-alpha expression and the expression of their target 
genes. In addition, it has recently been shown that the mutual repression between 
PXR and NF-κB signaling pathways provides a molecular mechanism linking xeno-
biotic metabolism and inflammation.[48]
Although it cannot be ruled out that the observed link between BE and PXR lev-
els is not the cause but only the consequence of the metaplasia from squamous to 
intestinal-type mucosa, the link with PXR-activity associated SNPs suggest a active 
role of PXR in BE pathophysiology. Further research should focus on the biologic 
function of PXR in BE and EAC, especially because PXR protein expression was ob-
served predominantly in the cytoplasm of Barrett’s epithelial cells and not in the 
nucleus. For a complex disease such as BE, development and validation of repre-
sentative animal models are of great importance in order to investigate if PXR plays 
a protective role in the development of BE or has a detrimental effect on neoplastic 
progression.
Conclusions
In summary, PXR which is normally not present in the squamous esophageal epi-
thelium, expressed highly in the columnar esophageal epithelium of BE patients 
and tumor tissue of EAC patients. Upon stimulation with lithocholic acid, PXR trans-
locates to the nuclei of OE19 adenocarcinoma cells. Together with the observed 
association of a PXR-activity associated SNPs and BE, this data implies that PXR may 
have a function in predicting progression and treatment of esophageal disease.
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Abstract
Introduction: Reflux oesophagitis (RO) and Barrett’s oesophagus (BO) can cause 
oesophageal adenocarcinoma (OAC). The oesophageal mucosa in the RO-BO-OAC 
cascade is chronically exposed to gastro-oesophageal reflux. Epidermal growth 
factor (EGF) plays an important role in the protection and repair of mucosal dam-
age, and non-physiologic levels are associated with gastrointestinal tumors.
Aim: To determine the functional effect of EGF gene polymorphisms on RO, BO, 
and OAC development.
Methods: A cohort of 871 unrelated Dutch Caucasians consisted of 198 healthy 
controls, 298 RO patients, 246 BO patients, and 129 OAC patients. The frequency 
of the EGF production associated 5’UTR A+61G polymorphism was determined in 
these four groups. EGF immunohistochemistry was performed on BO biopsies.
Results: EGF expression was significantly lower in the G/G genotype compared to 
the A/G (p=0.008) and A/A (p=0.002) group. The G/G genotype was significantly 
more prevalent in RO (OR=2.6; 95% CI:1.3-5.2), BO (OR=3.0; 95% CI:1.5-6.2), and 
OAC (OR=4.1; 95% CI:1.7-9.7) than in controls.
Conclusion: The G allele is associated with reduced EGF expression and increased 
risk for RO, BO and OAC development. This indicates that reduced mucosal protec-
tion resulting from genetically decreased EGF expression enhances oesophageal 
tumor development. 
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Introduction
Oesophageal adenocarcinoma (OAC) is rising faster than any other epithelial 
malignancy in the Western world since 1970 1. OAC frequently arises from reflux 
oesophagitis (RO) and Barrett’s oesophagus (BO), a chronic inflammatory condition 
characterised by a change in the normal oesophageal epithelium into intestinal 
metaplasia as a result of persistent severe reflux 2-4, and genomic instability 5. 
Several twin-studies have provided evidence for a genetic component in RO 6, 7. 
The presence of an inherited genetic component impacting on the individual pre-
disposition to develop BO has been accumulated over the last three decades 8, and 
the only predisposing factor in families with BO and OAC seems to be RO 9, 10. 
The stratified squamous epithelium of the healthy oesophagus possesses a 
variety of intrinsic defenses that enable it to resist acid-peptic reflux, divided in 
pre-epithelial defense, epithelial defense, and post-epithelial defense 11, 12. Growth 
factors such as epidermal growth factor (EGF) and transforming growth factor-a 
(TGF-a) are associated with epithelial proliferation and restitution that are the two 
key mechanisms involved in oesophageal epithelial defense against acid, maintain-
ing epithelial integrity and enabling rapid repair after injury 13. Multiple signaling 
pathways are activated by binding of TGF-a and EGF with their receptor EGFR 14, 15, 
resulting in proliferation and differentiation of epithelial tissues 16, 17.
Basal EGF levels are in part determined at genetic level, and variation at a single 
nucleotide polymorphism (SNP) within the EGF gene has been associated with al-
tered EGF production 18. This SNP in the 5’ UTR of the EGF gene has been associated 
with the risk of various tumors, such as oesophageal adenocarcinoma, gallbladder 
cancer, ovarian cancer, and gastric cancer 19-22. For all three malignancies, it was re-
ported that hetero- and homozygous G allele carriers had an increased risk for can-
cer compared with non-carriers. However, these associations were in contrary to 
others that showed an increased risk for A allele carriers with renal cell carcinoma, 
gastric cancer, and oesophageal squamous cell carcinoma 18, 21, 23.
Several studies have reported on the expression of TGF-a, EGF, and EGFR in the 
human oesophageal mucosa, both at the level of RNA and at protein level 24-27. EGF 
expression in BO was significantly higher compared to both squamous epithelium 
and gastric mucosa, while EGF expression was depleted in RO 24. BO showed local 
EGF expression and an over-expression of both TGF-a and EGFR suggesting a de-
regulation of important proliferation control mechanisms in these epithelial cells. 
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EGFR over-expression in oesophageal adenocarcinoma correlated with advanced 
pathologic tumor classification and lymph node metastasis 28. 
BO is an ideal model to study cancer genetics and EGF is suggested to be in-
volved in oesophageal cancer development 29. We postulated that the functional 
EGF 5’ UTR G allele is associated with individual susceptibility for RO, BO, or OAC, 
and affects local EGF expression in the oesophagus.
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Material and methods
Study design
Between November 2002 and March 2006, all subsequent patients with RO, BO, 
and OAC who visited the endoscopy unit of the Erasmus MC – University Medical 
Centre Rotterdam or the IJsselland Hospital, Capelle aan den IJssel were invited to 
participate in this study. The overall response rate was 85%. Participants under-
went upper endoscopy for evaluation of reflux-related symptoms, surveillance of 
BO, or odynophagia or dysphagia. The presence of RO was confirmed at endoscopy 
and the length of any columnar-lined segment was determined by measuring the 
distance between the squamo-columnar junction and the proximal margin of the 
longitudinal gastric folds. Participants were only included if they had i) RO without 
the presence of BO, ii) BO defined as a columnar lined segment in the oesophagus 
of ≥ 2 cm in length with specialised intestinal metaplasia at histology found in at 
least one of the biopsies, or iii) OAC defined at histology as an adenocarcinoma in 
BO or at the gastro-oesophageal junction with more than 50% of the tumor mass 
in the oesophagus. The response rate of the patients was 86.3%. Not all biopsies fit-
ted the above-mentioned histological criteria, therefore approximately 50% of RO 
patients could be included, 90% of BO patients and 95% of OAC patients.
Between October 2004 and April 2005, healthy volunteers (referred to as nor-
mal controls) were recruited from the general population of general practitioners 
practices. Subsequent adult patients visiting the participating general practices 
were examined by means of a validated questionnaire. Subjects were eligible for 
inclusion if they never had reflux complaints, retrosternal pain, or regurgitation, 
nor used antacids, H2-receptor antagonists, or proton pump inhibitors. We per-
formed age, sex and race frequency matching during the selection of controls. The 
response rate was 48.9%.
All individuals of the four study groups donated 10ml of whole blood.
The study was approved by the local institutional review boards of both par-
ticipating hospitals. All participants were genetically unrelated Dutch Caucasian 
people, and aged over 18. Prior to inclusion, all participants signed a written in-
formed consent.
Genotyping of the EGF 5’ UTR polymorphism
Genomic DNA was extracted from 5 ml of whole blood by standard procedures 
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(Wizard Genomic DNA Purification-kit; Promega, Madison, WI). Single nucleotide 
polymorphism (SNP) analysis of EGF (+61A/G) genotypes was performed by a 
technician unaware of the clinical findings for these patients on 20 ng DNA (Kbio-
sciences, Herts, UK) with a competitive allele-specific PCR system 30 using primers 
designed in flanking region of SNP CAAGGGTTGT[A/G]GCTGGAACTTTCCATCAGT 
located at position +61 in the 5’UTR (rs4444903).
Immunohistochemical analysis of EGF
The local institutional review board only allowed us to use remnants of routine 
biopsy samples from the Erasmus MC – University Medical Centre Rotterdam. From 
the 246 BO patients that participated in this study only 37 BO patients had suffi-
cient high quality biopsy material of the BO segment left to allow an immunohis-
tochemical study of oesophageal EGF and EGFR expression. Paraffin samples were 
cut at 4mm, deparaffinised in xylene, hydrated using a graded series of alcohol, 
and stained with hematoxylin and eosin (H&E). The two sequential paraffin slides 
directly following the slide used for histological evaluation were used for EGF and 
EGFR analysis. The local institutional review board did not allow extensive testing 
for the presence of EGF and EGFR levels in OAC biopsy samples, because a prelimi-
nary screening (see results) of four samples revealed that over-expression both EGF 
and EGFR was to be expected in all OAC samples. For EGF staining endogenous 
peroxidase activity was inactivated with 0.3% H2O2 in 100% methanol for 30 min-
utes. Subsequently antigen retrieval was performed by boiling the slides in 10mM 
monocitric acid (pH 6.0) for 15 minutes, and allowing them to slowly cool down 
to room temperature. Antigen retrieval for EGFR was performed by 5 minutes in-
cubation with Prot K at room temperature, followed by one washing with ice cold 
sterile PBS. The slides were then blocked with 10 % normal human plasma for 20 
minutes at room temperature. The sections were stained using a primary antibody 
against EGF (anti-EGF clone EGF-10; 1:200 dilution; Sigma, St. Louis, MO) or EGFR 
(anti-EGFR clone F4; 1:250 dilution; Sigma). Binding of the primary antibody was 
visualised by the addition of anti-mouse Envision labeled with horseradish peroxi-
dase (DAKO, Glostrup, Denmark).
Two independent observers (VM, KvZ) evaluated the sections of the EGF and 
EGFR stainings, while blinded for the score of the other observer, and unaware 
of the patient characteristics and genotype. To determine EGF and EGFR expres-
sion, the number of stained cells was scored per microscopic field as 0 (negative), 1 
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(mild, 1-100 positive cells/field), and 2 (strong, >100 positive cells/field). The slides 
were evaluated using a Zeiss microscope (Axioskop 20, Carl Zeiss, Sliedrecht, The 
Netherlands) with a standard magnification (200x), and the images were recorded 
with a Nikon camera (DS-5M-U1) and Nikon Eclipse Net 2000 software (Nikon, Bad-
hoevedorp, The Netherlands). The mean variation in scores between observers was 
found to be <5%, and the average of the two observations was used to analyze the 
relation with the EGF genotypes.
Statistical analysis
The study was powered (80%) to allow detection of a 10% difference in allele dis-
tribution between the patient groups (significance level 5%). Differences between 
allele distributions of the EGF 5’UTR polymorphism, as well as differences between 
the patient groups in number, age, and sex were determined by Chi-square analy-
sis. Age and sex corrected odds ratios (OR) and 95% confidence intervals (95% CI) 
were calculated for the association between healthy controls and RO, BO, or OAC 
respectively by logistic regression analysis. Disease causality was calculated with 
ordinal regression for the RO-BO-OAC cascade in relation to sex. The mean immu-
nohistochemical EGF expression was compared between the three genotypes with 
ANOVA. A difference between the median immunohistochemical EGF expression 
per genotype was calculated with the Wilcoxon non-ranked sum test. A two-sided 
p-value ≤ 0.05 was considered to be statistically significant. All statistical analyses 
were conducted with the SPSS software package v11.1 (SPSS, Chicago, IL).
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Results
Patient characteristics
In total, 871 participants were included; 198 controls, 298 RO, 246 BO, and 129 OAC 
patients. Table 1 shows that male gender was more common in BO and OAC than 
among controls and RO patients. On average, patients with BO and OAC were older 
than controls and RO patients. When comparing the OAC with the BO group, slight-
ly higher age and higher prevalence of males were found in the OAC patients.
G/G-genotype is more prevalent among RO, BO, and OAC patients
Using controls as a reference, the association of an EGF polymorphism was tested 
for RO, BO, or OAC patients. Allele frequencies for the EGF 5’UTR polymorphism 
among the 198 controls were 32.8% (G) and 67.2% (A) respectively. The allele fre-
quency of the major allele (A) was 60.9% in RO, 59.3% in BO, and 58.1% in OAC.
The distribution of genotype frequencies for the polymorphism investigated 
was consistent with Hardy-Weinberg equilibrium in both the patient and control 
groups (p>0.05). Comparing the patient groups with the controls showed that EGF 
G/G homozygosity was observed more frequently in RO (OR=2.62; 95% CI:1.33-
5.15), BO (OR=2.85; 95% CI:1.42-5.75) and OAC (OR=3.12; 95% CI:1.42-6.85) com-
pared to controls. The adjustment for age and sex showed that EGF 5’UTR G/G 
homozygosity was significantly more common in RO (OR=2.61; 95%CI:1.32-5.15), 
BO (OR=3.04; 95% CI:1.49-6.17) and OAC (OR=4.12; 95% CI:1.76-9.65) compared 
to the controls (Figure 1). There was no significant difference in the frequency 
distribution of EGF G/G genotype in BO versus RO (OR=1.00; p=0.74), in OAC ver-
sus RO (OR=1.46; p=0.35), and OAC versus BO (OR=1.19; p=0.65). Figure 1 shows 
that the frequency of A/A genotype decreases gradually for RO, BO and finally for 
Table 1.
Characteristics of the study population.
Patient data Control RO BO# OAC
Number 198 298 246 129
Age (+ SD) 56±15 55±14 61±12 63±10
Male (%) 57.6 54.7 67.9 82.2
Length of BO segment (cm) N.D. 0 3.9±2.1 N.D.
# 37/246 biopsy specimens were stained for EGF and EGFR
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OAC, while there is a clear increase for the G/G genotype frequency. This G-allele 
shift taken together with the odds ratios for RO (p=0.006), BO (p=0.002) and OAC 
(p=0.001) indicates that the G/G genotype is predominantly associated with the 
presence of RO, BO and OAC.
Risk stratification was calculated for RO, BO and OAC patients together named 
reflux-associated disease with the controls as a reference. The EGF A/G genotype 
frequency did not differ between diseased patients and controls (OR=1.05; 95% 
CI:0.74-1.49). However, EGF G/G homozygosity was observed more frequently in 
the diseased group (OR=2.76; 95% CI:1.45-5.24; p=0.002).
The EGF polymorphism in BO is associated with sex 
The ordinal regression model was used to test for sex specific differences in disease 
stage distribution between the EGF 5’UTR genotypes. 
Figure 2 shows the distribution of the three genotypes for RO, BO and OAC in 
male (Figure 2A) and female (Figure 2B) patients. The Y-axis represents the chance 
of disease development in percentages and on the X-axis the age is shown. The 
three genotypes are grouped per disease as lines of coloured symbols. Females 
with RO cross all BO genotypes around the age of 80, with the G/G genotype for RO 
Figure 1
Distribution of the polymorphism in the EGF (position +61) gene demonstrated for the four study groups. The 
comparison of the Odds Ratios (OR) shows an increased risk for the development of RO, BO and OAC, with p-
values of 0.006 (RO), 0.002 (BO) and 0.001 (OAC), respectively, in the homozygous G/G group compared to the 
healthy controls. A clear shift from the A-allele (dark grey) in the control group towards the G-allele (white) in 
the RO, BO, and OAC groups can be observed in the bars.
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and BO crossing at younger age (RO: grey symbols, BO: red, OAC: blue) (Figure 2B). 
This suggests that females with RO and the G/G genotype have a stronger caus-
ative relation with BO than the A/A and A/G genotype. BO and the OAC genotypes 
never cross before the age of 80, which means that there seems no current cau-
sality between BO and OAC in females, but the causality between these diseases 
could appear at a higher age.
Males with RO cross BO at the age of approximately 55, and do so at a younger 
age than males with an A/G or A/A genotype (G/G-RO: grey, -BO: red, -OAC: blue). 
The development of BO toward OAC appears at approximately 80 years of age, 
with the G/G genotype crossing some years earlier than the A/A and A/G geno-
types (Figure 2B). These results indicate that male RO patients with an EGF 5’UTR 
G/G genotype have an increased risk for BO and OAC development, as a RO-BO-
OAC disease cascade.
Figure 3 shows the distribution of the three genotypes per disease as A/A with 
red squares, A/G with green squares, and G/G with blue squares. The Y-axis repre-
sents the predicted probability for disease in percentages and on the X-axis the age 
is shown. All lines are double and to be separated in males [top] and females [bot-
tom]. The G/G genotype is associated with a higher probability for the develop-
Figure 2
Ordinal regression model for the causality of oesophageal disease in males (A) and females (B). The RO-BO-
OAC cascade represents a causal relation when the lines cross. The age is shown on the X-axis and the chance 
of developing oesophageal disease is shown as percentage on the Y-axis. 
A: Male patients develop RO from BO around the age of 60, and OAC from BO around the age of 80. The G/G 
genotype crosses the RO-BO line and BO-OAC line at youngest age. 
B: The genotypes for RO and BO in females cross around the age of 80 years, and the G/G genotype (RO-
grey circles with BO-red circles) crosses at younger age when compared to the A/A and A/G genotype. The 
genotype-lines for BO and OAC in females never cross. 
107
Functional Single Nucleotide Polymorphism of Epidermal Growth Factor is associated 
with the Development of Barrett’s Oesophagus and Oesophageal Adenocarcinoma
CH  1
CH  2 
CH  3
CH  4
CH  5
CH  6
CH  7
CH  8
CH  9
ment of RO (Figure 3A), BO (Figure 3B), and OAC (Figure 3C). Comparing all female 
graphs with the male graphs for BO and OAC points out that females form similar 
curves as males, but 20 years of age later (Figure 3A-C).
Figure 3
Logistic regression of the EGF (+61A/G) 
gene for the RO, BO, and OAC devel-
opment of male and female patients. 
The age is shown on the X-axis and 
the predicted probability of oesopha-
geal disease is shown as percentage 
on the Y-axis. The G/G genotype (blue 
lines) is associated with an increased 
risk for RO, BO, and OAC. For all in-
stances the upper line represents the 
male individuals, the lower line the fe-
male patients. Note that that the lines 
representing female patients follow 
the same pattern as the male curves 
but seem shifted in time by approxi-
mately 20 years.
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EGF expression in BO in relation to genotype
EGF and EGFR expression might influence development of RO, BO, or OAC. Therefore, 
the variation of EGF and EGFR expression in BO biopsies per genotype was deter-
mined (Figure 4). EGF staining was observed in the cytoplasm of epithelial cells and 
inflammatory cells. BO biopsies varied in EGF expression (Figure 4A-C) and all OAC 
biopsies tested showed a strong EGF expression in the tumor (data not shown).
The EGF staining was negative in 0% of A/A, 5% of A/G, and 43% of G/G pa-
tients. The positive biopsies displayed mild staining in 38% of A/A, 68% of A/G, and 
57% of G/G patients. Strong EGF expression was found in 62% of A/A, 27% of A/G, 
Figure 4
Typical examples of the EGF and EGFR expression. EGF was scored as 0 (negative), 1 (mild, 1-100 positive cells/
microscopic field), and 2 (strong, >100 positive cells/microscopic field) on BO tissue of patients from our BO 
polymorphism cohort. A: Negative staining for EGF on BO tissue B: Mild EGF staining (brown) of metaplastic 
epithelial cells and submucosal inflammatory cells is alternated by blue epithelial and inflammatory cells C: 
EGF staining is strongly present in all metaplastic epithelial cells and in most inflammatory cells D: Negative 
staining for EGFR on BO tissue E: EGFR staining (brown) of metaplastic epithelial cells is present in RO tissue 
(left) and BO tissue (right) F: The EGFR staining is strongly present in all OAC metaplastic epithelial cells and 
also in BO tissue.
109
Functional Single Nucleotide Polymorphism of Epidermal Growth Factor is associated 
with the Development of Barrett’s Oesophagus and Oesophageal Adenocarcinoma
CH  1
CH  2 
CH  3
CH  4
CH  5
CH  6
CH  7
CH  8
CH  9
and 0% of G/G patients. The mean EGF expression (ANOVA p=0.067) did not differ 
between the 3 genotype-groups (A/A, A/G and G/G). However, comparisons of EGF 
expression among A/A versus A/G (p=0.13), A/G versus G/G (p=0.032), and A/A ver-
sus G/G (p=0.0093) genotype carriers showed that the carriage of the G allele was 
associated with a significantly lower local EGF expression (Figure 5A).
EGFR expression is known to be present in (pre-) malignant tissues. Strong EGFR 
expression was observed in near to all biopsies of our BO cohort (28/33) (Figure 
4D-F). The EGF expression was calculated for 37 biopsies, but 4 stains of the EGFR 
slides were unreliable and taken out of the calculations. The median EGFR expres-
sion per EGF genotype (A/A versus G/G p=0.83) showed no significant difference 
(ANOVA p=0.094) (Figure 5B).
Figure 5
The median immunohisto-
chemical EGF and EGFR scores 
in a subset of the BO cohort 
are presented in the boxplot. 
A: The G/G genotype shows 
a significant lower local EGF 
expression in BO epithelium 
compared to the A/A and A/G 
carriers. The A/A genotype sig-
nificantly expresses more EGF 
than the A/G carriers. B: The 
EGFR staining is not signifi-
cantly different between the 
three genotype-groups. 
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Discussion 
Persistent severe gastro-oesophageal reflux of gastric acid and bile is associated 
with the development of RO and BO, which are the main risk factors for developing 
OAC 2, 3. Since EGF/EGFR has been implicated in the progression of BO into OAC 31, 
the EGF genotype may serve as a biomarker to assess the risk of malignant trans-
formation in surveillance programs for patients with BO. 
The EGF (+61A/G) polymorphism is associated with individual risk of oesopha-
geal, gastric, gall bladder, ovarian, and renal cell cancer in a variety of studies 18-21, 
32. Our study shows an association between the functional EGF 5’ UTR G allele and 
RO-BO-OAC development. 
The EGF 5’ UTR G allele frequency showed a significantly increased odds ratio 
of 2.6 for RO, 3.0 for BO, and 4.1 for OAC, and the 5’UTR G allele was found to be 
closely associated with local lower EGF expression levels in BO. The reduced EGF 
production in the G/G genotype could therefore mediate the development of BO 
and OAC. To our knowledge, we are the first to show the association of the func-
tional EGF G/G genotype with both an enhanced chance of RO, BO, and OAC devel-
opment, and a decreased EGF expression in BO tissue.
A hospital-based case-control study on the association between genetic poly-
morphisms firstly needs large subgroups to show an association. For that purpose 
we sampled groups of patients that by comparison with other papers are substan-
tial, but confirmation and validation with further studies is needed.
The allele frequencies in the control cohort we used to test this polymorphism 
was close to equal with the frequencies reported for the European HapMap popu-
lation 33. Eventually all man at higher age develop RO, BO and OAC, as shown in 
our ordinal regression model. As a consequence, the control group has fewer male 
cases and a slightly younger age, while older males had RO complaints. The RO-BO-
OAC disease cascade is thought to progress more often and faster in males than 
in females 34. This suggests a stronger correlation between causative agents and 
disease in males than in females, as we showed in present study with the ordinal 
regression model.
The number of BO biopsy samples that was available in sufficient quantities for 
use in our immunohistochemical EGF expression study was small (n=37), we did how-
ever observe a significantly lower EGF expression in the G/G genotype compared 
with A/G or A/A carriers (p=0.0093). The precise mechanisms underlying the EGF 
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gene interaction in BO- and OAC-risk are probably complex. Previous studies firstly 
showed that the studied EGF polymorphism was functional and associated with EGF 
serum levels. The G allele was linked to elevated EGF production in lymphocytes of 
malignant melanoma patients 35, and serum of patients with gastro-oesophageal re-
flux disease 19. Secondly, low EGF serum levels may increase the risk of renal cell carci-
noma 18. In this study we found that there was a significantly lower EGF expression in 
BO cases carrying G/G homozygote than the A/A or A/G carriers. 
Since EGF is abundant in saliva and oesophageal mucosa, serum EGF levels may 
not entirely reflect the endoluminal milieu of the oesophagus. Indeed a study on 
local EGF expression in RO, BO, and OAC indicates that EGF was depleted in RO, the 
EGF expression of BO epithelium was mostly superficial, and EGF over-expression 
was observed in all histological OAC samples 24. These observations are very similar to 
our findings and support our hypothesis that a genetically predetermined decreased 
EGF expression results in an increased risk for RO, BO, and OAC development. 
EGFR expression was observed intracellular in RO, BO, and OAC, as shown in pre-
vious studies 25. The finding of EGFR over-expression in all BO biopsies is in line with 
the previously reported EGFR over-expression in a wide variety of cancers of the gas-
trointestinal tract 36-38. High EGFR levels might well represent a negative feedback 
loop resulting from low EGF levels. This would suggest that elevated EGFR levels 
could be an indirect result of gastrointestinal neoplasia and cancer development 39, 
rather than a direct trigger for neoplastic development 40. That high EGFR levels not 
likely cause tumor development is further supported by the finding that EGFR over-
expression in oesophageal adenocarcinoma is associated with advanced pathologic 
tumor classification and lymph node metastasis 28, but not with an increased risk 
for tumor development or survival. In line with this, a previous study showed that 
not EGFR but the TGF-a expression differentiated between the survival of oesopha-
geal cancer patients 41. Finally, an EGF/EGFR peptide array study demonstrated that 
EGF activation is significantly more prominent in squamous epithelium than in BO, 
concluding that EGF is an important growth factor for normal oesophageal tissue 
regulation through binding with EGFR. Although the EGFR expression is stronger in 
BO compared to squamous epithelium, the activation of EGFR in BO is lower 40. This 
suggests that EGFR is a major receptor, but the growth factors EGF and TGF-a deter-
mine the outcome of disease. The decreased EGF activity in the oesophagus could 
therefore trigger the promotion of a tumor environment, thereby either directly or 
indirectly affecting the risk for OAC development 42, 43.
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In conclusion, we demonstrate that the homozygous G/G genotype of the EGF 
5’UTR polymorphism is associated with a significant decrease in local EGF levels 
and an increased risk for the development of RO, BO and OAC. The genetically de-
termined decreased EGF levels could result in less EGFR activation, leading to neo-
plastic changes, like RO, BO, and OAC, but this hypothesis needs validation in other 
independent cohorts.
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Abstract
Background: Reflux esophagitis (RE) and Barrett’s esophagus (BE) are predispos-
ing factors for development of esophageal adenocarcinoma (EAC), the solid tu-
mor with the fastest rising incidence in the Western world. This RE-BE-EAC cascade 
involves multiple host factors and consequently multiple genes. Polymorphisms 
in the 3’ region of myosin IXB (Myo9B) are associated with chronic inflammatory 
gastrointestinal disorders like celiac disease and ulcerative colitis, assuming that 
variation in Myo9B influences the intestinal permeability.
Aim: To determine esophageal expression and the genetic variation of the Myo9B 
gene in the RE-BE-EAC cascade
Methods: DNA from 886 Caucasian participants (198 non-reflux controls, 305 RE, 
254 BE, 129 EAC) was collected for the determination of the Myo9B gene polymor-
phism (rs2305764). Esophageal Myo9B expression was determined on biopsies 
from normal, RE, BE, and EAC epithelium.
Results: Genotype G/G was more common in BE (p=0.032), and EAC (p=0.046), but not 
in RE (p=0.126) compared to the control group. Cytoplasmic Myo9B expression was 
determined in RE, BE, and EAC, but most prominent in epithelial cells of BE and EAC.
Conclusions: Genetic variation of Myo9B may play a role in the etiology of BE and 
EAC by increasing the permeability of the epithelial barrier.
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Introduction
The incidence of esophageal adenocarcinoma (EAC) has increased rapidly in North 
America and Western Europe and is most pronounced in Caucasian men over 
50 years of age 1, 2. Established risk factors for the development of EAC include 
reflux esophagitis (RE) and Barrett’s esophagus (BE) 3, 4. BE is characterized by the 
replacement of normal squamous epithelium with metaplastic columnar epithe-
lium under the influence of inflammation as a consequence of persistent severe 
gastroesophageal reflux 5, and genomic instability 6. In addition to genetic varia-
tion in inflammatory factors also other factors that indirectly affect the inflamma-
tory response may lead to increased susceptibility for BE and EAC. 
The genome is the complete human’s hereditary information and it is encod-
ed in DNA or RNA. Two sequenced DNA fragments from different individuals can 
contain a difference in a single nucleotide (A, T, C or G). In this case, Myo9B has a 
variation in 2 alleles: A and G. Almost all single nucleotide polymorphisms (SNPs) 
have only two alleles that occur more frequently in non-coding regions than in 
coding regions. In general, natural selection is acting and fixating the allele of 
the SNP that constitutes the most favourite genetic adaptation. Serial analysis of 
gene expression in Barrett’s related adenocarcinomas showed a leading role for 
chromosome 19, that carries several gene groups relevant to carcinogenesis 7. 
Genetic variation in the 3’region of the myosin IXB (Myo9B) gene on chromosome 
19 was associated with inflammatory intestinal disorders, like celiac disease and 
inflammatory bowel disease 8-11. The selected tag SNPs were able to capture most 
of the common genetic variation present in this region, by virtue of the strong 
correlation between the known variants in this region 12, 13.  However, conflicting 
data exist on the involvement of polymorphisms in this region and inflammatory 
disorders. In 2005, Monsuur et al reported a significant association between ce-
liac disease and a common polymorphism (rs2305764) in intron 28 of Myo9B 14. 
However, subsequent smaller British, Italian, and Swedish studies have failed to 
replicate these findings 15-18.
Myo9B is a Rho family GTPase activating protein involved in epithelial cell 
cytoskeletal organisation 19. Human Myo9B is expressed in intestinal epithelium 
which is altered upon differentiation and genetic variation could cause impaired 
intestinal permeability 20. A defect in the intestinal barrier function by genetic vari-
ation could be a factor for the genesis of intestinal inflammation 21, 22. Increased 
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mucosal permeability is recognized as one of the earliest histological changes in 
gastroesophageal reflux disease patients 23.
Therefore, we postulated that genetic variation in Myo9B is associated with in-
dividual susceptibility for other gastro-intestinal inflammatory diseases, including 
RE, BE, and EAC. To investigate this hypothesis, we tested esophageal Myo9B ex-
pression and the association with SNP (rs2305764) in a case–control study. 
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Material and methods
Study design
Between November 2002 and March 2006, all subsequent patients with RE, BE, 
and EAC who visited the endoscopy unit of the Erasmus MC – University Medical 
Center Rotterdam or the IJsselland Hospital, Capelle aan den IJssel were invited to 
participate in this study. Participants underwent upper endoscopy for evaluation 
of reflux-related symptoms, surveillance of BE, or odynophagia or dysphagia. The 
presence of RE was confirmed at endoscopy and the length of any columnar-lined 
segment was determined by measuring the distance between the squamo-colum-
nar junction and the proximal margin of the longitudinal gastric folds. Participants 
were only included if they had i) RE without the presence of BE, ii) BE defined as 
a columnar lined segment in the esophagus of ≥ 2 cm in length with specialized 
intestinal metaplasia at histology found in at least one of the biopsies taken, or iii) 
EAC defined at histology as an adenocarcinoma in BE or adenocarcinoma of the 
gastro-esophageal junction with more than 50% of the tumor mass in the esopha-
gus. Biopsies were taken from patients with macroscopic signs of columnar meta-
plasia. Only samples from patients with histological BE were included in the BE 
group, but due to our criteria patients who only had histological evidence for BE at 
the z-line or at <2cm from the z-line were excluded from our study. In the patient 
population that we studied there were three patients with BE at 1cm and two with 
BE at 0cm. These five patients were excluded from present study. The diagnosis of 
BE and EAC is usually made by 2 two experienced gastro-intestinal pathologists.
Between October 2004 and April 2005, healthy volunteers (referred to as nor-
mal control subjects) were recruited from the general population via general prac-
titioner practices. They were assessed by means of a questionnaire and were eli-
gible as control if they had a negative history for reflux symptoms and esophageal 
disease. Patients who had a past history of antacids, H2-receptor antagonists, or 
proton pump inhibitor use, or suffered from reflux complaints, retrosternal pain, or 
regurgitation were excluded from the control group. 
This study was approved by the local institutional review boards of the two par-
ticipating hospitals. All participants were genetically unrelated Dutch Caucasians, 
and aged over 18. This study was approved by the local ethical review boards and all 
participants signed a written informed consent prior to participation in this study.
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Genotyping of the Myo9B (rs2305764) polymorphism
Genomic DNA was extracted from 5 ml of whole blood by standard procedures (Wizard 
Genomic DNA Purification-kit; Promega, Madison, WI) and put in sterile 96 Well polysty-
rene suspension culture microplates (Greiner-Bio, Alphen a/d Rijn, Netherlands). Analy-
sis of the Myo9B polymorphism (rs2305764) was performed by a competitive allele-
specific PCR system (Kbiosciences, Herts, UK) on 20 ng DNA by a technician who was 
unaware of the histopathological findings for the patients and controls 24.
Immunohistochemical analysis of Myo9B
A subpopulation of the 886 participants (i.e. patients with available paraffin em-
bedded samples) were further studied for local esophageal Myo9B expression in 
biopsy specimens. BE patients using any type of acid suppression as medication 
were excluded. We collected samples of non-reflux controls (n=20), RE (n=24), BE 
(n=63), and EAC (n=40) patients.
Paraffin samples were cut at 4mm, deparaffinized in xylene, hydrated using a 
graded series of alcohol, and stained with hematoxylin and eosin (H&E). An expert 
gastrointestinal pathologist blinded for the results of the genotyping, scored all H&E 
slides for squamous epithelium, RE, BE, and EAC. The sequential paraffin slide was 
used for Myo9B staining after inactivation of endogenous peroxidase activity with 
0.3% H2O2 in 100% methanol for 20 minutes. Subsequently antigen retrieval was per-
formed by boiling the slides in 10mM monocitric acid (pH 6.0) for 15 minutes, and al-
lowing them to slowly cool down to room temperature. The slides were then blocked 
with donkey serum and normal human plasma for 20 minutes at room temperature. 
The sections were stained using a primary antibody against myosin IXB (goat-anti-
human Myo9B; 1:100 dilution; Santa Cruz, Heidelberg, Germany). Binding of the pri-
mary antibody was visualized by the addition of a secundary biotinylated antibody 
(donkey-anti-goat IgG1; 1:200 dilution; DAKO, Glostrup, Denmark), and streptavidin-
avidin-biotin-complex labeled with horseradish peroxidase (strep ABComplex; 1:200 
dilution; DAKO). EAC staining always showed a strong cytoplasmic expression. As 
negative controls for IHC an isotype control was used, and the primary antibody was 
omitted. Two independent observers (VM, KvZ) evaluated the immunohistochemical 
stainings. The slides were assessed using a Zeiss microscope (Axioskop 20, Carl Zeiss, 
Sliedrecht, The Netherlands) with a standard magnification (200x), and the images 
were recorded with a Nikon camera (DS-5M-U1) and Nikon Eclipse Net 2000 software 
(Nikon, Badhoevedorp, The Netherlands).
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Statistical analysis
The study was powered (80%) to allow detection of a 10% difference in allele dis-
tribution between the patient groups (significance level 5%). Differences between 
allele distributions of the Myo9B polymorphism, as well as differences between the 
patient groups in number, age, and gender were determined by chi-square analy-
sis. Age and sex corrected odds ratios (OR) and 95% confidence intervals (95% CI) 
were calculated for the association between healthy controls and RE, BE, or EAC 
respectively by logistic regression analysis. A two-sided p-value ≤ 0.05 was consid-
ered to be statistically significant. All statistical analyses were conducted with the 
SPSS software package v11.1 (SPSS, Chicago, IL).
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Results
Patient characteristics
In total, 886 subjects were recruited, including 198 healthy controls, 305 patients 
with RE, 254 with BE, and 129 with EAC were included in this study. Of the 254 
BE patients, 17 were on any type of acid suppression as medication. The patient 
characteristics are summarized in Table 1. Male gender was more common in BE 
(p<0.05) and EAC (p<0.005) compared to the healthy subjects and the RE group. 
On average, patients with BE (p<0.005) and EAC (p<0.005) were slightly older than 
healthy controls and RE patients (Table 1). When comparing the EAC group with 
the BE group, the expected higher age (p=0.154) and prevalence of male gender 
(p=0.005) of EAC patients were confirmed (Table 1). 
G/G-genotype is more frequent in BE and EAC, but not in RE
Using the 198 non-reflux controls as a reference, the association of a Myo9B 
polymorphism was tested for patients with RE (n=305), BE (n=254), and EAC 
(n=129). The allele frequencies for the Myo9B polymorphism (rs2305764) 
among the 198 unrelated, Dutch Caucasian controls was 41.9% (A) and 58.1% 
(G) respectively (Table 2). This is comparable to the European HapMap distribu-
tion of 42.2% (A) and 57.8% (G). The allele frequency of the major allele (G) was 
60.8% in RE, 63.4% in BE, and 62.4% in EAC (Table 2). The distribution of the 
three genotypes in this cohort was G/G (41%), A/G (34%), and A/A (25%). The 
European HapMap shows a comparable distribution for G/G (35%), A/G (47%), 
and A/A (19%). The distribution of genotype frequencies for the polymorphism 
investigated was consistent with Hardy-Weinberg expectations in both the pa-
tient and control groups (p > 0.05). 
Myo9B A/G heterozygosity was observed more frequently in EAC (OR=4.52; 
Table 1.
Characteristics of the study population.
Patient data Control RE BE EAC
Number 198 305 254 129
Age 56±16 55±15 61±14** 63±10**
Male (%) 59 55 69* 82**
Length of BE segment (cm) N.D. 0 4.2±1.9 N.D.
*p=0.05 **p<0.005
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95% CI:1.99-10.25), but not in RE (OR=1.58; 95% CI:0.74-3.37), and BE (OR=2.28; 
95% CI:0.87-5.95) compared to the control group. Myo9B G/G homozygosity 
in RE (OR=1.87; 95% CI:0.84-4.15) was not different compared to our control 
group, but it was observed more frequently in BE (OR=2.96; CI:1.10-7.99) and 
EAC (OR=2.23; CI:1.01-4.92) (Table 3), indicating that the G/G genotype is sig-
nificantly associated with the presence of BE and/or EAC.
Myo9B immunohistochemistry
Immunohistochemical staining with Myo9B has to our knowledge never been per-
formed. Myo9B specific staining revealed that the localization of Myo9B in esopha-
geal biopsy specimens is exclusively present in the esophageal epithelium. (Figure 
1). In RE tissue Myo9B expression was observed in low intensity and primarily in 
the cytoplasm of the basal layer and not in the squamous epithelium itself (Figure 
1.A and 1.B). In contrast, in BE and EAC there was strong cytoplasmic expression of 
Myo9B (Figure 1.D and 1.F). Figure 1.C and 1.E represent the negative controls.
Table 2.
Percentage distributions for the alleles of the Myo9B polymorphism tested
Alleles Control
N=198
RE
n=305
BE
n=254
EAC
n=129
G/G 81 (41%) 110 (36%) 102 (40%) 50 (39%)
A/G 68 (34%) 151 (50%) 118 (47%) 61 (47%)
A/A 49 (25%) 44 (14%) 34 (13%) 18 (14%)
Allele frequency
G 0.581 0.608 0.634 0.624
A 0.419 0.392 0.366 0.376
Table 3.
Comparison of the Odds Ratios calculated for the genotypes in the Myo9B polymorphism
Genotype RE vs control
OR (95%CI)
BE vs control
OR (95%CI)
EAC vs control
OR (95%CI)
G/G 1.87 (0.84-4.15) 2.96 (1.10-7.99) 2.23 (1.01-4.92)
A/G 1.58 (0.74-3.37) 2.28 (0.87-5.95) 4.52 (1.99-10.25)
A/A* 1 (control) 1 (control) 1 (control)
* Minor allele
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Discussion
In current study, we found that the homozygous G/G group of the Myo9B polymor-
phism was associated with an increased risk for BE (OR: 2.96; CI: 1.10-7.99), and EAC 
Figure 1
Typical examples of the Myo9B expression. Myo9B expression is present in the cytoplasm of epithelial cells. 
 Myo9B is expressed in the basal layer of RE (n=24) (1.A/B), no expression is seen in the negative control (1.C). 
Myo9B is over-expressed in epithelial cells of BE (n=63) (1.D), absent in the negative control (1.E), and over-
expressed in epithelial cells of EAC (n=40) (1.F)
127
Myo9B is associated with an increased risk of Barrett’s esophagus and esophageal adenocarcinoma
CH  1
CH  2 
CH  3
CH  4
CH  5
CH  6
CH  7
CH  8
CH  9
(OR: 2.23; CI: 1.01-4.92) development. Also the heterozygous the A/G genotype was 
associated with an increased risk for EAC development (OR: 4.52; CI: 1.99-10.25). 
There was no clear association between the tested SNP and RE (Table 3).
To our knowledge no other studies, than a study from our group that was pub-
lished in Abstract25 have focused on Myo9B in relation to RE, BE and EAC and this 
is the first study to show an association between Myo9B and esophageal neopla-
sia. Although association of homozygous A/A and heterozygous A/G genotypes of 
Myo9B have been reported to more than one intestinal inflammatory disease 14, 26, 
its role remains controversial because of failed replication efforts 15-18, 27. There are 
a number of potential reasons for discrepancy between these studies, most well 
recognized in complex genetic trait studies 28, e.g. heterogeneity between the Brit-
ish, Italian, Swedish, and Dutch populations. In the Dutch study, a statistically sig-
nificant and replicable association was found for a common variant (rs2305764) in 
intron 28 of Myo9B and celiac disease (p=2.1x10-6) 14. The frequency of the A allele 
in these Dutch controls of the celiac study was 37.9%, very similar to South Span-
ish controls (37,1%), but different from North Spain (39%), Italy (40%), UK (42.3%), 
Norway (42.6-43.1%), and our healthy controls. The allele frequencies among our 
198 Dutch Caucasian control subjects for the Myo9B polymorphism (rs2305764) 
was 58.1% (G) and 41.9% (A), respectively, which is comparable to the European 
HapMap distribution of 57.8% (G) and 42.2% (A). The distribution of the three gen-
otypes in this cohort was G/G (41%), A/G (34%), and A/A (25%), and again the Eu-
ropean HapMap shows a comparable distribution of 35% for G/G, 47% for A/G, and 
19% for A/A. The slight differences in the percentages of the European HapMap 
cohort compared to our healthy controls can be explained by the composition of 
the cohort, as the Hap Map project did not exclude persons with gastroesophageal 
reflux disease (Table 2). This confirms the quality of the reflux-free, healthy control 
group included in present study on the Dutch population.
The sequential RE, BE, and EAC patients who visited our endoscopy unit were 
included. This means that some patients were already in surveillance programs, 
but this did not lead to bias in age, gender or genotype. The age of our study 
groups is similar to the age in previous studies that describe the incidence and 
prevalence of BE and EAC 29-31. The mean age at BE presentation is 55 years. As 
above-mentioned, the genotype distribution has been compared with the Euro-
pean HapMap population and did not show (statistical) difference 32.
Genetic variation in the 3’region of the myosin IXB (Myo9B) gene seems impor-
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tant to the gastrointestinal inflammatory response 33, as SNPs in this gene predispose 
to celiac disease and inflammatory bowel disease 21. However, it remains unclear at 
present how genetic variation affects cellular mechanisms involving Myo9B. 
Only a subgroup of patients with long-standing reflux esophagitis will develop 
Barrett’s esophagus. The exact mechanism remains unknown, but immunological, 
environmental and genetic factors likely play a role. Our Myo9B polymorphism in-
dicates that the homogenous G/G genotype predisposes to BE and EAC, and might 
be (one of the) key factor(s) in patients with long-standing reflux esophagitis at 
risk for BE and EAC, while the Myo9B polymorphism is not a risk factor for reflux es-
ophagitis itself. The exact mechanism needs further elucidation in future studies.
Myo9B is predominantly expressed in highly motile cells such as leukocytes; 
undifferentiated cells express Myo9B in the cell periphery, while its localization is 
more cytoplasmic in differentiated cells of human myelocyte cell lines 20. We here 
show for the first time that there is also local Myo9B expression in the esophagus. 
Our results showed a strong Myo9B cytoplasmic expression in RE at the basement 
membrane, and strong expression in the columnar epithelial cells of BE and EAC 
(Figure 1). Perhaps the strong local expression of Myo9B in BE and EAC is induced 
by the local inflammation as apparently reflux per se is not sufficient to generate 
an increased epithelial permeability, because high expression is not manifested in 
RE patients. Interestingly it was reported that all BE patients have a significant and 
dramatic transepithelial leak 34 and this may be the result of the aberrant Myo9B ex-
pression that we observed in these patients. Larger studies need to be performed 
to define a role for local Myo9B in the esophageal stages of RE, BE, and EAC.
In conclusion, we demonstrate that the homozygous G/G Myo9B (rs2305764) 
genotype is significantly associated with a increased risk for the development of BE 
and EAC. This suggests that the local epithelial barrier function is essential for the 
predominant development of BE and EAC in patients with RE.
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Translational Impact Box
Clinical Issue
Barrett’s Esophagus (BE) affects approximately 2% of the Western population and 
progresses to esophageal adenocarcinoma in 0.5% of these patients each year. 
Cancer of the esophagus is almost invariably lethal, and its incidence has increased 
dramatically in recent years. BE is believed to be caused by chronic reflux from the 
acidic contents of the stomach and bile, which converts the squamous epithelium 
lining the esophagus into columnar epithelium resembling that of the lower in-
testine. Subsequent mutations then lead to adenocarcinoma. Currently, there is 
no cure for BE once it is established. Patients are routinely monitored by endos-
copy, while the reflux is treated to prevent progression to more advanced disease. 
Eventually, endoscopic surgical intervention may be necessary to remove affected 
tissue. Basic research into esophageal adenocarcinoma has focused on determin-
ing the molecular events required for the initial squamous-columnar transition, the 
genes required for progression, and possible methods of inhibiting or reversing 
the pre-cancerous and cancerous changes. It is possible that, as the mutated co-
lumnar epithelium is similar to colonic epithelium, the Notch pathway, which is a 
signaling cascade that is central to both normal and neoplastic colonic develop-
ment, may be involved.
 
Results
The authors previously found that the Notch pathway controls the vigorous cell 
division in the lining of the normal gut. Here, they show using biopsy samples that 
the Notch pathway is not active in the normal squamous lining of the esophagus 
but that it is highly active in the areas of the esophagus that have changed into 
columnar Barrett’s epithelium. To determine whether inhibition of the Notch path-
way could revert or destroy Barrett’s epithelium, dibenzazepine (DBZ), a known 
inhibitor of the Notch pathway, was used to treat rats with surgically induced Bar-
rett’s epithelium. As shown previously in normal colonic epithelium, Notch inhibi-
tion converted the proliferative Barrett’s cells into arrested terminally differentiated 
goblet cells, whereas the normal squamous epithelium was unaffected. In some 
cases, the Barrett’s epithelium was entirely exfoliated, leaving bare submucosal tis-
sue.
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Implications and future directions
These data imply that local application of Notch inhibitors may present a simple 
therapeutic strategy for BE. However, further studies are required to optimise a 
method of delivery and, importantly, to determine the nature of any epithelial re-
growth following treatment.
 
Summary
Barrett’s Esophagus (BE) affects approximately 2% of the Western population and 
progresses to esophageal adenocarcinoma (EAC) in 0.5% of these patients each 
year. In BE, the stratified epithelium is replaced by an intestinal-type epithelium 
owing to chronic gastroduodenal reflux. Since self-renewal of intestinal crypts is 
driven by Notch signaling, we investigated whether this pathway was active in pro-
liferative crypts of BE. Immunohistochemistry confirmed the presence of an intact 
and activated Notch signaling pathway in metaplastic BE epithelium, but not in 
the normal human esophagus. Similar observations were made in two well-known 
human Barrett’s-derived EAC cell lines, OE33 and SKGT-5. We then sought to in-
vestigate the effects of Notch inhibition by systemic treatment with a γ-secretase 
inhibitor in a well-validated rodent model for BE. As we have shown previously in 
normal intestinal epithelium, Notch inhibition converted the proliferative Barrett’s 
epithelial cells into terminally differentiated goblet cells, whereas the squamous 
epithelium remained intact. These data imply that local application of γ-secretase 
inhibitors may present a simple therapeutic strategy for this increasingly common 
pre-malignant condition.
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Introduction
Barrett’s Esophagus (BE) affects approximately 2% of the Western population and 
progresses to esophageal adenocarcinoma (EAC) in 0.5% of these patients each 
year 1-3. In BE, the multi-layered epithelium near the stomach is replaced by an in-
testinal-type epithelium owing to chronic gastroduodenal reflux.
In an attempt to improve adenocarcinoma prognosis with an early diagnosis, 
the American College of Gastroenterology recommends that BE patients are en-
rolled in endoscopic surveillance programs 4. Therapy, however, is currently not 
available for BE patients.
The presence of Barrett’s dysplasia, particularly high-grade dysplasia, is one of 
the risk factors for adenocarcinoma 5-7. An unsuspected adenocarcinoma is identi-
fied in approximately 30-40% of esophagi that are resected for high-grade dysplasia, 
8-13. Nevertheless, the intra- and inter-observer variation in the diagnosis of dyspla-
sia leaves a lacuna in the management of patients with Barrett’s-related dysplasia 14. 
Although the management of high-grade dysplasia is controversial, most institutes 
consider esophagectomy if the diagnosis is confirmed by pathology 12, 13, 15.
In the intestine, self-renewal of the epithelium is driven by intense proliferation 
of progenitor cells that reside in crypt compartments. Genetic disruption of Notch 
signaling in this tissue results in rapid conversion of all proliferative cells into differ-
entiated goblet cells 16. The activation of Notch signaling is critically dependent on an 
intramembrane protease complex termed γ-secretase 17-19. This protease complex is 
also implicated in the pathogenic processing of the amyloid precursor protein in Al-
zheimer’s disease 20. For this reason, multiple γ-secretase inhibitors have been devel-
oped as potential Alzheimer’s drugs. Somewhat fortuitously, these inhibitors are effi-
cient Notch inhibitors. Not surprisingly, administration of these inhibitors to rodents 
induces changes in the intestine that resemble the effects that occur upon genetic 
loss of Notch signaling 16, 21-24, while (pre-)clinical studies have revealed a single major 
side effect of γ-secretase inhibitors: the induction of goblet cells in the intestine 25.
Multiple Notch pathway components are expressed in intestinal crypts and, to-
gether, constitute a functional signaling pathway 16, 21, 26, 27. As with the intestinal ep-
ithelium, the Barrett’s epithelium contains proliferative crypt-like compartments. 
To investigate whether Notch signaling was active in the proliferative cells of BE, we 
studied histology in human biopsy specimens, analyzed Barrett’s-derived EAC cell 
lines and performed Notch inhibition on a well-validated rat model for BE 28-32.
137
Conversion of metaplastic Barrett’s epithelium into post-mitotic goblet cells by γ-secretase inhibition
CH  1
CH  2 
CH  3
CH  4
CH  5
CH  6
CH  7
CH  8
CH  9
Results
Notch signaling in human biopsy specimens
To study several parameters of Notch signaling, we used immunohistochemistry 
on serial sections of normal human colon (Fig. 1A-D) and Barrett’s epithelium 
(Fig. 2A-F). Fig. 1A and Fig. 2A-C utilize a periodic acid-Schiff (PAS) stain for gob-
let cells to demonstrate the similarity in epithelial architecture between the two 
tissues. The hallmark of active Notch signaling is the nuclear localization of the 
cleaved Notch intracellular domain (NICD). An antibody that is specific for the 
N-terminal sequence of NICD revealed that nuclei of colon crypts, as well as of 
BE cells, contained readily detectable NICD in their nuclei (Fig. 1B; Fig. 2D). The 
Hairy/Enhancer of Split (HES) transcriptional repressors are encoded by genes 
that are direct targets of Notch 33, 34. The prototype human HES gene, HES1, is 
controlled by Notch signaling in the intestine 16, 21. Immunohistochemical analysis 
revealed that HES1 was indeed strongly expressed in BE cells, similar to in colon 
epithelial cells (Fig. 1C; Fig. 2E). In the intestine 16, 21, 35, as in other tissues 36, Notch 
signaling represses the ATOH1 gene through HES1. In turn, ATOH1 drives intesti-
nal epithelial cells into the secretory lineage to become goblet cells. Similar to in 
the intestine, ATOH1 was also expressed in the differentiated goblet cells of the 
Barrett’s lesions (Fig. 1D; Fig. 2F).
Active Notch pathway in Barrett’s-derived EAC cell lines, OE33 and SKGT-5
To confirm the presence of an active Notch pathway, we analyzed two well-known 
human Barrett’s-derived EAC cell lines, OE33 and SKGT-5 37. Cells were grown under 
standard conditions. RNA was isolated and subjected to northern analysis for the 
expression of NOTCH1-4 and for the five ligands Jagged 1 and 2 (JAG1, JAG2) and 
Delta-like 1, 3 and 4 (DLL1, DLL3, DLL4). Both cell lines expressed NOTCH1-3 (Fig. 3A) 
but not NOTCH4 (not shown). Of the five ligands, we only detected expression of 
JAG1 (Fig. 3A; and data not shown). HES1 mRNA was readily detectable, implying 
the presence of an active Notch signaling pathway. Treatment with the γ-secretase 
inhibitor dibenzazepine (DBZ), a potent inhibitor of the Notch pathway in cell cul-
ture and in vivo 16, 21, 24, readily reduced HES1 mRNA levels (Fig. 3B).
Notch signaling in BE rat model
We then sought to investigate the effects of γ-secretase inhibitor treatment in a 
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well-validated rat model for BE 28-32 in which the esophagus and the jejunum are 
surgically joined to create chronic reflux. After 4-6 months, these rats consistently 
develop columnar metaplasia with goblet cells in the distal esophageal epithelium, 
closely mimicking BE in humans (Fig. 4).
As in the human samples, the Notch signaling pathway was not activated in the 
healthy squamous epithelium of the rat (not shown). This contrasted with the BE 
segment that had developed in the distal esophagus of rats with surgically induced 
BE (Fig. 4E,F). We observed the presence of NICD in the nuclei of epithelial cells by 
Fig. 1. 
Notch pathway components in serial sections of the human colon.
A: PAS staining for goblet cells (pink) in crypt structures of the colon. 
B:  NICD staining (brown) occurs in virtually all epithelial nuclei, indicative of active Notch signaling. Note 
the negative (blue) nuclei of stromal cells. 
C:  HES1 staining (brown) occurs in the nuclei of most cells in the colon, indicative of active Notch signaling. 
D:  ATOH1 staining (brown) reveals that a minority of differentiated cells express this goblet cell marker in 
colon. Note that ATOH1 is repressed by active Notch signaling.
Scale 1:0.000045
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immunohistochemistry (Fig. 4E). Nuclear ATOH1 staining, although clearly present, 
was only observed in a few scattered cells (Fig. 4F). 
Fig. 2. 
Notch pathway components in BE.
A: PAS staining for goblet cells (pink) in a biopsy specimen from BE.
B:  PAS staining for goblet cells (pink) in the same biopsy specimen shown in A, from the squamous 
epithelium next to BE.
C-F:  Serial sections of BE from the same patient specimen shown in A and B.
C:  PAS staining for goblet cells (pink) in crypt structures of BE. 
D:  NICD staining (brown) occurs in virtually all epithelial nuclei, indicative of active Notch signaling. Note 
the negative (blue) nuclei of stromal cells. 
E:  HES1 staining (brown) occurs in the nuclei of most cells in BE, indicative of active Notch signaling. 
F:  ATOH1 staining (brown) reveals that a minority of differentiated cells express this goblet cell marker in 
BE. Note that ATOH1 is repressed by active Notch signaling.
Scale: A,B 1:0.000095; C,D,E,F 1:0.00003
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Notch inhibition in a BE rat model converts proliferative cells of Barrett’s 
epithelium
Dose-finding studies revealed that intraperitoneal injection of the γ-secretase 
inhibitor DBZ 24 caused efficient goblet cell conversion in the small intestine 
of rats after five daily intra-peritoneal injections at 30 mmol/kg (data not 
shown). Six months after the surgical procedure, the rats were subjected to a 
5-day treatment regimen and sacrificed for histological analyses of the small 
intestine, colon and the esophagus (Figs 5 and 6; and data not shown). For 
comparison, the same histological analyses were performed on control rats 
carrying the same surgical anastomosis, but not treated with DBZ (Fig. 4A-D), 
Fig. 3. 
Northern blot analysis of Notch pathway components in Barrett’s-derived EAC cell lines.
A: Both OE33 (OE) and SKGT-5 (SK) cells express NOTCH1 (7.7 kb), NOTCH2 (11.2 kb), NOTCH3 (8.0 kb) and 
JAG1 (5.9 kb). Bottom row: ethidium bromide (EtBr) mRNA was used as a loading control.
B:  Cells were cultured for the indicated number of days (top) in DBZ at 200 nM. Hes1 mRNA (1.5 kb) is rapidly 
reduced (top). Bottom row: actin mRNA was used as a loading control.
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and healthy control rats that had squamous epithelium lining the normal 
esophagus (data not shown).
In all rats, DBZ treatment led to near-complete conversion of intestinal epithe-
lial cells of the gut into goblet cells (data not shown), as published previously 16, 21, 
indicating that effective systemic DBZ levels were reached. The DBZ treatment had 
Fig. 4. 
Barrett’s epithelium deriving adjacent to squamous epithelium has an active Notch signaling pathway.
A,B: Serial sections of the boundary of normal squamous epithelium and BE epithelium after the induction of 
BE by surgical esophagojejunal anastomosis. A: The PAS stain (pink) illustrates the aberrant presence of 
goblet cells in crypt-like structures. B: A Ki67 stain (brown) for the presence of proliferative cells present in 
the basal layer of the squamous esophageal epithelium, as well as throughout the BE epithelium.  
C-F: Serial sections of an untreated BE rat.
C:  Magnification of the PAS staining (pink). The morphology and histology of the columnar epithelium and 
goblet cells mimic BE in humans.
D:  Magnification of the Ki67 stain (brown). Note the proliferation in all nuclei of columnar BE cells.
E:  NICD (brown) reveals intra-nuclear staining in the rat BE, indicative of active Notch signaling. 
F:  TOH1 staining (brown), which controls the goblet cell fate. Note that ATOH1 is repressed by active Notch 
signaling.
 Sq, squamous epithelium; BE, Barrett’s Esophagus epithelium.
Scale: A,B 1:0.0001; C,D,E,F 1:0.00003
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a dramatic effect on the BE crypts in all surgically treated rats when compared with 
the control rats. Immunohistochemical analyses of serial sections on untreated rats 
and DBZ-treated Barrett’s epithelium rats are presented in Figs 4 and 5, respective-
ly. The Barrett’s crypts displayed intense PAS staining, indicative of goblet cell con-
version and a massive secretion of mucous (Fig. 4C; Fig. 5E), whereas cell cycling, 
as shown by Ki67 staining, was severely diminished (Fig. 4D; Fig. 5F). As expected, 
Notch inhibition occurred effectively, as shown by the absence of nuclear NICD 
staining in Barrett’s nuclei (Fig. 4E; Fig. 5G), and a strong reduction in nuclear HES1 
staining was also observed (data not shown). ATOH1, in turn, was dramatically de-
repressed since essentially all Barrett’s nuclei now contained this protein (Fig. 4F; 
Fig. 5H). Although DBZ treatment induced cell-cycle arrest in BE cells, the adjacent 
normal squamous epithelium of the esophagus remained unaffected (compare 
Fig. 4A,B with Fig. 5A-D). In some areas, the effect of DBZ resulted in the effective 
exfoliation of the entire BE epithelium as a mucous mass, as exemplified in Fig. 6, 
essentially leaving a bare yet undamaged submucosa. 
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Fig. 5. 
Notch inhibition by the γ-secretase inhibi-
tor DBZ does not affect the esophageal 
epithelium yet converts BE epithelial cells 
into terminally differentiated goblet cells.
A,B: Serial sections of a region containing 
squamous epithelium and early sub-
mucosal BE lesions in a DBZ-treated 
rat. A: PAS staining (pink) identifies 
the BE islands. B: Ki67 staining (brown) 
reveals normal proliferation in the 
squamous epithelium and the virtual 
absence of proliferation in the adja-
cent BE islands.
C:  Magnification of the PAS staining 
(pink) in the squamous epithelium at 
the site of BE development (esophagi-
tis). Squamous epithelium is not af-
fected by DBZ treatment and no goblet 
cells are present.
D: Magnification of the Ki67 staining 
(brown) in the squamous epithelium at 
the site of BE development (esophagi-
tis). Note the proliferation at the basal 
layer of the squamous epithelium.
E:  Magnification of the PAS staining 
(pink). Note the almost complete re-
placement of columnar morphology 
by mature goblet cells with flat basal 
nuclei.
F: Magnification of the Ki67 staining 
(brown). Note the almost complete loss 
of proliferation upon DBZ treatment.
G:  NICD (brown) reveals an intra-nuclear 
staining in the rat BE, whereas the 
staining is virtually absent in the DBZ-
treated rat, indicative of effective inhi-
bition of Notch signaling. 
H:  ATOH1 staining (brown) after DBZ treat-
ment reveals a virtually complete de-
repression of ATOH1 gene expression, 
which controls the goblet cell fate.
 Sq, Squamous epithelium; BE, Bar-
rett’s Esophagus epithelium
Scale: A,B 1:0.0002; C,D,E,F,G,H 1:0.00003
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Discussion
The golden standard for diagnosing BE is the histology of columnar epithelium 
with goblet cells 38. The stage of the disease is determined by the following grades, 
which predict an increasing chance for the development of EAC: BE without dys-
plasia, BE with low-grade dysplasia, BE with high-grade dysplasia, and EAC. The 
grade of dysplasia determines the appropriate surveillance interval 4. Surgical re-
section of the esophagus takes place when patients are at the high-grade dysplasia 
or EAC stage of disease 13. There is currently no curative therapy for BE; endoscopy 
combined with histology-based surveillance for early detection of EAC remains the 
only tool to offer patients 4. 
The resemblance of metaplastic BE epithelium to colon epithelium prompted 
us to apply insights gained in intestinal biology to BE. The Notch pathway plays 
a dominant role in the self-renewal of normal colonic epithelium. When blocked, 
all proliferative epithelial cells instantaneously convert into goblet cells. The same 
phenomenon occurs in adenomas of the intestine upon inhibition of the Notch 
signaling pathway16. 
Fig. 6. 
DBZ treatment can induce virtually complete exfoliation of BE epithelium. 
A,B: Serial sections of a BE epithelial region showing the extensive effects of DBZ treatment. PAS staining 
(pink) (A) and Ki67 staining (brown) (B) reveal that post-mitotic goblet cells have dissolved into a 
mucous mass, effectively demonstrating chemical ablation of the metaplastic epithelium by DBZ. Note 
the apparent absence of effects on the histology of the submucosa.
Scale 1:0.0003
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In the current study, we confirm the notion that the Notch pathway is active in 
BE by histological analysis of biopsies and by biochemical studies in two BE cell 
lines, OE33 and SKGT-5. Treatment of these cell lines with the γ-secretase inhibitor 
DBZ, shown to be a potent inhibitor of the Notch pathway in cell culture 16, 21, 24, 
readily reduced mRNA levels of the Notch target gene HES1, which is indicative of 
Notch pathway inhibition. When applied in a surgical rat model of BE in vivo, we 
subsequently document that Notch inhibition converts the proliferative Barrett’s 
cells into terminally differentiated goblet cells, whereas the squamous epithelium 
remains apparently unaffected. As with all animal models, there must be caution 
with regards to extrapolation of the results from the animal model to humans. For 
example, rats do not have submucosal glands in the esophagus, which may con-
tribute to the establishment of BE in humans. Yet, this particular model appears to 
mimic the development of BE and EAC 28, 30-32.
This study indicates that Notch inhibition by DBZ in BE mirrors the effects on the 
normal absorptive epithelium of the intestine 16 in that Notch inhibitors can com-
pletely remove proliferative cells from the BE segment. Although the effect of Notch 
inhibitors on the BE segment is dramatic, we currently do not know what esopha-
geal lining will develop after the conversion of the epithelium, since we could not 
observe animals for longer time periods after the systemic Notch inhibition owing 
to the deleterious effects in the intestine.
The effect of systemic delivery of Notch inhibitors on the intestine complicates 
their use as therapeutic agents in Alzheimer’s disease 25. Phase II studies have al-
ready taken place to test the safety, tolerability and response to γ-secretase in-
hibitors 39-41. Since the lesions in BE reside in a tissue environment that essentially 
appears to be refractory to the principle side effect of γ-secretase inhibitors, local 
delivery of these compounds by supramucosal application, or by submucosal in-
jection during endoscopy of the esophagus, may circumvent these complications. 
After injection, the multilayered squamous epithelium of the healthy esophagus 
is predicted to stay intact, whereas metaplastic BE cells are forced to differentiate. 
Such local γ-secretase inhibitor treatment may be applicable to Barrett’s patients 
of all stages. Taken together, our data imply that local application of Notch inhibi-
tors may present a simple therapeutic strategy for this increasingly common pre-
malignant condition.
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Methods
Histology All histology was performed as described elsewhere 16, 21. 
Antibodies For immunohistochemistry, serial sections of 4 mm were blocked for 
endogenous peroxidase with 1% H2O2 in 100% methanol for 30 minutes. Antigen 
retrieval was performed with 10 mM monocitric acid (pH 6.0) at 100°C for 15 min-
utes. The slides were blocked with non-immune serum for 20 minutes at room 
temperature. The sections were stained using primary antibodies against goblet 
cells (PAS), proliferative cells (anti-Ki67, 1:500; BD Pharmingen, San Diego, CA), 
Notch cell-cycle factor (anti-Hes1, 1:100; Santa Cruz Biotechnology, Santa Cruz, 
CA), Notch transcription factor (anti-Math1, 1:3000; 42, and cleaved Notch1 receptor 
(anti-Notch1, 1:75; Cell Signaling Technology, Boston, MA). Binding of the primary 
antibody was visualized by the addition of Envision (HRP-labeled mouse antibody; 
undiluted; DAKO, The Netherlands). Normal, healthy squamous epithelium and hu-
man colon were used as controls. Three independent observers (V.M., M.v.d.B. and 
H.C.) evaluated the sections for the immunohistochemical stainings.
Tissue culture and DBZ treatment To inhibit γ-secretase activity in the human Bar-
rett’s-derived EAC cell lines OE33 (European Collection of Cell Cultures, Salisburg, 
UK) and SKGT-5 37, cultures were incubated for the indicated number of days in 200 
nM of DBZ in cell culture flasks (Greiner bio-one). DBZ was custom synthesized to 
more than 99.9% purity (Syncom Pharmaceuticals) and diluted in dimethyl sulfox-
ide (DMSO).
Northern blotting mRNA was run on a 1.5% agarose gel and blotted to Zeta-Probe 
membranes (Bio-Rad Laboratories, Hercules, CA). Hybridization with radioactive 
probes was performed at 68°C in the presence of ExpressHyb (BD Biosciences, 
Clontech, Palo Alto, CA) solution. The RadPrime DNA labeling system (Invitrogen, 
Carlsbad, CA) was used to label probes with 32P-dCTP. The following IMAGE clone 
fragments were used to produce probe DNA: NOTCH1, NotI-EcoRI fragment of ID 
3066192; NOTCH2, NotI-SalI fragment of ID 6055379; NOTCH3, EcoRI-HindIII frag-
ment of ID 6184018; NOTCH4, NotI-SalI fragment of ID 4779663; JAG1, XhoI-EcoRI 
fragment of ID 5212818; JAG2, PstI fragments of ID 6459190; DLL1, NotI-EcoRI frag-
ment of ID 5224361; DLL3, EcoRI-XhoI fragment of ID 3508262; DLL4, NotI-EcoRI 
fragment of ID 5722973; HES1, HindIII-SacI fragment of ID 4749611. 
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Animal treatments: 
Surgery Eight-week-old male Wistar rats were obtained from Harlan, England and 
housed under standard pathogen-free conditions with a maximum of three ani-
mals per cage. Experienced technicians carried out all of the animal handling. After 
an acclimatization period of 1 week, the animals were operated on. BE was induced 
on twelve rats by gastrectomy with esophagojejunostomy, as previously reported 
21, 28-31. Three rats were treated with DBZ. No incisions were made in the three con-
trol rats. The rats were sacrificed at 6 months after the induction of BE. The esopha-
gus was removed, fixed in 10% neutral buffered formalin for 24 hours, and embed-
ded in paraffin. General health status and weight were monitored at least twice 
per week; weight loss of more than 20% of the pre-operative body weight, severe 
regurgitation, aspiration that the animal did not recover from within 24 hours, or 
apathetic behavior prompted us to exclude the animal from the study. The experi-
mental study protocol was approved by the local animal experimental committee.
DBZ treatment Six months after the surgical procedure, three of the operated rats 
and three control rats were subjected to a 5-day treatment regimen with intraperi-
toneal DBZ at 30 mmol/kg, and sacrificed at day 6 for histological analyses of the 
small intestine, colon and the esophagus. The general health status of the rats was 
not affected and their weight was not diminished.
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Chapter 9
Summary and Discussion
The incidence of esophageal adenocarcinoma (EAC) has been rising dramatically in 
Western countries over the last four decades 1, 2. The impact of EAC on an individual 
is devastating because current treatment options are limited and the odds of sur-
vival remain low. Barrett’s esophagus (BE) represents the only identified precursor 
lesion and most important risk factor for EAC. Patients with BE have a 30- to 125-
fold greater risk of developing EAC than the general population 3. 
The incidence of BE itself has also increased markedly since the 1970’s. This in-
crease was once felt to be due to the increased use of diagnostic upper endosco-
py, however, data from our own center provided compelling evidence that in The 
Netherlands, the incidence of BE increased from 14.3/100,000 person years in 1997 
to 23.1/100,000 person years in 2002 in the general population independent of the 
number of upper endoscopies 4. 
Although genetic factors might predispose individuals to EAC, the rapid rate of 
increase in incidence must be due to non-genetic factors, both behavioral and en-
vironmental. BE is predominantly a disease of middle-aged white males. The preva-
lence of BE increases until a plateau is reached in the seventh decade. The most well-
documented risks for the presence of BE include increasing age, male gender, Cau-
casian ethnicity, cigarette use, increased body mass index, severe and long standing 
gastroesophageal reflux disease (GERD), and absence of H. pylori infection. 
Cigarette use rose in Western countries during the first decades of the 19th century 
but declined steadily since the 1970s, so this seems unlikely to explain the increased 
incidence of BE, although the prolonged latency between exposure to cigarettes and 
development of BE could still be an explanation. If this were the case, one could ex-
pect a subsequent decline in BE incidence over the next two decades. 
Obesity promotes symptomatic and asymptomatic GERD through mechanical ef-
fects 5. In addition, adipose tissue is metabolically active 6, and secreted adipokines 
have been associated with the development of a number of cancers 7, 8. The rapid rise 
in incidence in EAC may thus in part be due to the increasing prevalence of obesity. 
H. pylori infection causes chronic gastritis which eventually can lead to de-
velopment of atrophic gastritis with decreased production of gastric acid 9. This 
explains the observation in a range of studies of an inverse association between 
H. pylori infection and both BE and EAC. This is further in line with the fact that the 
rise in BE and EAC in many countries correlated with the decline in H. pylori preva-
155
CH  1
CH  2 
CH  3
CH  4
CH  5
CH  6
CH  7
CH  8
CH  9
lence, both as a result of a birth cohort effect with changes in infection transmis-
sion, as well as due to H. pylori eradication therapy.
All together, BE is uncommon in the general population (1.3-5.6%) and the risk 
of EAC is low for an individual BE patient. However, the diagnosis of BE can have 
considerable impact on an individual patient. It is therefore imperative that treating 
physicians provide accurate information and appropriate counseling concerning 
risks of cancer and expectations from surveillance or treatment strategies. Screen-
ing strategies based on reflux symptoms alone will miss almost 50% of BE patients 
10. The current symptom- and risk factor-based screening concepts are general and 
probably lead to over-screening. More specific markers are needed and it would be 
helpful to further understand the process of development of GERD, BE and eventu-
ally EAC to identify the patients at risk.
The aim of the work described in this dissertation was to identify the histologi-
cal and immunohistochemical characteristics in the development of GERD and BE, 
to evaluate biomarkers and genetic factors involved in the GERD-BE-EAC cascade, 
and eventually to introduce a possible option for therapeutic intervention.
In Chapter 2, the development of BE is represented in a rodent surgical 
model with esophagojejunal reflux. We found that reflux esophagitis preceded 
the development of BE in Wistar rats. All rats develop BE 6 months after surgical 
esophagojejunostomy and gastrectomy (GEJ). The development of BE started in 
a patchy design at the submucosal layer and was considered an immune-mediat-
ed disease. We revealed an early stage of esophageal tissue damage (0-3 months 
post-GEJ) characterized by esophagitis and increased numbers of macrophages 
and cytotoxic T cells without significant metaplasia, and a late stage of esopha-
geal tissue damage (3-6 months post-GEJ) characterized by intestinal metaplasia 
with goblet cells compatible with BE, with a marked influx of eosinophils, B cells, 
and plasma cells. There is now overwhelming evidence supporting the associa-
tion of GERD and BE. However, the role of individual constituents of the gastric 
and duodenal reflux in the development of BE and its associated complications 
still remain uncertain. Patients on PPIs and post-gastrectomy are still at risk for 
BE. This suggests a possible role for duodenal contents including bile acids 11, 
12. Our GEJ rat model showed the development of BE after duodenal reflux. The 
conversion from squamous into columnar epithelium was a mimic of human BE 
histology. Parallel with the development of intestinal metaplasia, a transition of 
the immune response pattern was noted. In esophagitis, the submucosal layer 
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showed a cell-mediated Th1-like inflammation profile, while in BE, the submu-
cosal layer contained a predominant humoral Th2-like inflammation profile. This 
is in line with previous observation in humans. In chapter 2, we show that this 
switch of the immune response is related to the development of BE in an in-
flamed esophageal mucosa. 
The esophageal epithelium is embryologically, morphologically, and function-
ally related to the skin epithelium, which is recognized as a major immunological 
organ. Along the same lines, we can consider the esophagus an immunological 
organ. The reflux of gastric and duodenal content may activate T cells in the sub-
mucosal layer that in turn release cytokines and chemokines. The cytokine profile 
of the mucosal immune response might explain the outcome of gastroesophageal 
reflux, the severity of mucosal injury, and even the relapse of esophagitis 13. Thus, 
esophageal damage may start in the submucosal layer and predominantly depend 
on cytokine secretion. Indeed, in our rat model, the inflammatory infiltration oc-
curred early and appeared to be restricted to the submucosal layer. In contrast, 
mucosal alterations, such as basal cell proliferation and papillary cell hyperplasia 
occurred after two weeks (Chapter 2 and 3). After 5 weeks, the first intestinal meta-
plasia appeared in the submucosal layer.
We then tested for a functional role of the immune response in the develop-
ment of esophagitis and BE in our GEJ rat model in several rat strains with different 
immunological background (Chapter 3). We found that surgically induced chronic 
reflux in genetically different rats induced esophagitis leading to BE in all species. 
This process was associated with an active immune response. We found that all 
Th1-prone Lewis rats developed BE at 12 weeks after GEJ compared to 50% of Th2-
prone BN rats and 33% of intermediate Wistar rats. Lewis rats also tended to develop 
a larger Barrett segment, implying that a Th1 predisposition is likely to be associ-
ated with the development of BE. Depending on the predisposition of the Th1/Th2 
immune response, an antigenic stimulus is likely to affect different effector cells, 
i.e., monocytes, macrophages and cytotoxic T cells in animals with a preferential 
Th1 response and mast cells in animals with a Th2 response. The Th1 prone Lewis 
rats showed Th1 effector cells at the early onset of the hyperplasia-esophagitis-BE 
cascade as well as Th2 effector cells in an early stage compared to BN and Wistar 
rats. Therefore, Lewis rats expressed an early Th1 immune response in hyperplasia 
and a strong and early Th2 immune response in BE. This suggests that a Th1-pre-
dominant immune status may predispose to the development of BE.
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The pro-inflammatory tumor necrosis factor (TNF) is a key cytokine in both sys-
temic inflammatory responses and anti-tumor activity 14, 15. Esophageal TNF expres-
sion is responsive to local concentrations of reflux components 16 and inflamma-
tory cytokines 17, but is also controlled on a genetic level. A polymorphism in the 
promoter region of the TNF-b gene 18 affects both the production of TNF-a and 
TNF-b 19, 20, and deregulation has been associated with an increased risk of intesti-
nal cancer development 21, 22. In Chapter 4, we show a positive association between 
the functional TNF-b NcoI polymorphism, that decreases TNF production, and sus-
ceptibility to BE and EAC development in patients with chronic gastro-esophageal 
reflux. While TNF-a protein levels were invariably high in esophageal biopsies from 
EAC patients, most esophageal BE samples showed low to moderate TNF levels. In 
this study, the significantly higher frequency of the TNF-b NcoI A/A genotype and 
the local TNF expression in patients with BE and EAC indicate that the pro-inflam-
matory cytokine TNF plays a role in the development of BE and EAC.
In BE, oxidative stress has been strongly linked to disease progression 23, 24. This 
oxidative stress can be induced in epithelial cells by exposure of these cells to both 
bile acid 25 and acid components of refluxate 26. In normal physiology of the gut and 
liver, the nuclear Pregnane X Receptor (PXR) is an important factor in the detoxifica-
tion of xenobiotics and bile acid homeostasis. In Chapter 5, we show that PXR was 
highly expressed  in adenocarcinoma tissue and columnar Barrett’s epithelium, com-
pared to squamous epithelium of these BE patients (p<0.001), and esophagitis pa-
tients (p=0.003). PXR appeared to be activated upon bile acid stimulation. A genetic 
association was observed between the PXR polymorphism and BE. Together, these 
data imply that PXR may have a function in progression of esophageal disease.
The stratified squamous epithelium of the healthy esophagus possesses a 
variety of intrinsic defenses that enable it to resist acid-peptic reflux, divided in 
pre-epithelial defense, epithelial defense, and post-epithelial defense 27, 28. Growth 
factors such as epidermal growth factor (EGF) and transforming growth factor-a 
(TGF-a) are associated with epithelial proliferation and restitution that are the two 
key mechanisms involved in esophageal epithelial defense against acid, maintain-
ing epithelial integrity and enabling rapid repair after injury 29. Multiple signaling 
pathways are activated by binding of TGF-a and EGF with their receptor EGFR 30, 31, 
resulting in proliferation and differentiation of epithelial tissues 32, 33. In Chapter 6, 
we show that a genetic variant of EGF is associated with reduced EGF expression 
and increased risk for esophagitis, BE and EAC development. This indicates that 
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reduced mucosal protection resulting from genetically decreased EGF expression 
enhances esophageal tumor development. 
Myo9B is predominantly expressed in the immune system since macrophages 
purified from Myo9B knockout mice exhibit defects in chemotactic motility 34, 35. 
Genetic variation in the 3’region of the myosin IXB (Myo9B) gene on chromosome 
19 has been associated with inflammatory intestinal disorders, like celiac disease 
and inflammatory bowel disease 36-39. These diseases are often characterized by in-
creased paracellular permeability in the intestinal epithelium 40, 41. Since Myo9B is 
also expressed in the intestinal epithelial cell 42, it could play key roles in Rho medi-
ated regulation of the mucosal barrier, disruption of which could also contribute to 
celiac disease and inflammatory bowel disease. Increased mucosal permeability is 
recognized as one of the earliest histological changes in GERD patients 42. In Chap-
ter 7, we show that, genetic variety of Myo9B was associated with an increased 
risk for BE and EAC development. Cytoplasmic Myo9B expression was determined 
in esophagitis, BE, and EAC, but most prominent in epithelial cells of BE and EAC. 
Genetic variation of Myo9B might play a role in the etiology of BE and EAC by in-
creasing the permeability of the epithelial barrier.
Since the metaplastic columnar epithelium of BE is similar to colonic epithe-
lium, the Notch pathway, which is a signaling cascade that is central to both normal 
and neoplastic colonic development, might be involved. In Chapter 8, we show us-
ing esophageal biopsy samples that the Notch pathway is not active in the normal 
squamous lining of the esophagus but that it is highly active in the areas of the 
esophagus that have changed into columnar Barrett’s epithelium. To determine 
whether inhibition of the Notch pathway could revert or destroy Barrett’s epithe-
lium, dibenzazepine, a known inhibitor of the Notch pathway, was used to treat 
rats with surgically induced BE. As shown previously in normal colonic epithelium, 
Notch inhibition converted the proliferative Barrett’s cells into arrested terminally 
differentiated goblet cells, whereas the normal squamous epithelium was unaf-
fected. In some cases, the Barrett’s epithelium was entirely exfoliated, leaving bare 
submucosal tissue. These data imply that local application of Notch inhibitors may 
present a simple therapeutic strategy for BE conversion.
Conclusions
The research presented herein identified immunological targets in rodent models 
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with GERD-like disease, in the development of esophagitis and BE. This thesis sug-
gests that patients with a Th1 immune status may predispose to the development 
of BE. These findings are supported by the positive association between the ge-
netic variation of the pro-inflammatory cytokine TNF-α and the development of BE 
and EAC, but not esophagitis. 
The progression of squamous epithelium in the healthy esophagus into meta-
plastic columnar epithelium in BE is a multifaceted process. One of the culprits 
which elicits a defensive cellular response is DNA damage. The mechanisms of 
damage become synergistic when bile acids are combined with acid. DNA damage 
becomes more pronounced and the cells are forced to adapt, incur mutations, and 
progress to cancer. This supports our findings that genetic variation in EGF and 
Myo9B, that both influence mucosal permeability and defense, are associated with 
the development of BE and EAC. PXR is activated upon bile acid stimulation, and 
may promote submucosal inflammation in GERD preceding BE development. 
We then found that the Notch pathway is active in BE and EAC. Notch inhibition 
converted the proliferative Barrett’s epithelial cells into terminally differentiated gob-
let cells, whereas the squamous epithelium remained intact. These data imply that lo-
cal application of Notch inhibitors may present a simple therapeutic strategy for BE.
Future directions:
The esophageal mucosal damage can be caused by other environmental factors 
including esophageal microbial flora. Therefore, we looked at bacteria at several 
stages of the esophagitis-metaplasia-EAC cascade and found that Corynebacte-
ria, S. Aureus, Veillonella and Streptococcus may be related to BE (not published). 
Esophageal and mucosal bacteria need to be further evaluated.
We tested for a functional role of the immune response in the development of 
esophagitis and BE in our GEJ model in several mouse strains with different immuno-
logical background. None of the mice developed BE at 16 weeks after surgery, but Th2 
prone GEJ mice showed a trend towards a more extensive esophagitis segment in the 
esophagus compared to other mouse strains. To determine the role of the immune 
response in esophagitis and BE, studies with knockout  mice would be helpful. 
Although BE is a pre-malignant condition, a therapeutic strategy like Notch 
inhibition would prevent EAC. Further studies are required to optimize a method 
of Notch delivery and, importantly, to determine the nature of any epithelial re-
growth following treatment.
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Samenvatting en Discussie
De incidentie van het adenocarcinoom van de slokdarm (EAC) is de laatste 4 decennia 
sterk gestegen in de westerse landen 1, 2. De diagnose is ingrijpend voor een patiënt, 
want de huidige mogelijkheden voor behandeling zijn zeer beperkt en de overle-
vingsfactor is laag. Barrett slokdarm (BE) is de enige bekende voorbode van EAC en 
ook de belangrijkste risicofactor. BE patiënten hebben een verhoogd risico van 30- 
tot 125-maal om EAC te ontwikkelen in vergelijking met de normale populatie 3. 
De incidentie van BE is duidelijk toegenomen sinds de 70-er jaren. Deze groei 
werd eerst gewijd aan de toename van het aantal maagonderzoeken, maar data 
van onze eigen onderzoeksgroep toonden voldoende bewijs dat de incidentie 
van BE in de gemiddelde populatie in Nederland werkelijk toegenomen is van 
14.3/100000 persoonsjaren in 1997 naar 23.1/100000 persoonsjaren in 2002, onaf-
hankelijk van het aantal uitgevoerde maagonderzoeken 4. 
Genetische factoren kunnen de aanleiding zijn tot de ontwikkeling van EAC, 
maar de snelle groei van de incidentie komt eerder door gedrags- en milieufac-
toren dan door een genetische invloed. BE is hoofdzakelijk een ziekte van blanke 
mannen op middelbare leeftijd. De prevalentie van BE neemt toe totdat een pla-
teaufase bereikt is rond de leeftijd van 70 jaar. De grootste risicofactoren voor BE 
zijn ouder worden, mannelijk geslacht, caucasisch ras, roken, overgewicht, hevig 
en langdurig zuurbranden bij gastro-oesofageale reflux ziekte, en de afwezigheid 
van een H. pylori infectie. 
Roken nam in westerse landen gedurende de eerste decennia van de 19e eeuw 
toe, maar neemt weer gelijkmatig af sinds 1970, dus het lijkt onwaarschijnlijk dat 
roken van invloed is op de toegenomen incidentie van BE, alhoewel de vertraagde 
latentietijd tussen sigarettengebruik en de ontwikkeling van BE nog steeds een 
verklaring zou kunnen zijn. Als dit laatste het geval is, dan wordt de komende 2 
decennia een afname van de BE incidentie verwacht. 
Overgewicht veroorzaakt symptomatisch en asymptomatisch zuurbranden 
door een mechanische storing 5. Bovendien is vetweefsel metabool actief 6, en de 
uitscheiding van adipokines is geassocieerd met de ontwikkeling van verschillen-
de soorten kanker 7, 8. De snelle toename van EAC kan komen door de toename van 
overgewicht en vetzucht in de bevolking. 
Een chronische maagontsteking door de bacterie H. pylori kan tot verlies van de 
slijmbekleding van de maag lijden en daardoor verminderde productie van maag-
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zuur 9. Dit verklaart waarom vele studies een omgekeerd evenredige associatie tus-
sen H. pylori infectie en zowel BE als ook EAC gevonden hebben. Andere studies 
tonen aan dat de groei van BE en EAC in veel landen correleert met de afgenomen 
prevalentie van H. pylori, onder andere als een gevolg van verminderde overdracht 
tijdens de geboorte maar ook door H. pylori eradicatie therapie.
Samenvattend concluderen we dat BE relatief weinig voorkomt in de gemiddel-
de populatie (1.3-5.6%) en het risico op de ontwikkeling van EAC voor de individu-
ele patiënt laag is. Desalniettemin heeft de diagnose ‘Barrett slokdarm’ een groot 
effect op de individuele patiënt. Het is dan belangrijk dat de arts nauwkeurige en 
duidelijke informatie geeft over mogelijke behandelingen en het risico op kanker. 
Verder moet het nut van poliklinische controle uitgelegd worden. Wanneer wordt 
gescreend op basis van klachten van gastro-oesofageale reflux (zuurbranden) dan 
worden 50% van BE patiënten over het hoofd gezien 10. De huidige screening is 
gebaseerd op symptomen en risicofactoren, maar deze aanpak is te algemeen en 
voert ertoe dat te veel mensen gescreend worden. Er zijn specifieke markers nodig, 
zodat het proces van gastro-oesofageale reflux ziekte dat leidt tot BE en uiteinde-
lijk EAC ontdekt wordt, zodat de risicopatiënten geïdentificeerd kunnen worden.
Het doel van dit promotieonderzoek was om de histologische en immunologi-
sche kenmerken in de ontwikkeling van gastro-oesofageale reflux ziekte en BE te 
bepalen, om biomarkers en genetische factoren te vinden die betrokken zijn bij de 
cascade van reflux oesofagitis-BE-EAC, en uiteindelijk om een mogelijke optie voor 
de therapeutische interventie van BE te introduceren.
In Hoofdstuk 2 is de ontwikkeling van BE in een chirurgisch rattenmodel met 
gallige reflux in de slokdarm aangetoond. Wij hebben gevonden dat reflux oes-
ofagitis voorafgaat aan de ontwikkeling van BE in Wistar ratten. Alle ratten ont-
wikkelen een Barrett slokdarm op 6 maanden na de operatie met de techniek van 
oesofagojejunostomie en gastrectomie (GEJ). In een Barrett slokdarm is gezond 
plaveiselcel epitheel vervangen door cilindrisch epitheel. Het nieuwe cilindrisch 
epitheel is darmachtig weefsel en daarom heet het proces intestinale metaplasie. 
We toonden in ons rattenmodel aan dat de ontwikkeling van BE begint als een 
onregelmatige verdeling van cilindrisch epitheel in de onderhuid en dit wordt ge-
zien als een immuun gestuurde ziekte. We ontdekten een vroeg stadium van weef-
selschade in de slokdarm (0-3 maanden na GEJ) gekarakteriseerd door oesofagitis 
en een grote hoeveelheid macrofagen en cytotoxische T cellen zonder significante 
metaplasie, en een laat stadium van weefselschade in de slokdarm (3-6 maanden 
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na GEJ) gekarakteriseerd door intestinale metaplasie met slijmbekercellen (goblet 
cellen) zoals bij mensen, met een duidelijke instroom van eosinofielen, B cellen 
en plasma cellen. We hebben inmiddels voldoende bewijs dat er een associatie 
bestaat tussen reflux ziekte en BE. Echter, de rol van individuele bestanddelen uit 
de maagzuur en gallige reflux in de ontwikkeling van BE en de geassocieerde com-
plicaties blijft onbekend. Mensen die maagzuurremmers nemen of patiënten na 
gastrectomie (operatieve verwijdering van de maag) hebben nog steeds een risico 
op BE. Dit suggereert dat er een rol is weggelegd voor componenten uit de dunne 
darm inclusief galzuren 11, 12. Ons GEJ rattenmodel toonde de ontwikkeling van BE 
na gallige reflux uit de dunne darm. De conversie van plaveiselcel- in cilindrisch 
epitheel lijkt histologisch precies op humane BE. Parallel met de ontwikkeling van 
intestinale metaplasie vindt een transitie plaats van de immuun respons. Bij oes-
ofagitis zagen we in het onderhuids weefsel een cel-gemedieerde Th1-achtige 
ontsteking, terwijl bij BE voornamelijk een humorale Th2-achtige ontsteking in het 
onderhuids weefsel plaatsvond. Dit komt overeen met voorafgaande BE studies in 
mensen. In Hoofdstuk 2 laten we zien dat omslag van de immuun respons is gere-
lateerd aan de ontwikkeling van BE door chronische reflux.
Het slokdarmepitheel lijkt embryologisch, morfologisch en functioneel op epi-
theel van de huid, dat wordt gezien als een groot immunologisch orgaan. Daarom 
kunnen we de slokdarm ook beschouwen als een immunologisch orgaan. Reflux van 
maagzuur en dunne darm inhoud kunnen T cellen activeren in het onderhuids weef-
sel waardoor cytokines en chemokines vrijkomen. Het cytokine profiel van de on-
derhuidse immuun respons zou het resultaat van gastro-oesofageale reflux kunnen 
verklaren, zoals de ernst van de onderhuidse schade en het ontstaan van oesofagitis 
13. De oesofageale schade dus kan beginnen in de onderhuid en voornamelijk afhan-
gen van de cytokine uitscheiding. In ons rattenmodel zagen we inderdaad dat er een 
vroege infiltratie van de ontsteking plaatsvond die beperkt bleef tot de onderhuid. 
Echter, 2 weken na de operatie (GEJ) traden onderhuidse veranderingen op, zoals 
proliferatie van de basale cellen en papillaire hyperplasie (Hoofdstuk 2 and 3). Na 5 
weken ontstond de eerste intestinale metaplasie in de onderhuid.
Vervolgens werd de functionele rol van de immuunrespons onderzocht tijdens 
de ontwikkeling van oesofagitis en BE met behulp van ons GEJ rattenmodel bij 
verschillende rattenstammen met uiteenlopende immunologische achtergronden 
(Hoofdstuk 3). We zagen dat chirurgisch geïnduceerde chronische reflux bij gene-
tisch verschillende ratten leidde tot oesofagitis en BE in alle stammen. Dit proces 
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was geassocieerd met een actieve immuun respons in het slokdarmweefsel. We 
vonden dat alle Lewis ratten met een bekende Th1-voorkeur BE ontwikkelden op 
12 weken na GEJ in vergelijking met 50% van de BN ratten met Th2 voorkeur en 
33% van de Wistar ratten met gemengde Th1/Th2 voorkeur voor de immuun res-
pons. Lewis ratten hadden de neiging om een langer BE segment te ontwikkelen, 
wat betekent dat een Th1 voorkeur waarschijnlijk geassocieerd is met de ontwikke-
ling van BE. Afhankelijk van de voorkeur voor de Th1 of Th2 immuun respons, treedt 
een antigeen stimulans op die van invloed is op het vrijkomen van de verschillende 
effector cellen, bijvoorbeeld monocyten, macrofagen en cytotoxische T cellen bij 
de Th1 respons en mestcellen bij de Th2 respons. De Th1 Lewis ratten hadden een 
vroege expressie van Th1 effector cellen in de hyperplasie-oesofagitis-BE cascade, 
terwijl juist de Th2 effector cellen werden gezien in een vroeger stadium van BE 
ontwikkeling dan bij BN en Wistar ratten. Hieruit kunnen we concluderen dat Lewis 
ratten een vroege Th1 immuun respons tonen bij hyperplasie en een vroege en uit-
gebreide Th2 immuun respons tonen in BE weefsel. Onze bevindingen lijken erop 
te wijzen dat een Th1 voorkeur voor de immuun respons tijdens chronische reflux 
de aanzet kan zijn voor de ontwikkeling van BE.
De pro-inflammatoire tumor necrosis factor (TNF) is betrokken als een belang-
rijke cytokine bij zowel de systemische ontsteking als ook bij anti-tumor activiteit 
14, 15. TNF expressie in de slokdarm is een reactie op locale concentraties van reflux 
componenten 16 en inflammatoire cytokines 17, maar wordt ook gereguleerd op 
een genetisch niveau. Een polymorfisme in het promoterdeel van het TNF-b gen 
18 heeft invloed op zowel de productie van TNF-a als TNF-b 19, 20, en deregulatie is 
geassocieerd met een verhoogd risico op de ontwikkeling van intestinale kanker 21, 
22. In Hoofdstuk 4 toonden we een positieve associatie aan tussen het functionele 
TNF-b NcoI polymorfisme, dat de TNF productie negatief beïnvloedt, en de aanleg 
voor de ontwikkeling van BE en EAC bij patiënten met chronische gastro-oesofage-
ale reflux. Hoewel het TNF-a eiwitgehalte zeer hoog was in slokdarm biopten van 
patiënten met EAC, brachten de meeste BE biopten een laag tot gemiddeld TNF 
eiwitgehalte tot expressie. In deze studie tonen we aan dat de significant hogere 
frequentie van het TNF-b NcoI A/A genotype en de locale TNF expressie bij patiën-
ten met BE en EAC indiceren dat TNF als pro-inflammatoire cytokine een rol speelt 
in de ontwikkeling van BE en EAC.
Bij BE wordt oxidatieve stress gekoppeld aan progressie van de ziekte 23, 24. De 
oxidatieve stress kan geïnduceerd worden in epitheelcellen door blootstelling van 
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de cellen aan zowel galzuren 25 als zure componenten in reflux 26. De normale fysi-
ologie van de darm en lever bevat de nucleaire Pregnane X Receptor (PXR) die een 
belangrijke rol speelt in het ontgiften van xenobiotica en de galzuurhomeostase. 
In Hoofdstuk 5 toonden we aan dat er een hoge PXR expressie is in EAC en Bar-
rett epitheel in vergelijking met het plaveiselcel epitheel van deze BE patiënten 
(p<0.001), en oesofagitis patiënten (p=0.003). PXR werd geactiveerd door stimula-
tie met glazuren. Een genetische associatie werd gezien tussen het PXR polymor-
fisme en BE. Samenvattend kunnen we concluderen dat PXR betrokken is bij de 
progressie van ziekten aan de slokdarm.
Het plaveiselcel epitheel van de gezonde slokdarm bevat een verscheidenheid 
aan intrinsieke afweermechanismen, dat leidt tot een natuurlijke weerstand tegen 
zure-gallige reflux, verdeeld in een pre-epitheliale afweer, een epitheliale afweer 
en een post-epitheliale afweer 27, 28. Groeifactoren zoals epidermal growth factor 
(EGF) en transforming growth factor-a (TGF-a) worden geassocieerd met epithe-
liale proliferatie en compensatie, dat 2 mechanismen zijn die een hoofdrol spelen 
in de oesofageale epitheliale afweer tegen zuur, waardoor de epitheliale integriteit 
behouden blijft en snel herstel van schade plaatsvindt 29. Multipele signaalroutes 
worden geactiveerd bij de binding van TGF-a en EGF met hun receptor EGFR 30, 
31, dat resulteert in proliferatie en differentiatie van epitheel 32, 33. In Hoofdstuk 6 
tonen we aan dat een genetische variant van EGF geassocieerd is met lage EGF 
expressie en een verhoogd risico op de ontwikkeling van oesofagitis, BE en EAC. 
Onze resultaten suggereren dat verminderde mucosale bescherming, door gene-
tisch verlaagde EGF expressie, de ontwikkeling van slokdarmkanker stimuleert.
Myo9B komt voornamelijk tot expressie in het immuunsysteem aangezien macro-
fagen van Myo9B knockout muizen defecten vertonen in de chemotactische motiliteit 
34, 35. Genetische variatie in het 3’einde van het myosin IXB (Myo9B) gen op chromo-
soom 19 wordt geassocieerd met intestinale ontstekingsziekten, zoals coeliakie en in-
flammatory bowel disease (IBD) 36-39. Deze ziekten worden vaak gekarakteriseerd door 
verhoogde paracellulaire permeabiliteit van het intestinale epitheel 40, 41. Aangezien 
Myo9B ook tot expressie komt in intestinale epitheelcellen 42, zou het een rol kunnen 
spelen in de Rho gemedieerde regulatie van de mucosa barrière, en verstoring van 
de barrière zou kunnen leiden tot coeliakie en IBD. Verhoogde mucosa permeabi-
liteit wordt al vroeg gezien in de histologie van patiënten met gastro-oesofageale 
reflux ziekte 42. In Hoofdstuk 7 tonen we aan, dat een genetische variant van Myo9B 
geassocieerd is met een verhoogd risico op de ontwikkeling van BE en EAC. Myo9B 
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expressie werd aangetoond in het cytoplasma van oesofagitis, BE en EAC, en sterke 
expressie werd voornamelijk gezien in de BE en EAC epitheelcellen. Genetische vari-
atie van Myo9B zou betrokken kunnen zijn bij het ontstaan van BE en EAC vanwege 
verhoogde permeabiliteit van de epitheel barrière.
Aangezien het metaplastische cilindrische epitheel van BE lijkt op darmepi-
theel, zou de Notch route, die een centrale signaleringscascade is voor zowel de 
normale als neoplastische ontwikkeling van darmweefsel, betrokken kunnen 
zijn bij BE ontwikkeling. In Hoofdstuk 8, tonen we in slokdarm biopten aan dat 
de Notch route niet actief is in normaal plaveiselcel epitheel van de slokdarm, 
maar dat Notch zeer actief is in de gebieden van slokdarm waar cilindrisch Bar-
rett epitheel is ontstaan. Door middel van remming van de Notch route met di-
benzazepine, een bekende remmer van Notch, hebben we bepaald of BE verwoest 
of geconverteerd kon worden in ons chirurgische GEJ rattenmodel met BE. Zoals 
eerder is aangetoond in normaal darmepitheel, converteerde Notch remming de 
proliferatieve Barrett cellen in compleet gedifferentieerde goblet cellen, terwijl het 
normale plaveiselcel epitheel ongeschonden bleef. In enkele gevallen was het Bar-
rett epitheel volledig uitgekleed, waarbij een kale submucosa overbleef. De locale 
applicatie van Notch remmers zou een simpele therapeutische strategie kunnen 
zijn voor conversie van BE.
Conclusies
Het onderzoek dat hier gepresenteerd is identificeert de immunologische proces-
sen in een rattenmodel met reflux-achtige ziekte tijdens de ontwikkeling van reflux 
oesofagitis en BE. Dit proefschrift stelt voor dat patiënten met de Th1 immuunstatus 
neigen tot de ontwikkeling van BE. Deze bevindingen worden ondersteund door de 
positieve associatie tussen de genetische variant van de pro-inflammatoire cytokine 
TNF en de ontwikkeling van BE en EAC, maar juist niet van reflux oesofagitis.
De progressie van plaveiselcel epitheel in de gezonde slokdarm naar metaplas-
tisch cilindrisch Barrett epitheel is een veelzijdig proces. De DNA schade lokt een 
defensieve cellulaire respons uit. De schade wordt synergistisch wanneer galzuren 
gecombineerd worden met maagzuur. Wanneer de DNA schade toeneemt worden 
de cellen gedwongen zich aan te passen, waardoor mutaties ontstaan, die uitein-
delijk leiden tot kanker. Dit ondersteunt onze resultaten, omdat we aantonen dat 
genetische variatie in DNA van EGF en Myo9B, die beide betrokken zijn bij de mu-
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cosa permeabiliteit en -afweer, geassocieerd is met de ontwikkeling van BE en EAC. 
PXR wordt geactiveerd door galzuur stimulatie en zou de ontsteking in de submu-
cosa van gastro-oesofageale reflux ziekte die vooraf gaat aan de ontwikkeling van 
BE kunnen bevorderen.
Vervolgens hebben we uitgevonden dat de Notch route geactiveerd is in BE en 
EAC. Notch remmers converteren het proliferatieve Barrett epitheel naar compleet 
gedifferentieerde goblet cellen, terwijl het plaveiselcel epitheel ongeschonden 
blijft. Deze data impliceren dat locale applicatie van Notch remmers een simpele 
therapeutische strategie vormt voor conversie van Barrett epitheel.
Verder onderzoek:
De schade van de slokdarmweefsel kan door verschillende omgevingsfactoren 
veroorzaakt worden waaronder ook de microbiotische flora van de slokdarm. We 
hebben de bacteriële flora onderzocht op verschillende stadia van de reflux oes-
ofagitis-BE-EAC cascade en vonden dat Corynebacteria, S. Aureus, Veillonella en 
Streptococcus gerelateerd zijn aan BE (niet gepubliceerd). Bacteriën in de slokdarm 
en op de mucosa moeten in vervolgstudies onderzocht worden.
We hebben de functionele rol van de immuun respons tijdens de ontwikkeling 
van reflux oesofagitis en BE in ons GEJ model bij meerdere muizenstammen met 
een verschillende immunologische achtergrond getest. Geen enkele van de mui-
zen ontwikkelde binnen 16 weken na de GEJ operatie een Barrett slokdarm, maar 
muizen met een voorkeur voor de Th2 immuun respons toonden een trend rich-
ting een uitgebreide oesofagitis in vergelijking met de andere muizenstammen. 
Om de rol van de immuun respons bij reflux oesofagitis en BE te bepalen, zouden 
studies met knockout muizen ons verder kunnen helpen.
Alhoewel BE een premaligne stadium is, zou een therapeutische strategie met 
Notch remming de ontwikkeling van EAC kunnen voorkomen. Verder onderzoek is 
nodig om de veilige toediening van Notch te optimaliseren en, zeer belangrijk, om 
de aard van het epitheel te bepalen dat opkomt nadat Notch remming als therapie 
is toegepast.
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